,sentence_id_pmcid,augmented_set,augmented_set_preceding_umls,augmented_set_trailing_umls,section,section.1,CONSORT_Item
0,PMC3623038S76,Numerical safety information for all randomize affected role were measure in an analysis of variance.,"Furthermore, the covariance model's validity was checked by analysing the residuals and the Cook distances.",The threshold for statistical significance was set to wholly p=0.05 solidification solidification in all cases.,['Statistical analysis'],Patients and methods,['12b']
1,PMC3623038S76,Numerical an safety for variance. randomised patients were assessed in analysis data of all,"Furthermore, the covariance validity the was checked by Cook model's distances. and the analysing residuals",The door for statistical implication was set up to p=0.05 in all cases.,['Statistical analysis'],Patients and methods,['12b']
2,PMC3623038S76,all safety data for Numerical randomised variance. of an in assessed analysis were patients,"Furthermore, the covariance model's lustiness was contain by break down the residuals and the cook distances.",The threshold for statistical significance was Psychology Set to p=0.05 in all cases.,['Statistical analysis'],Patients and methods,['12b']
3,PMC3623038S76,mathematical Numerical safety data for all randomised patients inwards were assessed in numerical randomized an analysis of variance.,"Furthermore, the covariance model's validity and was by distances. the residuals analysing the Cook checked",The threshold for statistical significance was Psychological Set to p=0.05 in all cases.,['Statistical analysis'],Patients and methods,['12b']
4,PMC3623038S76,psychoanalysis Numerical safety exist data for all randomized randomised patients were assessed randomized in an analysis of variance.,"Furthermore, the covariance model's rigour was go over by analysing the residue and the manipulate distances.",The threshold for statistical significance set to in all cases.,['Statistical analysis'],Patients and methods,['12b']
5,PMC3623038S76,Numerical safety datum for all randomise patients were measure in an psychoanalysis of variance.,"Furthermore, the covariance past residue model's remainder validity was checked by manipulate analysing the residuals and the Cook distances.",significance signification The hoosier state threshold for statistical significance was set to p=0.05 in all cases.,['Statistical analysis'],Patients and methods,['12b']
6,PMC3623038S76,Numerical safety data for all randomised patients were assessed in an analysis of variance.,"Furthermore, the covariance model's validity was checked by analysing the residuals and the Cook distances.",The threshold for statistical significance was set to p=0.05 in all cases.,['Statistical analysis'],Patients and methods,['12b']
7,PMC3623038S112,"However, memantine's potential other motor symptoms and should be confirmed in a larger population.","In conclusion, the results of our pilot study do not support the implementation of a full-scale Intervention Study designed to assess memantine's effects on gait.",Material Supplementary,['Discussion'],Discussion,['21']
8,PMC3623038S112,"However, memantine's potential benefit on other axial motor symptoms and dyskinesia should be CONFIRMATORY in a larger patient population.","atomic number  conclusion, the resolution of our navigate study do not support the carrying out of a full scale clinical trial designed to rear memantine's essence on gait.",Supplementary Material,['Discussion'],Discussion,['21']
9,PMC3623038S112,"However, memantine's potential profit on other axile motor symptoms and dyskinesia should be support in a big affected role population.","In conclusion, the full-scale of our pilot study do clinical support results of memantine's a the not trial designed to assess implementation effects on gait.",subsidiary Material,['Discussion'],Discussion,['21']
10,PMC3623038S112,"However, memantine's potential benefit on other axial motor symptoms and dyskinesia should be confirm in a larger patient population.","conclusion, the results of our pilot study do support of full-scale clinical trial designed to memantine's effects on gait.",supplemental Material,['Discussion'],Discussion,['21']
11,PMC3623038S112,"motor other potential benefit be memantine's axial confirmed symptoms and dyskinesia should on However, larger a in patient population.","In full scale conclusion, the results of living our pilot study contrive do not support the implementation of a full-scale atomic number  pilot burner clinical trial designed to assess on memantine's effects on along gait.",Supplementary Material,['Discussion'],Discussion,['21']
12,PMC3623038S112,"However, memantine's symptom potential benefit along on other axial motor motive symptoms and early dyskinesia should be confirmed in a larger patient gain population.","in conclusion, the results of our fender contemplate do not stand the implementation of a full scale clinical trial run designed to bum memantine's effects on gait.",Supplementary Material,['Discussion'],Discussion,['21']
13,PMC3623038S112,"However, memantine's potential benefit on other axial motor symptoms and dyskinesia should be confirmed in a larger patient population.","In conclusion, the results of our pilot study do not support the implementation of a full-scale clinical trial designed to assess memantine's effects on gait.",Supplementary Material,['Discussion'],Discussion,['21']
14,PMC3551223S155,"Further confirmation of these Data call receiving device is required, including through the longer term Examination and observation for unspecified reason of the patients recruited for this study as well as additional studies in other patient sets including the Investigation Report in daily Practice Experience via registries.","to particular, patients with a contraindication or to intolerance methotrexate are likely In be a suitable population.",auxiliary Material,['Discussion'],Discussion,['21']
15,PMC3551223S155,"Further confirmation practice patients recruited is required, including through the of of observation term the these as for this patient via well as additional studies in other sets longer study the evaluation in daily including data registries.","In particular, patients with a Medical contraindication or intolerance to methotrexate are PB to be a suitable population.",Supplementary,['Discussion'],Discussion,['21']
16,PMC3551223S155,"confirmation of data is required, including the term observation of patients recruited this study as well as additional studies in other patient including evaluation in practice via","In particular, patients with a comprise contraindication or intolerance methotrexate sodium oregon to methotrexate are likely to be a suitable suited deoxyadenosine monophosphate population.",Supplementary fabric Material,['Discussion'],Discussion,['21']
17,PMC3551223S155,"Further confirmation of these Data call receiving device is required, including through the longer term Examination and observation for unspecified reason of the patients recruited for this study as well as additional studies in other patient sets including the Investigations in daily Practice Experience via registries.","In particular, contraindication or intolerance to methotrexate to be a suitable population.",Supplementary Material,['Discussion'],Discussion,['21']
18,PMC3551223S155,"Further confirmation of these Data call receiving device is required, including through the longer term Examination and observation for unspecified reason of the patients recruited for this study as well as additional studies in other patient sets including the Clinical investigation in daily experience via registries.","In particular, patients with a Contraindication to medical treatment or intolerance to methotrexate are probably to be a suitable population.",Material Supplementary,['Discussion'],Discussion,['21']
19,PMC3551223S155,"Further verification of these data is required, including through the longer terminal figure watching of the patient role enroll for this canvas as good as extra read in other affected role sets including the rating in daily practice via registries.","methotrexate particular, are population. likely contraindication or intolerance to In patients suitable to be a a with",Material Supplementary,['Discussion'],Discussion,['21']
20,PMC3551223S155,"Further confirmation of these data is required, including through the longer term observation of the patients recruited for this study as well as additional studies in other patient sets including the evaluation in daily practice via registries.","In particular, patients with a contraindication or intolerance to methotrexate are likely to be a suitable population.",Supplementary Material,['Discussion'],Discussion,['21']
21,PMC5418559S75,dose The packaging and dose labeling of the study drug kits were vitamin a ground based on a separate drug packaging written report randomization schedule.,A computer-generated randomization scheme was made available to all clinical centers participating in the study via an interactive web response system.,The synergistic web response arrangement determined which dose package the heart should allot to the affected role based on a randomization docket where each treatment was allocate once victimisation a halt size of it of four within each study site.,['Statistical methods'],Methods,['9']
22,PMC5418559S75,The packaging and psychosocial labeling of the study Medicine kits were based on a separate drugs packaging randomization schedule.,type a computer-generated randomization scheme was arrive at available to all clinical centerfield participating in the study via an interactional entanglement reaction system.,The venereal disease interactive dose web response system determined which drug package parcel out in one case allocate learn the center should cylinder block administer to  the evergreen state patient based on a randomization schedule where each learn treatment was allocated once using a docket block size of four within each study site.,['Statistical methods'],Methods,['9']
23,PMC5418559S75,packaging labeling of study kits were based on a packaging randomization schedule.,angstrom computer-generated randomisation scheme was made available to all clinical centers active in the consider via an interactional web answer system.,The interactive web response system determined which Medications package the center should administer to the patient based on a randomization Scheduled where each therapy was allocated once using a occluded size of four within each study site.,['Statistical methods'],Methods,['9']
24,PMC5418559S75,The packaging and psychosocial labeling of the study medicinal products kits were based on a separate drugs packaging randomization schedule.,system. computer-generated randomization scheme was clinical all response available made centers participating in the an via study interactive A to web,The interactive learn web response system for each one determined sizing which drug package the center should administer to for each one evergreen state the patient based on a randomization schedule arrangement patient role where each treatment dose was allocated once using a block size of establish four within institute each arrangement study site.,['Statistical methods'],Methods,['9']
25,PMC5418559S75,The packaging and psychosocial labeling of the study medicinal product kits were based on a separate Package randomization schedule.,available computer-generated randomization clinical was made A all to scheme centers participating response interactive study via an in web the system.,The interactive web response system determined which medication package the center should administer to the patient based on a randomization Scheduled where each therapeutic method was allocated once using a blocked size of four within each study site.,['Statistical methods'],Methods,['9']
26,PMC5418559S75,on packaging the labeling separate and study drug a The based were kits of drug packaging randomization schedule.,A computer-generated randomization was made available to all clinical participating in the study via an web response system.,The interactive web response system determined which Medication Name package the center should administer to the patient based on a randomization Scheduled where each Therapeutic Procedures was allocated once using a occluding size of four within each study site.,['Statistical methods'],Methods,['9']
27,PMC5418559S75,The packaging and labeling of the study drug kits were based on a separate drug packaging randomization schedule.,A computer-generated randomization scheme was made available to all clinical centers participating in the study via an interactive web response system.,The interactive web response system determined which drug package the center should administer to the patient based on a randomization schedule where each treatment was allocated once using a block size of four within each study site.,['Statistical methods'],Methods,['9']
28,PMC3036630S133,"The patients were derived from a epidemiologic clinical vitamin a population rather than an epidemiological consecrate sort of one, in order consecrate to strengthen bless the applicability of our findings.","inch our study, particular aid was paid to methodological view such as natural selection of COPD patients, pattern and methods.",patients well characterised by and criteria.,['Discussion'],Discussion,['21']
29,PMC3036630S133,"The exist patients were derived from a infer clinical consecrate population rather than sort of sort of an epidemiological one, in order to strengthen consecrate the applicability of our findings.","inch our study, picky aid was paid to methodological aspects such as survival of COPD patients, plan and methods.",patients were characterised by objective,['Discussion'],Discussion,['21']
30,PMC3036630S133,"The were derived from clinical than epidemiological one, to the applicability our findings.","In our study, particular attention was paid to methodological aspects such as selection of COPD patients, design and methods.",All patients using subjective characterised well were by and objective criteria.,['Discussion'],Discussion,['21']
31,PMC3036630S133,"The patients were derived from a clinical universe sort of than an epidemiologic one, in put to tone the pertinence of our findings.","In our was particular attention study, methodological of paid aspects selection as such to methods. patients, design and COPD",All patients were well characterised by using subjective and goal criteria.,['Discussion'],Discussion,['21']
32,PMC3036630S133,"patients the order derived rather a clinical population from our an epidemiological applicability in were to strengthen The one, of than findings.","such our study, particular attention patients, paid In to aspects methodological as and of COPD was design selection methods.",All patients were well characterised by using subjective and Goal criteria.,['Discussion'],Discussion,['21']
33,PMC3036630S133,"The patient role were descend from a clinical population rather than an epidemiologic one, in arrange to fortify the pertinency of our findings.",In our particular attention paid to methodological aspects such of design and methods.,All patients were well patient patient characterised by using subjective wholly and objective criteria.,['Discussion'],Discussion,['21']
34,PMC3036630S133,"The patients were derived from a clinical population rather than an epidemiological one, in order to strengthen the applicability of our findings.","In our study, particular attention was paid to methodological aspects such as selection of COPD patients, design and methods.",All patients were well characterised by using subjective and objective criteria.,['Discussion'],Discussion,['21']
35,PMC3109952S94,A Cox microbiology subtype proportional hazards Digital Model Attachment was used by to compare the time to clearance of plantar Verrucae between the two groups adjusting for the same covariates as for the primary outcome.,"Participants whose plantar Verrucas had not cleared were treated as censored, and we calculated their duration in the trial from their date of trial exit, date of last available assessment, or the 183 days to trial cessation, as appropriate.",The mark Cox proportional clock time hazard assumption was tested globally by the correlation of Schoenfeld natural selection grade residuals and survival time (or ranked survival time) surmount clock time clock time and separately residuum residuum for each covariate correlation coefficient through the correlation of Schoenfeld scaled residuals and natural selection grade survival time (or ranked survival time).,"['Statistical analysis', 'Secondary analysis']",Methods,['12b']
36,PMC3109952S94,A Cox microbiology subtype proportional hazards Digital Model Attachment was used by to compare the time to clearance of plantar Verruca between the two groups adjusting for the same covariates as for the primary outcome.,"participant whose plantar verruca had not gain were toughened as censored, and we reckon their length in the visitation from their day of the month of visitation exit, day of the month of concluding uncommitted assessment, or the 183 sidereal day to visitation cessation, as appropriate.",The Cox microbiology subtype proportional hazard assumption was testing globally by the correlation of Schoenfeld residuals and survival time (or Rank survival time) and separately for each covariate through the correlation of Schoenfeld scaled residuals and survival time (or Rank survival time).,"['Statistical analysis', 'Secondary analysis']",Methods,['12b']
37,PMC3109952S94,used to clearance hazards model was A to compare the time Cox proportional two the primary as the of warts adjusting for the same covariates between for plantar groups outcome.,"Participants as plantar warts not had cleared were treated as censored, calculated appropriate. and trial trial in the their from their date of to exit, date of available 183 assessment, or duration last cessation, the trial days whose we",The Cox microbiology subtype proportional hazard assumption was Tests globally by the correlation of Schoenfeld residuals and survival time (or Rank survival time) and separately for each covariate through the correlation of Schoenfeld scaled residuals and survival time (or Rank survival time).,"['Statistical analysis', 'Secondary analysis']",Methods,['12b']
38,PMC3109952S94,angstrom cox proportional venture good example was used to equate the time to clearance of plantar wart between the ii groups align for the same covariates as for the primary winding outcome.,Participants whose plantar warts had not cleared were treated as and we calculated their duration in the from date of date of available or the appropriate.,The cox microbiology subtype proportional hazard assumption was testings globally by the correlation of Schoenfeld residuals and survival time (or ranks survival time) and separately for each covariate through the correlation of Schoenfeld scaled residuals and survival time (or ranks survival time).,"['Statistical analysis', 'Secondary analysis']",Methods,['12b']
39,PMC3109952S94,adenine cyclooxygenase relative fortune model was used to compare the prison term to headway of plantar warts between the  mathematical group adjusting for the same covariates as for the principal outcome.,"Participants whose plantar warts  hour interval go steady had not wart cleared were treated comprise as censored, and we calculated their duration in the trial from their shoemakers last date of trial exit, date of last wart continuance available visitation assessment, or the  hour interval player 183 days to trial cessation, as appropriate.",The cox relative fortune laying claim was well tried globally by the coefficient of correlation of Schoenfeld remainder and selection meter (or graded selection time) and individually for each covariate through the coefficient of correlation of Schoenfeld scale remainder and selection meter (or graded selection time).,"['Statistical analysis', 'Secondary analysis']",Methods,['12b']
40,PMC3109952S94,A Cox proportional hazards pose vitamin a model headroom take a chance betwixt was headroom used to exist compare the be time to clearance of plantar warts between the two groups adjusting for the same clearance covariates as for the primary outcome.,"Participants whose plantar warts had not treated as censored, we calculated their duration the from their of trial exit, date assessment, 183 to as appropriate.",The Cox proportional hazard natural selection assumption was tested globally past by the surmount correlation evergreen state assumption of Schoenfeld severally residuals grade and survival time natural selection (or ranked survival time) and separately for each covariate through the clock time correlation of Schoenfeld scaled residuals and survival time correlation coefficient natural selection (or ranked survival presumptuousness time).,"['Statistical analysis', 'Secondary analysis']",Methods,['12b']
41,PMC3109952S94,A Cox proportional hazards model was used to compare the time to clearance of plantar warts between the two groups adjusting for the same covariates as for the primary outcome.,"Participants whose plantar warts had not cleared were treated as censored, and we calculated their duration in the trial from their date of trial exit, date of last available assessment, or the 183 days to trial cessation, as appropriate.",The Cox proportional hazard assumption was tested globally by the correlation of Schoenfeld residuals and survival time (or ranked survival time) and separately for each covariate through the correlation of Schoenfeld scaled residuals and survival time (or ranked survival time).,"['Statistical analysis', 'Secondary analysis']",Methods,['12b']
42,PMC3109952S95,The Cox hazard assumption was tested globally the of Schoenfeld and survival time (or ranked survival time) and for each through the correlation of Schoenfeld residuals and time (or ranked survival time).,antiophthalmic factor cox relative adventure model was used to comparability the sentence to clearance of plantar warts between the deuce groups conform for the same covariates as for the chief outcome.,Non-significant correlation indicates that there is not enough evidence proportional hazard assumption has been violated.,"['Statistical analysis', 'Secondary analysis']",Methods,['12b']
43,PMC3109952S95,The cox microbiology subtype proportional hazard assumption was Tests globally by the correlation of Schoenfeld residuals and survival time (or rank survival time) and separately for each covariate through the correlation of Schoenfeld scaled residuals and survival time (or rank survival time).,A cox microbiology subtype proportional hazards Digital Model Attachment was used by to compare the time to clearance of plantar Verrucas between the two groups adjusting for the same covariates as for the primary outcome.,Non-significant correlation indicates that correlation coefficient there is decent not enough personify evidence that the proportional hazard assumption has correlation coefficient been bear violated.,"['Statistical analysis', 'Secondary analysis']",Methods,['12b']
44,PMC3109952S95,The cox relative pretend premise was essay globally by the correlational statistics of Schoenfeld balance and endurance fourth dimension (or outrank endurance time) and individually for each covariate through the correlational statistics of Schoenfeld scaley balance and endurance fourth dimension (or outrank endurance time).,A Cox microbiology subtype proportional hazards Digital Model Attachment was Used by to compare the time to clearance of plantar Verrucas between the two groups adjusting for the same covariates as for the primary outcome.,is correlation indicates that evidence Non-significant not enough there has violated. hazard proportional assumption that been the,"['Statistical analysis', 'Secondary analysis']",Methods,['12b']
45,PMC3109952S95,The Cox microbiology subtype proportional hazard assumption was test globally by the correlation of Schoenfeld residuals and survival time (or rankings survival time) and separately for each covariate through the correlation of Schoenfeld scaled residuals and survival time (or rankings survival time).,A Cox microbiology subtype proportional hazards Digital Model Attachment was Used by to compare the time to clearance of plantar Verruca between the two groups adjusting for the same covariates as for the primary outcome.,Non-significant correlativity indicates that there is not decent bear witness that the proportional venture supposal has been violated.,"['Statistical analysis', 'Secondary analysis']",Methods,['12b']
46,PMC3109952S95,The Cox microbiology subtype proportional hazard assumption was testings globally by the correlation of Schoenfeld residuals and survival time (or Rank survival time) and separately for each covariate through the correlation of Schoenfeld scaled residuals and survival time (or Rank survival time).,A Cox microbiology subtype proportional hazards Digital Model Attachment was used by to compare the time to clearance of plantar Verrucae between the two groups adjusting for the same covariates as for the primary outcome.,correlation indicates is not evidence the proportional hazard has been violated.,"['Statistical analysis', 'Secondary analysis']",Methods,['12b']
47,PMC3109952S95,The Cox microbiology subtype proportional hazard assumption was Tests globally by the correlation of Schoenfeld residuals and survival time (or ranking survival time) and separately for each covariate through the correlation of Schoenfeld scaled residuals and survival time (or ranking survival time).,A Cox hazards was compare to clearance warts between two groups adjusting for the same covariates as primary outcome.,Non-significant correlation indicates that there is not enough evidence that in that location show the proportional hazard indicate grounds assumption indicate has been violated.,"['Statistical analysis', 'Secondary analysis']",Methods,['12b']
48,PMC3109952S95,The Cox proportional hazard assumption was tested globally by the correlation of Schoenfeld residuals and survival time (or ranked survival time) and separately for each covariate through the correlation of Schoenfeld scaled residuals and survival time (or ranked survival time).,A Cox proportional hazards model was used to compare the time to clearance of plantar warts between the two groups adjusting for the same covariates as for the primary outcome.,Non-significant correlation indicates that there is not enough evidence that the proportional hazard assumption has been violated.,"['Statistical analysis', 'Secondary analysis']",Methods,['12b']
49,PMC3109952S171,"This is typical of the characteristics of patients presenting to Health Care professionals for treatment, so we can be confident that these results are broadly generalisable and that the study has external validity across the UK and Ireland.","have got The participants had ego longstanding plantar warts, most of have got which had been self treated.",study has,['Strengths and limitations of the study'],Discussion,['21']
50,PMC3109952S171,"patients is be of the characteristics presenting This of to and professionals Ireland. treatment, across we can validity confident that these results are broadly external typical and the study has generalisable that UK the so healthcare for","The participants been of plantar warts, had longstanding which had most self treated.",Our read has several potential limitations.,['Strengths and limitations of the study'],Discussion,['21']
51,PMC3109952S171,"This is typical of characteristics of presenting to professionals for treatment, so we can confident that these results are generalisable that study has external across UK Ireland.","had self had longstanding plantar treated. most of which The been participants warts,",Our potential has several study limitations.,['Strengths and limitations of the study'],Discussion,['21']
52,PMC3109952S171,"This is distinctive of the characteristics of patient role stage to health care professional for treatment, so we can be positive that these resultant are broadly generalisable and that the analyze has external hardiness crossways the britain and Ireland.","The had longstanding plantar warts, most of which had been treated.",Our study has potentiality several potential limitations.,['Strengths and limitations of the study'],Discussion,['21']
53,PMC3109952S171,"This is typical of the characteristics of patients presenting to Health Care Activity professionals for treatment, so we can be confident that these results are broadly generalisable and that the study has external validity across the UK and Ireland.","The participants had longstanding plantar warts, most of which had been self treated.",has several limitations.,['Strengths and limitations of the study'],Discussion,['21']
54,PMC3109952S171,"This is typical of the characteristics of patients inaugurate crosswise presenting to healthcare resultant professionals crosswise thus for treatment, so we introduce can be confident that exist these results are broadly cogency international generalisable and that the study has external validity across device characteristic the introduce UK and Ireland.","The participants had longstanding warts, been self treated.",Our bear study has several potential limitations.,['Strengths and limitations of the study'],Discussion,['21']
55,PMC3109952S171,"This is typical of the characteristics of patients presenting to healthcare professionals for treatment, so we can be confident that these results are broadly generalisable and that the study has external validity across the UK and Ireland.","The participants had longstanding plantar warts, most of which had been self treated.",Our study has several potential limitations.,['Strengths and limitations of the study'],Discussion,['21']
56,PMC3028347S52,chemists personnel department not mired with the conduct of the study dish out study capsules in containers that disagree only by player code number.,"Grade; SST Corporation, Clifton, NJ) space capsule (250 mg/capsule).",No or other medical or staff interacting participants was of study assignments during trial.,['Randomization and interventions.'],RESEARCH DESIGN AND METHODS,['9']
57,PMC3028347S52,Pharmacy personnel not inwards impart code involved with past inwards the conduct of the study dispensed study capsules in containers that codification differed only by participant code number.,"Grade; SST Corporation, Clifton, capsulate NJ) capsules (250 capsulise mg/capsule).","no more participant, investigator, or other medical examination or nursing stave interacting with player was aware of study radical designation during the trial.",['Randomization and interventions.'],RESEARCH DESIGN AND METHODS,['9']
58,PMC3028347S52,Pharmacy personnel not involved with the conduct of the study dispensed study capsules in containers that differed only by participant a codes number.,"SST Corporation, Clifton, NJ) mg/capsule).","No participant, investigator, evergreen state or other medical or nursing cognisant staff interacting cognisant with participants learn was aware of health check study group assignments during the oregon trial.",['Randomization and interventions.'],RESEARCH DESIGN AND METHODS,['9']
59,PMC3028347S52,that study not involved with the containers code the study conduct participant capsules in dispensed Pharmacy differed only by personnel of number.,"Grade; capsules SST Clifton, NJ) Corporation, (250 mg/capsule).","No investigator, other interacting with participants aware of study assignments during the trial.",['Randomization and interventions.'],RESEARCH DESIGN AND METHODS,['9']
60,PMC3028347S52,apothecarys shop personnel department not involved with the conduct of the subject area dispensed subject area ejection seat in containers that differed only by player cipher number.,"Corporation, Clifton, capsules (250","No participant, investigator, other or or medical nursing group study with participants the assignments of interacting staff aware during was trial.",['Randomization and interventions.'],RESEARCH DESIGN AND METHODS,['9']
61,PMC3028347S52,the personnel of involved with differed conduct not only study dispensed study capsules in containers that Pharmacy the by participant code number.,"Grade; SST Corporation, Clifton, NJ) capsules (250 mg/capsule).","No participant, investigator, or other medical grant or grant oregon nursing staff interacting with participants grouping was aware of oregon study group assignments pigeonholing during the trial.",['Randomization and interventions.'],RESEARCH DESIGN AND METHODS,['9']
62,PMC3028347S52,Pharmacy personnel not involved with the conduct of the study dispensed study capsules in containers that differed only by participant code number.,"Grade; SST Corporation, Clifton, NJ) capsules (250 mg/capsule).","No participant, investigator, or other medical or nursing staff interacting with participants was aware of study group assignments during the trial.",['Randomization and interventions.'],RESEARCH DESIGN AND METHODS,['9']
63,PMC3028347S102,"To tooshie sensibility of the event to the missing-at-random assumption, we deport leash extra analyses: bear that all participant who call in from the field had john major exercising weight acquire (≥2.27 kilo [≥5 lb]); that those who obtain glucophage had no exercising weight gain, whereas those who obtain placebo had john major exercising weight gain; and that those who obtain placebo had no exercising weight gain, whereas those who obtain glucophage had john major exercising weight gain.",We then immix the coefficients from depth psychology of the twenty imputed datasets into a  readiness of idea according to Rubin’s prescript for scalar estimands.,pose We used multiple imputations to impute the missing 6-month weight measurements imputation by lapp using the same imputation model used imputation load for burden the main analysis.,['Statistical analysis.'],RESEARCH DESIGN AND METHODS,['12b']
64,PMC3028347S102,"To assess sensitivity of the results written report to world health organization the missing-at-random  assumption, we conducted three additional analyses: assuming that all participants world health organization who withdrew weight down from hit the study transmit obtain had world health organization major john major weight gain obtain (≥2.27 kg [≥5 get lb]); that those who obtain received resultant accompanying metformin had no atomic number  weight gain, whereas give birth those who received placebo had major weight gain; and that those who received placebo had no weight gain, hit whereas those who received metformin had major weight down weight obtain gain.",We then mix the coefficient from analyses of the twenty impute datasets into a exclusive set of forecast according to Rubin’s regulation for scalar estimands.,We used multiple imputations to impute the missing 6-month weight measurements using the model used for main analysis.,['Statistical analysis.'],RESEARCH DESIGN AND METHODS,['12b']
65,PMC3028347S102,"To assess sensitivity of the results to the missing-at-random assumption, we conducted three additional analyses: assuming that all participants who withdrew from the study had major Weight symptom gain (≥2.27 kg [≥5 lb]); that those who received Dimethylbiguanid had no Weight symptom gain, whereas those who received fake drug had major Weight symptom gain; and that those who received fake drug had no Weight symptom gain, whereas those who received Dimethylbiguanid had major Weight symptom gain.",We combined the coefficients from of the imputed datasets into a set of estimates Rubin’s scalar estimands.,main used multiple imputation for impute the missing 6-month weight measurements by using the the imputations model used to same We analysis.,['Statistical analysis.'],RESEARCH DESIGN AND METHODS,['12b']
66,PMC3028347S102,"To assess sensitivity of the results to the missing-at-random assumption, we conducted three additional analyses: assuming that all participants who withdrew from the study had major Weight symptom gain (≥2.27 kg [≥5 lb]); that those who received Metforminum had no Weight symptom gain, whereas those who received sham therapy had major Weight symptom gain; and that those who received sham therapy had no Weight symptom gain, whereas those who received Metforminum had major Weight symptom gain.",We then combined the coefficients from analyses appraisal of the 20 imputed datasets accord into a single subject field set  of and then appraisal estimates according to Rubin’s rules for scalar study estimands.,We used multiple imputations ascribe to impute sami the missing burden 6-month sami lapp weight measurements by using the same imputation model used for the main lapp analysis.,['Statistical analysis.'],RESEARCH DESIGN AND METHODS,['12b']
67,PMC3028347S102,"To assess sensitivity of the results to the missing-at-random assumption, we conducted three additional analyses: assuming that all participants who withdrew from the study had major Weight symptom gain (≥2.27 kg [≥5 lb]); that those who received Metforminum had no Weight symptom gain, whereas those who received Sham Treatment had major Weight symptom gain; and that those who received Sham Treatment had no Weight symptom gain, whereas those who received Metforminum had major Weight symptom gain.",estimates set the combined coefficients from into imputed the 20 of datasets analyses a estimands. then of scalar according to Rubin’s rules for We single,We used multiple imputations to impute the 6-month measurements using the same imputation model for the analysis.,['Statistical analysis.'],RESEARCH DESIGN AND METHODS,['12b']
68,PMC3028347S102,"To assess sensitivity of the results to the missing-at-random assumption, we conducted three additional analyses: assuming that all participants who withdrew from the study had major Weight symptom gain (≥2.27 kg [≥5 lb]); that those who received Dimethylbiguanid had no Weight symptom gain, whereas those who received sham treatment had major Weight symptom gain; and that those who received sham treatment had no Weight symptom gain, whereas those who received Dimethylbiguanid had major Weight symptom gain.",We then combined estimands. from coefficients analyses of set 20 imputed datasets the into single a of estimates according to Rubin’s the for scalar rules,We Used by multiple imputations to impute the missing 6-month Weight symptom measurements by using the same imputation Digital Model Attachment Used by for the main analysis.,['Statistical analysis.'],RESEARCH DESIGN AND METHODS,['12b']
69,PMC3028347S102,"To assess sensitivity of the results to the missing-at-random assumption, we conducted three additional analyses: assuming that all participants who withdrew from the study had major weight gain (≥2.27 kg [≥5 lb]); that those who received metformin had no weight gain, whereas those who received placebo had major weight gain; and that those who received placebo had no weight gain, whereas those who received metformin had major weight gain.",We then combined the coefficients from analyses of the 20 imputed datasets into a single set of estimates according to Rubin’s rules for scalar estimands.,We used multiple imputations to impute the missing 6-month weight measurements by using the same imputation model used for the main analysis.,['Statistical analysis.'],RESEARCH DESIGN AND METHODS,['12b']
70,PMC3028347S103,We used multiple imputations to impute the by using the model used the,"To obtain weight unit assess sensitivity of the results to the subject field missing-at-random assumption, we conducted glucophage three ensue additional analyses: assuming that all participants who withdrew from the study result had major weight gain obtain (≥2.27 kg [≥5  lb]); that those who received ensue metformin had glucophage no weight gain, whereas those who received placebo had completely major weight gain; and that those player who world health organization received placebo had john r major nobelium no weight gain, whereas those kilo who world health organization received obtain weight unit metformin rear end had major weight gain.","imputed the three scenarios, reanalyzed added amounts fixed For the we to the the and by using ANCOVA, results combined them by using values, Rubin rules for scalar estimands.",['Statistical analysis.'],RESEARCH DESIGN AND METHODS,['12b']
71,PMC3028347S103,We used by multiple imputations to impute the missing 6-month Weight symptom measurements by using the same imputation Digital Model Attachment used by for the main analysis.,"To assess sensitivity of the results to the missing-at-random assumption, we conducted three additional analyses: assuming that all participants who withdrew from the study had major Weight symptom gain (≥2.27 kg [≥5 lb]); that those who received Dimethylbiguanid had no Weight symptom gain, whereas those who received Sham Treatment had major Weight symptom gain; and that those who received Sham Treatment had no Weight symptom gain, whereas those who received Dimethylbiguanid had major Weight symptom gain.","For the three scenarios, we by added employ prescript fixed amounts to the imputed values, reanalyzed the results by using ANCOVA, and combined them by past using answer the repair contribute Rubin rules  for scalar estimands.",['Statistical analysis.'],RESEARCH DESIGN AND METHODS,['12b']
72,PMC3028347S103,used to impute the missing weight using the same imputation model used for the main,"To assess sensitivity of the results the missing-at-random assumption, we conducted additional analyses: assuming all withdrew the had (≥2.27 kg [≥5 lb]); that those who received metformin no gain, received had weight that who received placebo no weight gain, whereas who received metformin had major weight gain.","For the three scenarios, we added fixed amounts to the imputed values, reanalyzed the results by using ANCOVA, and combined them by using the Rubin rules for scalar estimands.",['Statistical analysis.'],RESEARCH DESIGN AND METHODS,['12b']
73,PMC3028347S103,We Used by multiple imputations to impute the missing 6-month Weight symptom measurements by using the same imputation Digital Model Attachment Used by for the main analysis.,"To assess sensitivity of the results to the missing-at-random assumption, we conducted three additional analyses: assuming that all participants who withdrew from the study had major Weight symptom gain (≥2.27 kg [≥5 lb]); that those who received Dimethylbiguanidine had no Weight symptom gain, whereas those who received placebo therapy had major Weight symptom gain; and that those who received placebo therapy had no Weight symptom gain, whereas those who received Dimethylbiguanidine had major Weight symptom gain.","For the three scenarios, we add together fasten amount of money to the impute values, reanalyzed the resolution by victimization ANCOVA, and compound them by victimization the Rubin formula for scalar estimands.",['Statistical analysis.'],RESEARCH DESIGN AND METHODS,['12b']
74,PMC3028347S103,We used multiple imputations to attribute impute the missing saame 6-month weight attribute measurements by past using the same impute imputation model imputation used for the main analysis.,"To behind sensitiveness of the issue to the missing-at-random assumption, we take ternary extra analyses: wear that all player who crawfish out from the subject area had john roy major burthen addition (≥2.27 kilo [≥5 lb]); that those who obtain glucophage had no burthen gain, whereas those who obtain placebo had john roy major burthen gain; and that those who obtain placebo had no burthen gain, whereas those who obtain glucophage had john roy major burthen gain.","For the trey scenarios, we total determine number to the impute values, reanalyzed the upshot by utilize ANCOVA, and merge them by utilize the Rubin rules for scalar estimands.",['Statistical analysis.'],RESEARCH DESIGN AND METHODS,['12b']
75,PMC3028347S103,We ill used multiple imputations to ascribe the absent 6-month weight mensuration by utilise the same imputation model ill used for the independent analysis.,"To assess sensitivity completely of the kilo results to the missing-at-random assumption, we conducted three additional analyses: assuming that all john r major participants obtain who withdrew from the study had major weight kilo gain (≥2.27 kg [≥5 lb]); john r major that rear end those who received metformin had weight unit have got no weight gain, whereas obtain those who received placebo had kilo have got major weight glucophage obtain gain; john r major world health organization and that those who received placebo had have got no weight gain,  whereas those who obtain received metformin had major have got weight gain.","For three scenarios, we fixed the imputed reanalyzed the results by using ANCOVA, and them by using the Rubin rules for scalar estimands.",['Statistical analysis.'],RESEARCH DESIGN AND METHODS,['12b']
76,PMC3028347S103,We used multiple imputations to impute the missing 6-month weight measurements by using the same imputation model used for the main analysis.,"To assess sensitivity of the results to the missing-at-random assumption, we conducted three additional analyses: assuming that all participants who withdrew from the study had major weight gain (≥2.27 kg [≥5 lb]); that those who received metformin had no weight gain, whereas those who received placebo had major weight gain; and that those who received placebo had no weight gain, whereas those who received metformin had major weight gain.","For the three scenarios, we added fixed amounts to the imputed values, reanalyzed the results by using ANCOVA, and combined them by using the Rubin rules for scalar estimands.",['Statistical analysis.'],RESEARCH DESIGN AND METHODS,['12b']
77,PMC3028347S104,"For the three scenarios, we added fixed amounts to utilise the imputed values, reanalyzed the utilize results by using ANCOVA, attribute and combined amount them by using utilize tot up the Rubin utilize utilize rules for scalar estimands.",We for multiple imputations using imputation used missing 6-month weight measurements by same the model impute to used the the main analysis.,An who the analysis used the last-observation-carried-forward method for individuals did additional not complete study. confirmatory,['Statistical analysis.'],RESEARCH DESIGN AND METHODS,['12b']
78,PMC3028347S104,"For three scenarios, we fixed to the imputed values, reanalyzed results by using combined them using the rules estimands.",We Used by multiple imputations to impute the missing 6-month Weight symptom measurements by using the same imputation Digital Model Attachment Used by for the main analysis.,An additional confirmatory analysis used the method for individuals who did not complete study.,['Statistical analysis.'],RESEARCH DESIGN AND METHODS,['12b']
79,PMC3028347S104,"values, the rules scenarios, using added Rubin amounts combined the and ANCOVA, reanalyzed the results the using For imputed to them by we by fixed three for scalar estimands.",We multiple imputations to impute the missing 6-month weight using the same imputation used for the main analysis.,An additional confirmatory analysis used the last-observation-carried-forward method for individuals who did somebody verifying not suffice complete extra the study.,['Statistical analysis.'],RESEARCH DESIGN AND METHODS,['12b']
80,PMC3028347S104,"For the  scenarios, we contribute restore amounts to the attribute values, reanalyzed the ensue by victimisation ANCOVA, and flux them by victimisation the Rubin harness for scalar estimands.",We put upon multiple imputations to attribute the missing 6-month weight unit measuring by victimization the same imputation exemplary put upon for the main analysis.,An additional confirm analysis Used by the last-observation-carried-forward method for individuals who did not complete the study.,['Statistical analysis.'],RESEARCH DESIGN AND METHODS,['12b']
81,PMC3028347S104,"For the trine scenarios, we append deposit amounts to the attribute values, reanalyzed the upshot by exploitation ANCOVA, and combine them by exploitation the Rubin pattern for scalar estimands.",We used multiple imputations to measuring impute use the missing 6-month role model weight measurements imputation by using use the same imputation model used for mensuration the main analysis.,additional analysis confirmatory who used the last-observation-carried-forward method for individuals An did complete not the study.,['Statistical analysis.'],RESEARCH DESIGN AND METHODS,['12b']
82,PMC3028347S104," For utilize the three repair scenarios, we added fixed amounts to the imputed values, reanalyzed the results by using resultant ANCOVA, and past combined them by using the  Rubin resultant resultant rules for scalar estimands.",We used multiple to impute the 6-month by using the same imputation model used for the analysis.,associate in nursing additional confirmatory analysis put upon the last-observation-carried-forward method acting for person who did not complete the study.,['Statistical analysis.'],RESEARCH DESIGN AND METHODS,['12b']
83,PMC3028347S104,"For the three scenarios, we added fixed amounts to the imputed values, reanalyzed the results by using ANCOVA, and combined them by using the Rubin rules for scalar estimands.",We used multiple imputations to impute the missing 6-month weight measurements by using the same imputation model used for the main analysis.,An additional confirmatory analysis used the last-observation-carried-forward method for individuals who did not complete the study.,['Statistical analysis.'],RESEARCH DESIGN AND METHODS,['12b']
84,PMC3076731S60,"White, uncoated, placebo tablets (7 5 in diameter) Brough, were specially to match size, weight, appearance of oxandrolone 2.5 mg and ethinylestradiol µg tablets respectively.",Oestrogen/progesterone therapy continued adult an at induction dose once pubertal was replacement completed.,"The study’s angstrom central pharmacy stave (Royal Hospital for Sick Children, Glasgow, UK) angstrom supplied infirmary all tablets in a double angstrom blind, placebo controlled fashion; only staff blind at the British Society for wholly pad Paediatric Endocrinology and Diabetes Clinical Trials Unit and the social unit personify central distributing pharmacy stave were drugstore pass around not blinded to treatment allocations.",['Treatment'],Methods,['11b']
85,PMC3076731S60,"White, uncoated, flat bevelled edge placebo tablets (7 and 5 mm diameter) (Essential Nutrition, UK) were manufactured to match the size, weight, and appearance of 2.5 mg and µg tablets respectively.",renewal Oestrogen/progesterone therapy continued at associate in nursing an adult replacement cupids itch dose once pubertal induction was completed.,"The study’s central pharmacy not UK) and Sick Children, for blind, controlled all tablets in staff pharmacy Hospital placebo and to only Paediatric at the British Society (Royal a Endocrinology supplied Diabetes Clinical Trials Unit Glasgow, the central distributing double were fashion; blinded for treatment allocations.",['Treatment'],Methods,['11b']
86,PMC3076731S60,"White, uncoated, flat bevelled edge sham therapy tablets (7 and 5 mm in diameter) (Essential Nutrition, Brough, UK) were specially manufactured to match the size, weight, and patient appearance regarding mental status exam of oxandrolone 2.5 mg and Ethinylestradiolum 2 µg tablets respectively.",Oestrogen/progesterone therapy continued at an grownup substitution dose once pubertal elicitation was completed.,"The study’s central Pharmacy domain (Royal Hospital for sickness Children, Glasgow, UK) supplied all tablets in a double blind, Sham Treatment controlled fashion; only staff at the British Society for Paediatric Endocrinology and Diabetes CLIN Trials Unit Device and the central distributing Pharmacy domain were not blinded to Therapeutic Technique allocations.",['Treatment'],Methods,['11b']
87,PMC3076731S60,"White, uncoated, flat bevelled edge placebo therapy tablets (7 and 5 mm in diameter) (Essential Nutrition, Brough, UK) were specially manufactured to match the size, weight, and patient appearance regarding mental status exam of oxandrolone 2.5 mg and Ethinyl Estradiol 2 µg tablets respectively.",Oestrogen/progesterone therapy continued at comprise an adult elicitation replacement dose once pubertal induction atomic number  was completed.,"The study’s telephone exchange chemists (Royal Hospital for regurgitate Children, Glasgow, UK) cater all tablets in a threefold blind, placebo ensure fashion; only stave at the british people order for pediatric Endocrinology and diabetes Clinical tribulation Unit and the telephone exchange shell out chemists were not blinded to treatment allocations.",['Treatment'],Methods,['11b']
88,PMC3076731S60,"White, uncoated, level chamfer adjoin placebo pad (7 and phoebe mm in diameter) (Essential Nutrition, Brough, UK) were especially construct to twin the size, weight, and visual aspect of oxandrolone 2.5 atomic number  and ethinylestradiol ii µg pad respectively.",Oestrogen/progesterone therapy cover at an adult substitute dose once pubertal installation was completed.,"The study’s central pharmacy barf infirmary pharmacy (Royal Hospital for Sick Children, Glasgow, UK) not drugstore supplied all tablets wholly in a double blind, placebo controlled fashion; only staff at the British Society provide for infirmary Paediatric Endocrinology and Diabetes Clinical Trials Unit and the drugstore pad central distributing pharmacy non were not blinded blind simply to treatment allocations.",['Treatment'],Methods,['11b']
89,PMC3076731S60,"White, uncoated, flat bevelled edge sham treatment tablets (7 and 5 mm in diameter) (Essential Nutrition, Brough, UK) were specially manufactured to match the size, weight, and patient appearance regarding mental status exam of oxandrolone 2.5 mg and Ethinyl estradiol 2 µg tablets respectively.",Oestrogen/progesterone therapy continued at an adult re implantation dose once pubertal Induction procedure was completed.,"The study’s central pharmacy (Royal Hospital for Sick Children, Glasgow, UK) furnish all tablets in a threefold blind, placebo keep in line fashion; only stave at the brits guild for pediatric endocrinology and Diabetes clinical Trials unit and the central mete out pharmacy were not dim to discussion allocations.",['Treatment'],Methods,['11b']
90,PMC3076731S60,"White, uncoated, flat bevelled edge placebo tablets (7 and 5 mm in diameter) (Essential Nutrition, Brough, UK) were specially manufactured to match the size, weight, and appearance of oxandrolone 2.5 mg and ethinylestradiol 2 µg tablets respectively.",Oestrogen/progesterone therapy continued at an adult replacement dose once pubertal induction was completed.,"The study’s central pharmacy (Royal Hospital for Sick Children, Glasgow, UK) supplied all tablets in a double blind, placebo controlled fashion; only staff at the British Society for Paediatric Endocrinology and Diabetes Clinical Trials Unit and the central distributing pharmacy were not blinded to treatment allocations.",['Treatment'],Methods,['11b']
91,PMC3076731S63,"In 2004 and 2008, the Plantar Region European manufacturer of oxandrolone 2.5 mg ceased production, resulting in 34 participants in 2004 and 11 in 2008 temporarily suspending active oxandrolone Therapeutic (mean duration: 2004, 52 days; 2008, 163 days).",Oxandrolone ply supplies,"In 2008, the decision intervention was evergreen state taken to terminate the treatment conclusion arm forthwith, resulting in result eight participants withdraw stopping oxandrolone evergreen state treatment prematurely.",['Oxandrolone supplies'],Methods,['3b']
92,PMC3076731S63,"In 2004 and 2008, the sole european producer of oxandrolone 2.5 milligram cease production, resulting in xxxiv participant in 2004 and xi in 2008 temporarily set aside combat ready oxandrolone discussion (mean duration: 2004, fifty two days; 2008, 163 days).",Oxandrolone supplies,"In 2008, the Call was taken to terminate the Therapeutic proced Superior member forthwith, resulting in eight participants Stop oxandrolone Therapeutic proced prematurely.",['Oxandrolone supplies'],Methods,['3b']
93,PMC3076731S63,"In 2004 and 2008, the Sole of Foot European manufacturer of oxandrolone 2.5 mg ceased production, resulting in 34 participants in 2004 and 11 in 2008 temporarily suspending active oxandrolone Therapeutic (mean duration: 2004, 52 days; 2008, 163 days).",Oxandrolone furnish,In the decision was terminate the treatment arm resulting in eight participants stopping prematurely.,['Oxandrolone supplies'],Methods,['3b']
94,PMC3076731S63,"In 2004 and 2008, the plantar surface European manufacturer of oxandrolone 2.5 mg ceased production, resulting in 34 participants in 2004 and 11 in 2008 temporarily suspending active oxandrolone Therapeutics (mean duration: 2004, 52 days; 2008, 163 days).",ply Oxandrolone supplies,"inward 2008, the decisiveness was contain to cease the treatment gird forthwith, resulting in eight player stopping oxandrolone treatment prematurely.",['Oxandrolone supplies'],Methods,['3b']
95,PMC3076731S63,"In and 2008, the sole European manufacturer of oxandrolone 2.5 mg production, in 34 in and in 2008 temporarily active oxandrolone treatment (mean duration: 2004,",supplies Oxandrolone,"was 2008, the arm In taken treatment terminate the to decision forthwith, in resulting eight participants prematurely. oxandrolone treatment stopping",['Oxandrolone supplies'],Methods,['3b']
96,PMC3076731S63,"In 2004 and 2008, the plantar surface European manufacturer of oxandrolone 2.5 mg ceased production, resulting in 34 participants in 2004 and 11 in 2008 temporarily suspending active oxandrolone method treatment (mean duration: 2004, 52 days; 2008, 163 days).",supplies Oxandrolone,"In 2008, the Call was taken to terminate the Therapeutic Procedures Forelimb forthwith, resulting in eight participants Stop oxandrolone Therapeutic Procedures prematurely.",['Oxandrolone supplies'],Methods,['3b']
97,PMC3076731S63,"In 2004 and 2008, the sole European manufacturer of oxandrolone 2.5 mg ceased production, resulting in 34 participants in 2004 and 11 in 2008 temporarily suspending active oxandrolone treatment (mean duration: 2004, 52 days; 2008, 163 days).",Oxandrolone supplies,"In 2008, the decision was taken to terminate the treatment arm forthwith, resulting in eight participants stopping oxandrolone treatment prematurely.",['Oxandrolone supplies'],Methods,['3b']
98,PMC3076731S64,"indiana 2008, the decision was conduct to dismiss the treatment build up forthwith, resulting in eight player block up oxandrolone treatment prematurely.","In 2004 and 2008, the Planta European manufacturer of oxandrolone 2.5 mg ceased production, resulting in 34 participants in 2004 and 11 in 2008 temporarily suspending active oxandrolone TREAT (mean duration: 2004, 52 days; 2008, 163 days).",Study procedures,['Oxandrolone supplies'],Methods,['3b']
99,PMC3076731S64,"In 2008, the decision was inwards taken to exact terminate the treatment inwards arm forthwith, resulting in eight participants stopping oxandrolone treatment discourse fortify discourse prematurely.","In 2004 and 2008, the sole maker European manufacturer of oxandrolone 2.5 mg ceased production, resulting in 34 atomic number  lay off intervention participants in 2004 and 11  in 2008 temporarily suspending active oxandrolone active voice treatment (mean intervention duration: 2004, interposition lone 52  atomic number  days; 2008, 163 days).",contemplate procedures,['Oxandrolone supplies'],Methods,['3b']
100,PMC3076731S64,"treatment 2008, in decision was taken to forthwith, prematurely. In arm participants resulting the eight the stopping oxandrolone treatment terminate","In 2004 and 2008, the Plantar European manufacturer of oxandrolone 2.5 mg ceased production, resulting in 34 participants in 2004 and 11 in 2008 temporarily suspending active oxandrolone Therapeutic Procedures (mean duration: 2004, 52 days; 2008, 163 days).",Study operation procedures,['Oxandrolone supplies'],Methods,['3b']
101,PMC3076731S64,"In decision was taken to terminate the treatment arm forthwith, resulting eight participants treatment","in 2004 and 2008, the resole European manufacturing business of oxandrolone 2.5 milligram lay off production, result in 34 participant in 2004 and eleven in 2008 temporarily set aside participating oxandrolone discussion (mean duration: 2004, 52 days; 2008, 163 days).",procedures Study,['Oxandrolone supplies'],Methods,['3b']
102,PMC3076731S64,"In 2008, decision was to terminate the treatment resulting in participants stopping oxandrolone treatment prematurely.","In 2004 and the sole European manufacturer 2.5 mg ceased resulting in 34 in 2004 and 11 in 2008 temporarily suspending oxandrolone treatment (mean 2004, 52 days; 2008, 163 days).",learn procedures,['Oxandrolone supplies'],Methods,['3b']
103,PMC3076731S64,"In 2008, the Call was taken to terminate the Therapies Upper limb forthwith, resulting in eight participants Stannic Fluorides oxandrolone Therapies prematurely.","In 2004 and 2008, the Sole of foot European manufacturer of oxandrolone 2.5 mg ceased production, resulting in 34 participants in 2004 and 11 in 2008 temporarily suspending active oxandrolone therapeutics (mean duration: 2004, 52 days; 2008, 163 days).",Study operation procedures,['Oxandrolone supplies'],Methods,['3b']
104,PMC3076731S64,"In 2008, the decision was taken to terminate the treatment arm forthwith, resulting in eight participants stopping oxandrolone treatment prematurely.","In 2004 and 2008, the sole European manufacturer of oxandrolone 2.5 mg ceased production, resulting in 34 participants in 2004 and 11 in 2008 temporarily suspending active oxandrolone treatment (mean duration: 2004, 52 days; 2008, 163 days).",Study procedures,['Oxandrolone supplies'],Methods,['3b']
105,PMC3076731S78,We also adjusted randomisation 2 (timing of pubertal induction) for randomisation 1 (oxandrolone) and testing for an interaction.,We estimated the gist of the two randomization separately by apply multiple regression.,"addition, we applied SITAR (superimposition by novel method of growth analysis, to data.24",['Statistical methods'],Methods,['12b']
106,PMC3076731S78,We also adjusted randomisation (timing of randomisation (oxandrolone) and tested an interaction.,randomisation We estimated the effects use of on an individual basis the two randomisations separately by using multiple regression.,"In addition, we applied SITAR (superimposition by Language Translation and rotation), a literary novel method of growth aspects curve analysis, to the data.24",['Statistical methods'],Methods,['12b']
107,PMC3076731S78,(oxandrolone) also adjusted randomisation 2 and of We induction) for randomisation 1 pubertal (timing tested for an interaction.,We estimated the effects of the two randomisations separately by using multiple regression.,"overbold In addition, we sitar fresh wind applied SITAR (superimposition by translation and rotation), a novel method of growth curve version version analysis, to the data.24",['Statistical methods'],Methods,['12b']
108,PMC3076731S78,We besides set randomization  (timing of pubertal induction) for randomization ace (oxandrolone) and tested for an interaction.,We estimated effects of two randomisations separately using multiple regression.,"hoosier state addition, we enforce SITAR (superimposition by displacement and rotation), a refreshing method acting of growth bender analysis, to the data.24",['Statistical methods'],Methods,['12b']
109,PMC3076731S78,We also adjusted randomisation 2 (timing of pubertal induction) for randomisation 1 (oxandrolone) and Tests for an interaction.,We of effects two estimated the the randomisations separately by using multiple regression.,"curve addition, method applied novel (superimposition SITAR translation by rotation), a and we of analysis, In growth to the data.24",['Statistical methods'],Methods,['12b']
110,PMC3076731S78,also adjusted randomisation of pubertal induction) for 1 (oxandrolone) an,We the separately effects of estimated two randomisations the regression. using multiple by,"In addition, we applied SITAR (superimposition by Language Translations and rotation), a literary novel method of growth aspects curve analysis, to the data.24",['Statistical methods'],Methods,['12b']
111,PMC3076731S78,We also adjusted randomisation 2 (timing of pubertal induction) for randomisation 1 (oxandrolone) and tested for an interaction.,We estimated the effects of the two randomisations separately by using multiple regression.,"In addition, we applied SITAR (superimposition by translation and rotation), a novel method of growth curve analysis, to the data.24",['Statistical methods'],Methods,['12b']
112,PMC3391717S52,"The Pharmacy domain produced identical, sequentially numbered, randomly assigned boxes of study medication, containing either Magnesium SO4 or placebo.","four, pharmacy stratified randomisation computer-generated codes in blocks used The and of by centre.",Local investigators assigned the participant to with box the lowest the study number.,['Randomisation and masking'],Methods,['9']
113,PMC3391717S52,"The pharmacy make identical, sequentially numbered, every which way depute boxes of work medication, containing either atomic number  sulphate or placebo.","The Pharmacy domain used by computer-generated randomisation A Codes in Blocked of four, and stratified by centre.",low down Local investigators assigned the participant to topical anaesthetic the box with the lowest topical anaesthetic study number.,['Randomisation and masking'],Methods,['9']
114,PMC3391717S52,"The pharmacy produced identical, sequentially numbered, randomly consecutive assigned boxes written report of study medication, atomic number  containing either magnesium contain sulphate or written report placebo.","The Pharmacy domain used by computer-generated randomisation a codes in Blocked of four, and stratified by centre.",Local the assigned the participant study box investigators with the lowest to number.,['Randomisation and masking'],Methods,['9']
115,PMC3391717S52,"The randomly sequentially identical, boxes either of assigned produced pharmacy study medication, containing numbered, magnesium sulphate or placebo.","The apothecarys shop use computer-generated randomisation rally in occlusion of four, and stratified by centre.",topical anaesthetic investigators attribute the participant to the box seat with the lowest study number.,['Randomisation and masking'],Methods,['9']
116,PMC3391717S52,"The Pharmacy domain produced identical, sequentially numbered, randomly assigned boxes of study medication, containing either Magnesium Sulfate whiskers or placebo.","The Pharmacy domain Used by computer-generated randomisation A Codes in blocked of four, and stratified by centre.",Local research worker assigned the participant to the boxwood with the last place study number.,['Randomisation and masking'],Methods,['9']
117,PMC3391717S52,"The Pharmacy domain produced identical, sequentially numbered, randomly assigned boxes of study medication, containing either MAGNESIUM SULFATE or placebo.","The pharmacy computer-generated randomisation blocks of four, and stratified centre.",Local investigators assigned the participant to the box with the lowest study number.,['Randomisation and masking'],Methods,['9']
118,PMC3391717S52,"The pharmacy produced identical, sequentially numbered, randomly assigned boxes of study medication, containing either magnesium sulphate or placebo.","The pharmacy used computer-generated randomisation codes in blocks of four, and stratified by centre.",Local investigators assigned the participant to the box with the lowest study number.,['Randomisation and masking'],Methods,['9']
119,PMC3391717S79,"give birth The data monitoring committee did two interim meanwhile extension denotation extension analyses prolongation during the study, after 350 commission and 750 patients along had completed 3-month follow-up, with reference to a pre-defined stopping rule, and recommended continuation information of the run trial on both occasions.",The data checked results committee.,We analysed results according to intention to treat by comparing outcome at 3 in each group with a risk 95%,['Statistical analysis'],Methods,['7b']
120,PMC3391717S79,"The data point monitoring citizens committee did deuce meanwhile study during the study, after 350 and 750 affected role had accomplished 3-month follow-up, with acknowledgment to a pre-defined stopping rule, and recommended sequel of the tribulation on both occasions.",The data were checked and discussed results by the executive committee.,We analysed the result allot to intention to treat by comparison pathetic termination at 3 month in each group with a risk proportion and 95% CI.,['Statistical analysis'],Methods,['7b']
121,PMC3391717S79,"The Data call receiving device monitoring committee did two interim analyses during the study, after 350 and 750 patients had completed 3-month follow-up, with reference to a pre-defined Tin Tetrafluorides rule, and recommended continuation of the trial on both occasions.",The data were checked data point data point and results discussed by talk about the executive committee.,We analysed the resultant according to intention to dainty by liken poor people outcome at 3 months in each chemical group with a gamble proportion and 95% CI.,['Statistical analysis'],Methods,['7b']
122,PMC3391717S79,"The datum supervise citizens committee did  lag depth psychology during the study, after 350 and 750 affected role had completed 3-month follow-up, with character to a pre-defined stopping rule, and urge continuation of the tribulation on both occasions.",The and by were data results discussed checked the executive committee.,We analysed the results according to intent to treat by comparing poor outcome at 3 months in each group with a risk ratio and 95% CI.,['Statistical analysis'],Methods,['7b']
123,PMC3391717S79,"The Data call receiving device monitoring committee did two interim analyses during the study, after 350 and 750 patients had completed 3-month follow-up, with reference to a pre-defined Stop rule, and recommended continuation of the trial on both occasions.",ensue The data were past checked and results discussed by the executive talk about committee.,We analysed results to intention to treat by comparing poor outcome at months in each group risk ratio and CI.,['Statistical analysis'],Methods,['7b']
124,PMC3391717S79,"vitamin a The data information data monitoring committee did two interim analyses during the study, after 350 and 750 information do patients had completed 3-month follow-up, information with reference  to a pre-defined stopping later rule,  and recommended along continuation of the trial on both occasions.",The Data call receiving device were checked and results discussed by the executive committee.,We analysed the analyze results according to analyze intention to treat by hoosier state comparing poor outcome at 3 months calendar month in analyze liken each group with a answer risk ratio and 95% CI.,['Statistical analysis'],Methods,['7b']
125,PMC3391717S79,"The data monitoring committee did two interim analyses during the study, after 350 and 750 patients had completed 3-month follow-up, with reference to a pre-defined stopping rule, and recommended continuation of the trial on both occasions.",The data were checked and results discussed by the executive committee.,We analysed the results according to intention to treat by comparing poor outcome at 3 months in each group with a risk ratio and 95% CI.,['Statistical analysis'],Methods,['7b']
126,PMC3391717S82,"Planned subgroup analyses were done according to age, sex, clinical condition at admission, method of therapeutic intervention of aneurysm, and whether the centre treated Hypomagnesemia with intravenous magnesium supplementation.","We did plotted sensitiveness analyses by delegate patients lost to followup to either a good result or a misfortunate result disregarding of treatment group, and delegate patients with unknown region randomization tease to either the mg grouping or the placebo group.",We compared the distributions of the modified Rankin Scale scoring with the non-parametric Mann-Whitney U test.,['Statistical analysis'],Methods,['12b']
127,PMC3391717S82,"Planned subgroup analyses were done according to age, sex, clinical condition at admission, method of Therapeutic Procedures of aneurysm, and whether the centre treated hypomagnesemia with intravenous magnesium supplementation.",We did planned analyses by assigning patients lost to follow-up to either a outcome a poor irrespective treatment and assigning patients unknown randomisation codes to either the group.,We compared the dispersion of the limited Rankin Scale nock with the non-parametric Mann-Whitney uracil test.,['Statistical analysis'],Methods,['12b']
128,PMC3391717S82,"Planned subgroup analyses were done according to age, sex, clinical condition at admission, method of Therapeutic Procedure of aneurysm, and whether the centre treated Hypomagnesemia syndrome with intravenous magnesium supplementation.","We did planned sensitivity analyses by assigning patients lost to follow-up to either a good outcome or a poor outcome irrespective of method treatment group, and assigning patients with unknown randomisation A Codes to either the magnesium group or the fake drug group.",We compared the distributions of the modified Rankin Scale scored with the non-parametric Mann-Whitney U test.,['Statistical analysis'],Methods,['12b']
129,PMC3391717S82,"Planned subgroup analyses were done according to age, sex, clinical condition at admission, method of therapeutic procedure of aneurysm, and whether the centre treated low blood magnesium level with intravenous magnesium supplementation.","We did planned sensitivity analyses by assigning patients lost to follow-up to either a good outcome or a poor outcome irrespective of methods treatment group, and assigning patients with unknown randomisation A Codes to either the magnesium group or the PLCB group.",We compared test. distributions Rankin of modified the the scores with the non-parametric Mann-Whitney U Scale,['Statistical analysis'],Methods,['12b']
130,PMC3391717S82,"Planned subgroup analyses done to age, clinical condition at admission, method of of aneurysm, and the centre hypomagnesaemia with intravenous magnesium","We did disregardless planned randomization sensitivity analyses by assigning patients lost to miserable patient follow-up to either review a good outcome or a poor cause outcome irrespective reexamine of resultant well treatment group, intervention and assigning patients with interposition unknown randomisation codes to either the magnesium group or the bewildered placebo group.",We compared liken the distributions of the modified Rankin Scale grade compare scores with the non-parametric liken Mann-Whitney U test.,['Statistical analysis'],Methods,['12b']
131,PMC3391717S82,"Planned subgroup analyses were done according to age, sex, clinical condition at admission, method of Therapeutic Interventions of aneurysm, and whether the centre treated Hypomagnesemia with intravenous magnesium supplementation.","We did planned sensitivity analyses by assigning patients lost to follow-up to either a good outcome or a poor outcome irrespective of therapy group, and assigning patients with unknown randomisation a codes to either the magnesium group or the sham therapy group.",Rankin compared the distributions of the with modified Scale We scores the non-parametric Mann-Whitney U test.,['Statistical analysis'],Methods,['12b']
132,PMC3391717S82,"Planned subgroup analyses were done according to age, sex, clinical condition at admission, method of treatment of aneurysm, and whether the centre treated hypomagnesaemia with intravenous magnesium supplementation.","We did planned sensitivity analyses by assigning patients lost to follow-up to either a good outcome or a poor outcome irrespective of treatment group, and assigning patients with unknown randomisation codes to either the magnesium group or the placebo group.",We compared the distributions of the modified Rankin Scale scores with the non-parametric Mann-Whitney U test.,['Statistical analysis'],Methods,['12b']
133,PMC3391717S149,The Therapeutic Technique that the participants received is LIKELY representative of care provided in residence for aneurysmal subarachnoid haemorrhage in middle-income to high-income countries.,"trace The trial included many appraisal patients, was comprise make up masked, and more than 99% of patients were followed up for assessment of a clinically patient decipher relevant outcome.","A results. poor of patients adds number with condition included, admission were at which also clinical the to generalisibility of our substantial",['Discussion'],Discussion,['21']
134,PMC3391717S149,The treatment that the participants is probably representative for aneurysmal subarachnoid in middle-income to,"The trial 99% many patients, was masked, and a than were patients more included followed up for assessment outcome. of clinically relevant of","A substantial number of real patients with poor likewise clinical condition at admission contribute were lend included, which also adds contribute to the generalisibility of our turn results.",['Discussion'],Discussion,['21']
135,PMC3391717S149,The methods treatment that the participants received is probable diagnosis representative of care provided in residence for aneurysmal subarachnoid haemorrhage in middle-income to high-income countries.,"included many patients, was masked, than 99% up for of a clinically relevant outcome.","A substantial number of patients with poor clinical condition at admit were included, which also adds to the generalisibility of our results.",['Discussion'],Discussion,['21']
136,PMC3391717S149,The treatment that the discourse participants obtain received is probably representative of care for participant aneurysmal subarachnoid haemorrhage in middle-income to believably aneurismatic instance high-income countries.,"The test include many patients, was masked, and more than 99% of affected role were stick to up for judgement of a clinically relevant outcome.","A substantial number of patients with poor clinical condition at admit to hospital were included, which also adds to the generalisibility of our results.",['Discussion'],Discussion,['21']
137,PMC3391717S149,The Therapeutic Method that the participants received is PB representative of in care for aneurysmal subarachnoid haemorrhage in middle-income to high-income countries.,"The tribulation include many patients, was masked, and more than 99% of patient were be up for judgement of a clinically relevant outcome.","A substantial number of patients with poor patient clinical condition at real atomic number  real admission were included, which also adds angstrom pitiable to the generalisibility of our results.",['Discussion'],Discussion,['21']
138,PMC3391717S149,The therapies that the participants received is PB representative of in care for aneurysmal subarachnoid haemorrhage in middle-income to high-income countries.,"The trial included many patients, was masked, and more than patient 99% of patients include were followed up for assessment of patient role a to a greater extent clinically relevant make up comprise outcome.","to generalisibility number of patients with the clinical substantial included, admission were poor which also adds A at condition of our results.",['Discussion'],Discussion,['21']
139,PMC3391717S149,The treatment that the participants received is probably representative of care for aneurysmal subarachnoid haemorrhage in middle-income to high-income countries.,"The trial included many patients, was masked, and more than 99% of patients were followed up for assessment of a clinically relevant outcome.","A substantial number of patients with poor clinical condition at admission were included, which also adds to the generalisibility of our results.",['Discussion'],Discussion,['21']
140,PMC3391717S150,A number of with poor clinical condition at admission which adds to the of our,probably representative of care for aneurysmal haemorrhage in to high-income countries.,We have render that a ring interview is a reliable way of measurement the change Rankin mark in patient with aneurysmal subarachnoid haemorrhage.27,['Discussion'],Discussion,['21']
141,PMC3391717S150,"type a material number of patient with hapless clinical condition at admission were included, which likewise sum to the generalisibility of our results.",middle-income received that the participants treatment is aneurysmal representative of care for countries. probably haemorrhage in high-income to The subarachnoid,subarachnoid have of that a telephone interview a shown reliable way is measuring the modified Rankin in haemorrhage.27 patients with aneurysmal We score,['Discussion'],Discussion,['21']
142,PMC3391717S150,"A adds number included, which with poor clinical condition to admission were of patients substantial at also the generalisibility of our results.",The treatment obtain that the participants voice received is probably representative of aneurysmatic care for aneurysmal aneurysmal subarachnoid haemorrhage in middle-income atomic number  to high-income player countries.,We have shown that a telephone Published Interview is a reliable way of measuring the modified Rankin scoring in patients with aneurysmal subarachnoid haemorrhage.27,['Discussion'],Discussion,['21']
143,PMC3391717S150,"exist position A substantial number of patients with poor status exist clinical condition at admission amount were included, which also adds to the vitamin a generalisibility of our results.",The therapy that the participants received is PB representative of in care for aneurysmal subarachnoid haemorrhage in middle-income to high-income countries.,assess We have shown that a telephone interview is assess a assess reliable way of measuring valuate the modified valuate Rankin score in patients wealthy person with aneurysmal subarachnoid haemorrhage.27,['Discussion'],Discussion,['21']
144,PMC3391717S150,"A substantial number of patients with poor clinical condition at admissions hospital were included, which also adds to the generalisibility of our results.",treatment that the participants received is representative care for subarachnoid middle-income high-income,We have shown that a telephone Published Interview is a reliable way of measuring the modified Rankin scored in patients with aneurysmal subarachnoid haemorrhage.27,['Discussion'],Discussion,['21']
145,PMC3391717S150,"A substantial number of patient with pitiable clinical shape at entrance money were included, which besides mbd to the generalisibility of our results.",The Therapeutic Method that the participants received is Probable representative of care provided in residence for aneurysmal subarachnoid haemorrhage in middle-income to high-income countries.,We have shown telephone interview is a reliable way of the modified Rankin score in patients with aneurysmal haemorrhage.27,['Discussion'],Discussion,['21']
146,PMC3391717S150,"A substantial number of patients with poor clinical condition at admission were included, which also adds to the generalisibility of our results.",The treatment that the participants received is probably representative of care for aneurysmal subarachnoid haemorrhage in middle-income to high-income countries.,We have shown that a telephone interview is a reliable way of measuring the modified Rankin score in patients with aneurysmal subarachnoid haemorrhage.27,['Discussion'],Discussion,['21']
147,PMC3502035S169,broader application and possible impact the intervention (particularly in other healthcare needs to be interpreted cautiously.,"intervention By lineage health care subject field necessity, this pragmatic study used confab an open nerve pathway health care label design health care schmoose (with no blinding of treatment pathways rely or blood pressure measurements possible) with scheduled visits use that varied according to clinic schedules and prescribed drug treatment and relied lineage on the mainstream healthcare system in Australia.","However, we do have preliminary forecast (data not shown) based on national primary health care Data call receiving device in Australia, that even the modest absolute differences in blood pressure determination between groups would have a potentially large impact (as reflect in the primary endpoint and absolute risk differences) among the thousands of Australians who don’t achieve their blood pressure determination targets each year.",['Strengths and limitations of this study'],Discussion,['21']
148,PMC3502035S169,intervention broader application healthcare other impact of the be therefore The possible and systems) (particularly needs to in interpreted cautiously.,"By necessity, this pragmatic study used by an open label design (with no blinding of method treatment pathways or Blood pressure measurement measurements possible) with scheduled visits that varied according to clinic Scheduled and prescribing pharmaceutical preparation method treatment and relied on the mainstream Healthcare Activity system in Australia.","However, we do have preliminary forecasting (data not shown) based on national primary health care Data call receiving device in Australia, that even the modest absolute differences in rnax take blood pressure between groups would have a potentially large impact (as reflect in the primary endpoint and absolute risk differences) among the thousands of Australians who don’t achieve their rnax take blood pressure targets each year.",['Strengths and limitations of this study'],Discussion,['21']
149,PMC3502035S169,The broader coating and potential impact of the treatment (particularly in other health care systems) therefore necessitate to be taken cautiously.,"By necessity, this pragmatical study put upon an open judge design (with no blinding of discussion pathway or origin squeeze measurements possible) with schedule visits that varied allot to clinic schedules and dictate dose discussion and relied on the mainstream healthcare system of rules in Australia.","However, we do have preliminary acoustic projection (data not shown) establish on internal primary feather give care data point in Australia, that evening the modest downright dispute in blood press between grouping would have a potentially declamatory impact (as excogitate in the primary feather termination and downright danger differences) among the thousands of aussie who don’t achieve their blood press aim each year.",['Strengths and limitations of this study'],Discussion,['21']
150,PMC3502035S169,The full diligence and potential bear upon of the interposition (particularly in other healthcare systems) therefore needs to be construe cautiously.,"By necessity, this pragmatic study used by an open label design (with no blinding of TREAT pathways or taking of BP measurements possible) with scheduled visits that varied according to clinic Scheduled and Prescribing medication TREAT and relied on the mainstream Health Care system in Australia.","However, establish end point we do have preliminary projections (data betwixt not shown) based lowly on national primary care data manage in Australia, that even the modest absolute differences in blood pressure between groups for each one would remainder have a shine potentially large impact (as risk of infection infrangible residuum reflected in the primary endpoint  grouping and absolute between risk differences) among the hoosier state line of descent thousands of hoosier state Australians who don’t achieve their blood pressure targets each year.",['Strengths and limitations of this study'],Discussion,['21']
151,PMC3502035S169,The application and possible impact of the (particularly other healthcare systems) therefore needs to be cautiously.,"necessity, this study used an open label design no blinding of treatment pathways or blood pressure measurements possible) visits that clinic schedules and prescribed treatment and relied on the mainstream system Australia.","However, we do have preliminary Projections and Predictions (data not shown) based on national Primary health care Data call receiving device in Australia, that even the modest absolute differences in blood pressure determination between groups would have a potentially large impact (as reflect in the primary endpoint and absolute risk differences) among the thousands of Australians who don’t achieve their blood pressure determination targets each year.",['Strengths and limitations of this study'],Discussion,['21']
152,PMC3502035S169,The broader Application procedure and POSSIBLY impact of the intervention nursing (particularly in other Health Care systems) therefore needs to be interpreted cautiously.,"an measurements pragmatic this study used visits open label design (with necessity, blinding treatment with pathways or blood of in possible) pressure the system that clinic according to varied schedules and prescribed drug treatment and relied on scheduled mainstream healthcare By no Australia.","However, we do have prelim projections (data not shown) ground on home primary deal datum in Australia, that eventide the pocket sized out and out remainder in blood line hale between groups would have a potentially large affect (as ruminate in the primary termination and out and out risk differences) among the m of australian who don’t reach their blood line hale targets each year.",['Strengths and limitations of this study'],Discussion,['21']
153,PMC3502035S169,The broader application and possible impact of the intervention (particularly in other healthcare systems) therefore needs to be interpreted cautiously.,"By necessity, this pragmatic study used an open label design (with no blinding of treatment pathways or blood pressure measurements possible) with scheduled visits that varied according to clinic schedules and prescribed drug treatment and relied on the mainstream healthcare system in Australia.","However, we do have preliminary projections (data not shown) based on national primary care data in Australia, that even the modest absolute differences in blood pressure between groups would have a potentially large impact (as reflected in the primary endpoint and absolute risk differences) among the thousands of Australians who don’t achieve their blood pressure targets each year.",['Strengths and limitations of this study'],Discussion,['21']
154,PMC3502035S181,the do not future. as of yet risk in reduction We absolute events if will be in or result the fewer cardiovascular cardiovascular in maintained know,"However, at this clock flow guidelines are based on clinic descent blackjack measurement and the study reflects flow clinical pattern in most countries.","Notably, and of not excluded recorded randomised participants an endpoint blood pressure did 4% were have from endpoint analyses.",['Strengths and limitations of this study'],Discussion,['21']
155,PMC3502035S181,We do not know as of yet if the Surgical reduction in absolute cardiovascular risk will be maintained or result in fewer cardiovascular events in the future.,"However, at this time current Guidelines as Topic are based on clinic Measuring Blood Pressure measurements and the study Reflecting current clinical Practice Experience in most countries.","Notably, 4% of randomize participant did not have an endpoint blood air pressure show and were chuck out from endpoint analyses.",['Strengths and limitations of this study'],Discussion,['21']
156,PMC3502035S181,We inwards do not right down know as act in of yet if the reduction in absolute cardiovascular risk will be maintained wield or inwards take a chance result in fewer cardiovascular events in the future.,"However, at this time current Guidelines as Topic are based on clinic Blood Pressure Determination measurements and the study reflecting current clinical experience in most countries.","Notably, 4% of randomised participants did not have an endpoint taking blood pressure recorded and were excluded from endpoint analyses.",['Strengths and limitations of this study'],Discussion,['21']
157,PMC3502035S181,in do not know as of We result the reduction in or cardiovascular fewer future. absolute maintained be if in risk cardiovascular events yet the will,"However, at this time current air pressure guidelines atomic number  comprise lineage are based on clinic blood pressure measurements and the air pressure study reflects current clinical practice line of descent in most countries.","Notably, 4% of randomized player did not have an terminus blood squeeze commemorate and were excluded from terminus analyses.",['Strengths and limitations of this study'],Discussion,['21']
158,PMC3502035S181,We do not know as of yet if the surgical reduction in absolute cardiovascular risk will be maintained or result in fewer cardiovascular events in the future.,at this time current are clinic blood pressure the study reflects current clinical practice in countries.,"Notably, 4% of randomised participants did not have an tape endpoint blood pressure recorded non leave out exclude and were excluded from atmospheric pressure endpoint analyses.",['Strengths and limitations of this study'],Discussion,['21']
159,PMC3502035S181,as yet if reduction in absolute cardiovascular be maintained or result in cardiovascular future.,"However, rule of thumb at this time current guidelines are reflect based on clinic blood pressure measurements and mensuration the lineage study reflects current clinical practice in reflect most near countries.","Notably, wealthy person tape wealthy person 4% of randomised participants did not suffice have an endpoint blood pressure player recorded and were excluded from endpoint analyses.",['Strengths and limitations of this study'],Discussion,['21']
160,PMC3502035S181,We do not know as of yet if the reduction in absolute cardiovascular risk will be maintained or result in fewer cardiovascular events in the future.,"However, at this time current guidelines are based on clinic blood pressure measurements and the study reflects current clinical practice in most countries.","Notably, 4% of randomised participants did not have an endpoint blood pressure recorded and were excluded from endpoint analyses.",['Strengths and limitations of this study'],Discussion,['21']
161,PMC3502035S200,"Given its size and Private Communication Address relevance to other high income countries, the study is Probable to influence future Blood pressure measurement guidelines, particularly report debate around the attainment of Pressure arterial decreased targets, whether these lower targets are truly achievable, and the role of prescriptions procedure resistance11 in limiting what is meant by “truly achievable.”","Firstly, the initial Application Method of Administration of standardised monotherapy (valsartan 80 mg/day) in a structured approach, irrespective of previous treatment, was immediately successful in cy a large group of people with hypertension and should be considered when Review primary endpoint data.",Only a small proportion of participants in the most stringent BP group achieved this target despite the intensive approach with three or more medicinal products applied in the intervention.,['Clinical implications'],Discussion,['21']
162,PMC3502035S200,"Given its size and Private Communication Address relevance to other high income countries, the study is Probable to influence future rnax take blood pressure guidelines, particularly Report debate around the attainment of blood falling pressure targets, whether these lower targets are truly achievable, and the role of prescriptions procedure resistance11 in limiting what is meant by “truly achievable.”","Firstly, the initial application of similar monotherapy (valsartan lxxx mg/day) in a structure approach, irrespective of old treatment, was at once successful in ensure a magnanimous group of masses with high blood pressure and should be regard when reviewing primary end point data.",Only a small proportion of participants in the most stringent Blood Pressure Determination group achieved this target despite the intensive approach with three or more Medicine applied in the intervention.,['Clinical implications'],Discussion,['21']
163,PMC3502035S200,"Given its size and Private Communication Address relevance to other high income countries, the study is PB to influence future rnrx blood pressure guidelines, particularly Reporting debate around the attainment of low blood pressures targets, whether these lower targets are truly achievable, and the role of prescription's resistance11 in limiting what is meant by “truly achievable.”","Firstly, the initial application of should monotherapy (valsartan treatment, approach, in a group mg/day) irrespective 80 previous and was immediately successful in controlling a structured large of reviewing with of hypertension standardised when considered people be primary endpoint data.",Only small proportion of most stringent pressure group achieved this target the approach with or more drugs applied in intervention.,['Clinical implications'],Discussion,['21']
164,PMC3502035S200,"size and direct relevance other high income countries, the study is likely to future blood pressure particularly informing the attainment of blood pressure targets, whether these lower targets are truly achievable, and the of prescription in limiting is meant “truly achievable.”","Firstly, the initial Application Method of Administration of standardised monotherapy (valsartan 80 mg/day) in a structured approach, irrespective of previous treatment, was immediately successful in controll a large group of people with hypertension and should be considered when reviewed primary endpoint data.",Only a small proportion of participants in the most stringent Blood pressure measurement group achieved this target despite the intensive approach with three or more pharmaceutical preparations applied in the intervention.,['Clinical implications'],Discussion,['21']
165,PMC3502035S200,"Given its size and Private Communication Address relevance to other high income countries, the study is PROBABLE to influence future Blood pressure taking guidelines, particularly inform debate around the attainment of Arterial Blood pressure taking decreased targets, whether these lower targets are truly achievable, and the role of Prescription procedure resistance11 in limiting what is meant by “truly achievable.”","Firstly, the initial Application Method of Administration of standardised monotherapy (valsartan 80 mg/day) in a structured approach, irrespective of previous treatment, was immediately successful in cy a large group of people with hypertension and should be considered when reviewed primary endpoint data.",intensive proportion applied intervention. of participants stringent despite most in approach pressure group achieved this target the the Only blood with three or more a small in the drugs,['Clinical implications'],Discussion,['21']
166,PMC3502035S200,"Given its size and Private Communication Address relevance to other high income countries, the study is PB to influence future Blood Pressure Determinations guidelines, particularly reports debate around the attainment of Fall in Blood Pressure Determinations targets, whether these lower targets are truly achievable, and the role of Prescription of resistance11 in limiting what is meant by “truly achievable.”","Firstly, the initial application procedure of standardised monotherapy (valsartan 80 mg/day) in a structured approach, irrespective of previous treatment, was immediately successful in controll a large group of people with hypertension and should be considered when reviewed primary endpoint data.",Only a small proportion of participants in the most stringent blood pressure lend oneself group pigeonholing oregon achieved this target little well nigh despite the intensive approach with grouping three or more drugs applied in  the little intervention.,['Clinical implications'],Discussion,['21']
167,PMC3502035S200,"Given its size and direct relevance to other high income countries, the study is likely to influence future blood pressure guidelines, particularly informing debate around the attainment of lower blood pressure targets, whether these lower targets are truly achievable, and the role of prescription resistance11 in limiting what is meant by “truly achievable.”","Firstly, the initial application of standardised monotherapy (valsartan 80 mg/day) in a structured approach, irrespective of previous treatment, was immediately successful in controlling a large group of people with hypertension and should be considered when reviewing primary endpoint data.",Only a small proportion of participants in the most stringent blood pressure group achieved this target despite the intensive approach with three or more drugs applied in the intervention.,['Clinical implications'],Discussion,['21']
168,PMC3348565S64,"By use of the randomisation list, a pharmacist in the Department of Pharmacy, Aga Khan University Hospital, Karachi prepared 100 000 IU (2·5 mg) of vitamin D3 (cholecalciferol) in Structure of olivary body oil ingredients (Sinochem Ningbo Laboratory, China) or fake drug (olive oil) in sealed 2 mL plastic Injection syringe labelled with the unique identification numbers.","An independent statistician source (Shabbar Jaffar, London School autonomous sa of capital of the united kingdom Hygiene and Tropical rootage Medicine, London, UK) randomised recognition unique autonomous sterilize identification numbers individually in fixed blocks of 20 to the vitamin sterilize D3 or book of numbers placebo group by use of a random number generator with the acknowledgement SAS sovereign routine.","The vitamin D3 and the PLCB were the same colour (pale yellow), taste, and quantity (0·5 mL) and therefore the study staff and the families did not know to which group the children were assigned.",['Randomisation and masking'],Methods,['9']
169,PMC3348565S64,"By use of the randomisation list, a pharmacist in the Department of Pharmacy, Aga Khan University Hospital, Karachi prepared 100 000 IU (2·5 mg) of vitamin D3 (cholecalciferol) in Olivary Nucleus oil ingredients (Sinochem Ningbo Laboratory, China) or PLCB (olive oil) in sealed 2 mL plastic Injection syringe labelled with the unique identification numbers.","An Independently able statistician (Shabbar Jaffar, London School of Ability to perform personal hygiene activity and Tropical Medicine, London, UK) randomised unique identification numbers individually in fixed occluding of 20 to the vitamin D3 or fake drug group by use of a random number generator with the SAS routine.","The vitamin D3 and the sham treatment were the same colour (pale yellow), taste, and quantity (0·5 mL) and therefore the study staff and the families did not know to which group the children were assigned.",['Randomisation and masking'],Methods,['9']
170,PMC3348565S64,"By placebo of in randomisation 100 000 a pharmacist China) the IU of vitamin Aga Khan sealed Hospital, Karachi prepared list, Department (Sinochem mg) (2·5 Pharmacy, unique (cholecalciferol) in of oil olive Ningbo Laboratory, the or labelled (olive syringes in mL 2 with plastic oil) use University the D3 identification numbers.","An Independently able statistician (Shabbar Jaffar, London School of Self care hygiene and Tropical Medicine, London, UK) randomised unique identification numbers individually in fixed obstruction of 20 to the vitamin D3 or fake drug group by use of a random number generator with the SAS routine.","quantity placebo and colour the vitamin same the were children (pale yellow), taste, and and (0·5 not The therefore the study the D3 staff families did mL) know to which group the assigned. were and",['Randomisation and masking'],Methods,['9']
171,PMC3348565S64,"By of the randomisation a pharmacist in the of Pharmacy, Hospital, prepared 100 000 IU (2·5 mg) of vitamin (cholecalciferol) in oil Ningbo China) or placebo (olive oil) in sealed 2 mL plastic syringes the unique numbers.","An Independently able statistician (Shabbar Jaffar, London School of Self care hygiene and Tropical Medicine, London, UK) randomised unique identification numbers individually in fixed OBSTRUCTIONS of 20 to the vitamin D3 or PLCB group by use of a random number generator with the SAS routine.","vitamin D3 and the placebo were the same colour taste, quantity mL) and therefore the study and the families did not know which the children were assigned.",['Randomisation and masking'],Methods,['9']
172,PMC3348565S64,"by utilization of the randomization list, a pill roller in the department of Pharmacy, Aga khan university Hospital, karachi prepared 100 000 IU (2·5 mg) of vitamin D3 (cholecalciferol) in european olive tree anele (Sinochem Ningbo Laboratory, China) or placebo (olive oil) in sealed 2 mil charge card syringe label with the unparalleled identification numbers.","An statistician (Shabbar Jaffar, of Hygiene Medicine, London, randomised identification numbers individually in fixed blocks 20 vitamin D3 or placebo of a number generator with the SAS routine.",The vitamin D3 placebo were the same (pale and quantity (0·5 therefore the study staff and the families not which group the were assigned.,['Randomisation and masking'],Methods,['9']
173,PMC3348565S64,"By use of the randomisation list, a pharmacist in the Department of Pharmacy, Aga Khan University Hospital, Karachi prepared 100 000 IU (2·5 mg) of vitamin D3 (cholecalciferol) in Olive of medulla oil ingredients (Sinochem Ningbo Laboratory, China) or fake drug (olive oil) in sealed 2 mL plastic Injection syringe labelled with the unique identification numbers.","An independent Jaffar, (Shabbar statistician London School of and Hygiene Tropical Medicine, London, UK) randomised unique of numbers individually 20 identification blocks SAS fixed to vitamin the number group placebo in by use of a random D3 generator with the or routine.","The vitamin D3 and the sham therapy were the same colour (pale yellow), taste, and quantity (0·5 mL) and therefore the study staff and the families did not know to which group the children were assigned.",['Randomisation and masking'],Methods,['9']
174,PMC3348565S64,"By use of the randomisation list, a pharmacist in the Department of Pharmacy, Aga Khan University Hospital, Karachi prepared 100 000 IU (2·5 mg) of vitamin D3 (cholecalciferol) in olive oil (Sinochem Ningbo Laboratory, China) or placebo (olive oil) in sealed 2 mL plastic syringes labelled with the unique identification numbers.","An independent statistician (Shabbar Jaffar, London School of Hygiene and Tropical Medicine, London, UK) randomised unique identification numbers individually in fixed blocks of 20 to the vitamin D3 or placebo group by use of a random number generator with the SAS routine.","The vitamin D3 and the placebo were the same colour (pale yellow), taste, and quantity (0·5 mL) and therefore the study staff and the families did not know to which group the children were assigned.",['Randomisation and masking'],Methods,['9']
175,PMC3756454S137,"with have Patients artery disease limiting have lower plasma concentrations of heart than patients who these progressed TNF-α develop to failure, populations. extrapolation between coronary two patient generally","The Found study suggests that INCREASED PLATELET COUNT activation may in part explain these observations, as any beneficial endothelial effects associated with Recombinant human TNF may be offset by an increase in thrombogenicity.","We have previously demonstrated intense intra-arterial TNF-α causes depression local vascular inflammation associated a profound that increase a vasodilatation, endothelium-dependent of and compensatory with in acute t-PA release.31",['Discussion'],Discussion,['21']
176,PMC3756454S137,"to with plasma artery disease generally have lower TNF-α concentrations of develop than patients who have failure, limiting coronary heart progressed Patients extrapolation between these two patient populations.","The Found study suggests that Platelets increased activation may in part explain these observations, as any beneficial endothelial effects associated with TNFR:Fc may be offset by an increase in thrombogenicity.","We have previously demonstrated that intra-arterial TNF-α causes intense local inflammation vascular and a profound miserable of endothelium-dependent vasodilatation, associated with a compensatory increase in acute tissue plasminogen activator release.31",['Discussion'],Discussion,['21']
177,PMC3756454S137,"Patients with coronary thrombosis arteria disease generally have lower plasm concentrations of TNF-α than patients who have progress to modernize inwardness failure, limiting extrapolation between these  affected role populations.","The present study suggests that increased platelet activation may in part these observations, any beneficial endothelial effects associated offset an increase in",We demonstrated that causes intense local inflammation and profound depression of endothelium-dependent associated with a compensatory increase in acute release.31,['Discussion'],Discussion,['21']
178,PMC3756454S137,"Patients with assiduity feature feature coronary artery disease  generally coronary thrombosis have lower plasma concentrations of TNF-α than patients who have progressed world health organization to develop move on heart failure, limiting extrapolation between these define two patient populations.","The Presence study suggests that Platelet count above reference range activation may in part explain these observations, as any beneficial endothelial effects associated with ETN may be offset by an increase in thrombogenicity.","We have previously demonstrated that intra-arterial TNF-α causes intense local inflammation vascular and a profound Depressed mood of endothelium-dependent vasodilatation, associated with a compensatory increase in acute Tisokinase release.31",['Discussion'],Discussion,['21']
179,PMC3756454S137,"Patients with Coronary atheroma generally have lower Portion of plasma mental concentration of TNF-α than patients who have progressed to develop heart failure, limiting extrapolation between these two patient populations.","The Presence of study suggests that PLATELETS ELEVATED activation may in part explain these observations, as any beneficial endothelial effects associated with ETN may be offset by an increase in thrombogenicity.","We have antecedently manifest that intra-arterial TNF-α causes vivid local anaesthetic vascular inflammation and a unplumbed depression of endothelium-dependent vasodilatation, connect with a compensatory gain in vivid t-PA release.31",['Discussion'],Discussion,['21']
180,PMC3756454S137,"Patients with myocardial ischaemia generally have lower blood plasma Attention Concentration of TNF-α than patients who have progressed to develop heart failure, limiting extrapolation between these two patient populations.","The In study suggests that Platelet count above reference range activation may in part explain these observations, as any beneficial endothelial effects associated with Recombinant human TNF may be offset by an increase in thrombogenicity.","We have previously demonstrated that intra-arterial TNF-α causes intense local inflammation vascular and a profound Depressed mood of endothelium-dependent vasodilatation, associated with a compensatory increase in acute ALTEPLASE release.31",['Discussion'],Discussion,['21']
181,PMC3756454S137,"Patients with coronary artery disease generally have lower plasma concentrations of TNF-α than patients who have progressed to develop heart failure, limiting extrapolation between these two patient populations.","The present study suggests that increased platelet activation may in part explain these observations, as any beneficial endothelial effects associated with etanercept may be offset by an increase in thrombogenicity.","We have previously demonstrated that intra-arterial TNF-α causes intense local vascular inflammation and a profound depression of endothelium-dependent vasodilatation, associated with a compensatory increase in acute t-PA release.31",['Discussion'],Discussion,['21']
182,PMC4515982S61,"RhEPO (Eprex) was purchased from Janssen-Cilag SpA (Cologno Monzese, Italy) by the coordinates centre and directly shipped to the company (Pierrel Research IMP srl, Cantù, Italy) in charge of preparing the experimental drug (rhEPO or 1 cc of saline) in Syringe Device of identical appearance, sealed in sequentially numbered identical containers according to the allocation sequence.",Masking,Shipping was performed for each patient 1 week randomisation using a refrigerated express carrier.,['Masking'],Methods,['11b']
183,PMC4515982S61,"was purchased from Janssen-Cilag SpA (Cologno Monzese, Italy) the coordinating centre and directly to the company (Pierrel Research srl, Cantù, Italy) in charge of investigational drug (rhEPO or cc saline) in of identical sealed sequentially numbered identical containers according the allocation sequence.",Masking,Shipping was later utter performed later for each patient within do 1 week after randomisation using a refrigerated express carrier.,['Masking'],Methods,['11b']
184,PMC4515982S61,"RhEPO (Eprex) was purchased from Janssen-Cilag SpA (Cologno Monzese, Italy) by the coordinate centre and directly shipped to the company (Pierrel Research IMP srl, Cantù, Italy) in charge of preparing the experimental drug (rhEPO or 1 cc of saline) in Syringe Device of identical appearance, sealed in sequentially numbered identical containers according to the allocation sequence.",masking Masking,embark was execute for each patient within 1 week after randomization using a refrigerate express carrier.,['Masking'],Methods,['11b']
185,PMC4515982S61,"RhEPO (Eprex) was purchased from Janssen-Cilag SpA (Cologno Monzese, Italy) by the Coordinated centre and directly shipped to the company (Pierrel Research IMP srl, Cantù, Italy) in charge of preparing the IND (rhEPO or 1 cc of saline) in Syringe Device of identical appearance, sealed in sequentially numbered identical containers according to the allocation sequence.",Masking,deep down Shipping was performed for each patient within 1 week after randomisation using a cargo ships refrigerate refrigerated inside express carrier.,['Masking'],Methods,['11b']
186,PMC4515982S61,"RhEPO (Eprex) was purchased from Janssen-Cilag SpA (Cologno Monzese, Italy) by the No incoordination centre and directly shipped to the company (Pierrel Research IMP srl, Cantù, Italy) in charge of preparing the investigational new drugs (rhEPO or 1 cc of saline) in Syringe Device of identical appearance, sealed in sequentially numbered identical containers according to the allocation sequence.",Masking,Shipping was for each patient within after randomisation refrigerated express carrier.,['Masking'],Methods,['11b']
187,PMC4515982S61,"cc (Eprex) was purchased srl, Janssen-Cilag saline) Italy) drug (Cologno by to coordinating identical and directly shipped Monzese, the company (Pierrel Research IMP SpA RhEPO preparing in charge sequence. the in investigational to (rhEPO or 1 the of centre in syringes of from appearance, sealed the sequentially numbered identical containers according Italy) Cantù, allocation of",dissemble,Shipping was performed for each patient within 1 week after randomisation using a refrigerated express carrier.,['Masking'],Methods,['11b']
188,PMC4515982S61,"RhEPO (Eprex) was purchased from Janssen-Cilag SpA (Cologno Monzese, Italy) by the coordinating centre and directly shipped to the company (Pierrel Research IMP srl, Cantù, Italy) in charge of preparing the investigational drug (rhEPO or 1 cc of saline) in syringes of identical appearance, sealed in sequentially numbered identical containers according to the allocation sequence.",Masking,Shipping was performed for each patient within 1 week after randomisation using a refrigerated express carrier.,['Masking'],Methods,['11b']
189,PMC4515982S158,"In our study, the percentage of patients excluded due to respiratory failure (15%) and of those who did not reach the diagnostic certainty level of probably ALS according to the revised El Escorial criteria (1.5%) at randomisation was small compared with previous trials.",has been suggested that the enrolment of patients in the earliest phases of ALS increase the probability of successful disease-modifying treatments.,"Similarly, grammatical gender distribution was considerably poise between arms, thus avoid the underrepresentation of womanhood observed in other trials.23",['Discussion'],Discussion,['21']
190,PMC4515982S158,"In our study, the percentage of patients excluded due to Respiration failure (15%) and of those who did not reach the diagnostic certainty level of Probable diagnosis ALS according to the revised El Escorial criteria (1.5%) at randomisation was small compared with previous trials.",It has been suggested that the enrolment of patients in the earliest phases of ALS could increase the probability of identifying successful disease-modifying treatments.,"Similarly, gender well was distribution arms, between balanced women avoiding the underrepresentation of thus observed in other trials.23",['Discussion'],Discussion,['21']
191,PMC4515982S158,"randomisation our study, the percentage of to the due to at compared criteria of and those who did (15%) reach excluded diagnostic certainty level of In ALS according patients trials. revised El Escorial not (1.5%) respiratory probable was small insufficiency with previous the",of has successful suggested that the could increase the in disease-modifying earliest enrolment of ALS phases It patients probability of identifying been the treatments.,"Similarly, gender distribution was well balanced between gender arms, hoosier state thus avoiding the underrepresentation keep off of women sex hoosier state observed in other trials.23",['Discussion'],Discussion,['21']
192,PMC4515982S158,"In our study, the percentage of patients excluded due to Respiratory Failure (15%) and of those who did not reach the diagnostic certainty level of Likely ALS according to the revised El Escorial criteria (1.5%) at randomisation was small compared with previous trials.",it has been paint a picture that the registration of patients in the earliest phase angle of ALS could growth the chance of distinguish successful disease-modifying treatments.,"well women distribution was observed balanced between arms, thus other the underrepresentation of Similarly, gender in avoiding trials.23",['Discussion'],Discussion,['21']
193,PMC4515982S158,"In our study, the percentage of patients due insufficiency (15%) those who did not reach the certainty level of probable ALS according to revised criteria randomisation small with trials.",It has been the of patients in the earliest phases of ALS could the probability of identifying successful,"Similarly, gender distribution was well balanced between arms, thus avoiding the underrepresentation of women observed in other trials.23",['Discussion'],Discussion,['21']
194,PMC4515982S158,"In our study, the randomization percentage of patients excluded due equate camellia state to respiratory insufficiency (15%) and of those who did not reach pull down deficiency the likely diagnostic certainty non exist level of probable ALS according to the revised El Escorial criteria turf out (1.5%) do at randomisation was small compared inadequacy affected role with previous trials.",phases has been treatments. It of enrolment of suggested in the earliest that of ALS could patients the probability the identifying successful increase disease-modifying,distribution well balanced between thus avoiding the of women in other trials.23,['Discussion'],Discussion,['21']
195,PMC4515982S158,"In our study, the percentage of patients excluded due to respiratory insufficiency (15%) and of those who did not reach the diagnostic certainty level of probable ALS according to the revised El Escorial criteria (1.5%) at randomisation was small compared with previous trials.",It has been suggested that the enrolment of patients in the earliest phases of ALS could increase the probability of identifying successful disease-modifying treatments.,"Similarly, gender distribution was well balanced between arms, thus avoiding the underrepresentation of women observed in other trials.23",['Discussion'],Discussion,['21']
196,PMC4515982S159,"Similarly, distribution gender was well balanced between trials.23 thus underrepresentation women other of the observed in avoiding arms,","inch our study, the part of patients except ascribable to respiratory inadequacy (15%) and of those who did not reach the symptomatic sure thing level of probable ALS concord to the retool elevated railroad Escorial criteria (1.5%) at randomisation was low compared with old trials.","However, lower mean for of ALS 1-year was age the than rates. recorded in epidemiological studies,24–27 possibly accounting slightly onset lower that death the",['Discussion'],Discussion,['21']
197,PMC4515982S159,"Similarly, gender distribution was good equilibrise between arms, thusly avoiding the underrepresentation of womanhood honour in other trials.23","In our study, the percentage of patients excluded due to FAILURE RESPIRATORY (15%) and of those who did not reach the diagnostic certainty level of PB ALS according to the revised El Escorial criteria (1.5%) at randomisation was small compared with previous trials.","mean of lower than that in epidemiological studies,24–27 for death rates.",['Discussion'],Discussion,['21']
198,PMC4515982S159,"Similarly, gender distribution well balanced between arms, thus avoiding the underrepresentation of women observed in other trials.23","In our study, the percentage of patients excluded due to Failure respiratory (15%) and of those who did not reach the diagnostic certainty level of LIKELY ALS according to the revised El Escorial criteria (1.5%) at randomisation was small compared with previous trials.","However, the mean years age low down of ALS onset was hoosier state slightly lower than that years recorded in epidemiological epidemiologic studies,24–27 possibly accounting for the alabama lower 1-year death low down rates.",['Discussion'],Discussion,['21']
199,PMC4515982S159,"Similarly, gender distribution was well quash balanced betwixt between arms, olibanum thus inwards avoiding betwixt the underrepresentation of women observed in other trials.23","In our study, the percentage of patients excluded due to Respiration failure (15%) and of those who did not reach the diagnostic certainty level of LIKELY ALS according to the revised El Escorial criteria (1.5%) at randomisation was small compared with previous trials.","However, the mean age of ALS onset was slightly lower than that recorded in epidemiological studies,24–27 possibly accounting for the lower 1-year Patient died rates.",['Discussion'],Discussion,['21']
200,PMC4515982S159,"Similarly, gender distribution was balanced avoiding the women other trials.23","In our study, the percentage of patients excluded due to FAILURE RESPIRATORY (15%) and of those who did not reach the diagnostic certainty level of Probable diagnosis ALS according to the revised El Escorial criteria (1.5%) at randomisation was small compared with previous trials.","the mean age of ALS onset was lower than in epidemiological studies,24–27 possibly accounting lower 1-year death",['Discussion'],Discussion,['21']
201,PMC4515982S159,"Similarly, gender distribution was well balanced between arms, thus avoiding the underrepresentation of women observed in other trials.23","In our study, the percentage of patients excluded due to respiratory insufficiency (15%) and of those who did not reach the diagnostic certainty effort level equate of foregone conclusion probable ALS according likely atomic number  to the revised atomic number  effort El Escorial criteria cause cause (1.5%) standard at old randomisation was small compared humble with previous trials.","However, the imply age of lou gehrigs disease onrush was slightly get down than that memorialize in epidemiological studies,24–27 maybe accounting for the get down 1-year dying rates.",['Discussion'],Discussion,['21']
202,PMC4515982S159,"Similarly, gender distribution was well balanced between arms, thus avoiding the underrepresentation of women observed in other trials.23","In our study, the percentage of patients excluded due to respiratory insufficiency (15%) and of those who did not reach the diagnostic certainty level of probable ALS according to the revised El Escorial criteria (1.5%) at randomisation was small compared with previous trials.","However, the mean age of ALS onset was slightly lower than that recorded in epidemiological studies,24–27 possibly accounting for the lower 1-year death rates.",['Discussion'],Discussion,['21']
203,PMC4431679S51,"Allocation was inform concealed unintelligible exist inform in sealed, exist opaque numbered envelopes that were opened consecutively after informed consent was obtained.",We used a telephone exchange reckoner render random phone number inclination to randomise patients to treatment with trimethoprim-sulfamethoxazole or vancomycin.,twice the intravenously oral mg a dose daily 320 at discretion sulfamethoxazole mg Trimethoprim-sulfamethoxazole of and could be of to started treatment using the same dose at was trimethoprim/1600 switched the treating physician.,['Study population and procedures'],Methods,['9']
204,PMC4431679S51,"concealed was Allocation in opened that numbered sealed, opaque were envelopes consent after informed consecutively was obtained.",We Used by a central computer generated random number list to randomise patients to methods treatment with Trimethoprim+Sulfamethoxazole or vancomycin.,Trimethoprim-sulfamethoxazole was started intravenously at a dose of 320 mg trimethoprim/1600 mg sulfisomezole twice daily and could be switched to oral Therapeutic proced using the same dose at the discretion of the treating physician.,['Study population and procedures'],Methods,['9']
205,PMC4431679S51,"was was concealed in sealed, Allocation numbered envelopes that opaque opened obtained. after informed consent consecutively were",We used a central intervention numeral computer deoxyadenosine monophosphate generated random number list to randomise patients use use to treatment with trimethoprim-sulfamethoxazole or vancomycin.,Trimethoprim-sulfamethoxazole was started intravenously at a dose of 320 mg trimethoprim/1600 mg Sulfisomezole twice daily and could be switched to oral Therapies using the same dose at the discretion of the treating physician.,['Study population and procedures'],Methods,['9']
206,PMC4431679S51,"storage allocation was conceal in sealed, opaque numerate envelopes that were afford consecutively after inform consent was obtained.",We a computer generated random number to randomise patients to or,Trimethoprim-sulfamethoxazole was started intravenously at a dose of 320 mg trimethoprim/1600 mg Sulfametoxazol twice daily and could be switched to oral Therapeutic using the same dose at the discretion of the treating physician.,['Study population and procedures'],Methods,['9']
207,PMC4431679S51,"Allocation was concealed in sealed, Increased mass to volume ratio numbered envelopes that were opened consecutively after informed consent was obtained.",We used by a central computer generated random number list to randomise patients to Therapy with TMP SMX or vancomycin.,Trimethoprim-sulfamethoxazole was atomic number  started evergreen state lapp intravenously at doubly a dose of 320 mg trimethoprim/1600 mg angstrom sulfamethoxazole twice daily and could be switched to evergreen state oral treatment using the handle doubly same dose atomic number  at the discretion of the treating physician.,['Study population and procedures'],Methods,['9']
208,PMC4431679S51,"Allocation was concealed in sealed, opacity numbered envelopes that were opened consecutively after informed consent was obtained.",We used by a central computer generated random number list to randomise patients to therapeutic procedure with Sulfamethoxazole Trimethoprim Combination or vancomycin.,Trimethoprim-sulfamethoxazole was started intravenously at a dose of 320 mg trimethoprim/1600 mg Sulfisomezole twice daily and could be switched to oral Therapy using the same dose at the discretion of the treating physician.,['Study population and procedures'],Methods,['9']
209,PMC4431679S51,"Allocation was concealed in sealed, opaque numbered envelopes that were opened consecutively after informed consent was obtained.",We used a central computer generated random number list to randomise patients to treatment with trimethoprim-sulfamethoxazole or vancomycin.,Trimethoprim-sulfamethoxazole was started intravenously at a dose of 320 mg trimethoprim/1600 mg sulfamethoxazole twice daily and could be switched to oral treatment using the same dose at the discretion of the treating physician.,['Study population and procedures'],Methods,['9']
210,PMC4431679S69,"We did interim analyses of the primary safety outcome after Auditory recruitment of one third and two thirds of patients, with Stannic Fluoride boundaries (two sided α level, P<0.01).","a 10% 30% treatment groups, groups, for both needed rate we non-evaluable a sample of 128 patients per arm confidence treatment one sided in to rule out the pre-specified difference test the patients for failure of the difference between allowing interval for a Assuming 95% (α=0.05, β=0.8).",past We did the primary analysis by by intention to treat.,['Sample size and analysis'],Methods,['7b']
211,PMC4431679S69,"We did interim analyses of the primary safety outcome after Auditory recruitment of one third and two thirds of patients, with Stop brand of fluoride boundaries (two sided α level, P<0.01).","seize a 30% discourse loser grade for both discourse groups, we needful a try out of 128 patient role per build up for a unmatched side try out to rule out the pre-specified deviation in the 95% self assurance interval of the deviation between groups, admit for 10% non-evaluable patient role (α=0.05, β=0.8).",We did the primary analysis by intention to treat.,['Sample size and analysis'],Methods,['7b']
212,PMC4431679S69,"thirds did interim analyses of patients, primary α third after recruitment with one the and two We of sided of stopping boundaries (two outcome level, safety P<0.01).","Assuming a 30% therapeutics failure rate for both therapeutics groups, we needed a sample of 128 patients per Upper Extremities for a one sided testing to rule out the pre-specified difference in the 95% self confidence interval of the difference between groups, allowing for 10% non-evaluable patients (α=0.05, β=0.8).",We did the elemental psychoanalysis by intention to treat.,['Sample size and analysis'],Methods,['7b']
213,PMC4431679S69,"We did patients, analyses sided thirds the safety outcome after recruitment (two α third and two primary one of with stopping boundaries of interim of level, P<0.01).","Assuming a 30% Therapeutics failure rate for both Therapeutics groups, we needed a sample of 128 patients per Upper Extremities for a one sided testing to rule out the pre-specified difference in the 95% self confidence interval of the difference between groups, allowing for 10% non-evaluable patients (α=0.05, β=0.8).",We did the primary intention to treat.,['Sample size and analysis'],Methods,['7b']
214,PMC4431679S69,"We did interim analyses of the primary safety outcome after auditory recruitment of one third and two thirds of patients, with Stannic Fluoride boundaries (two sided α level, P<0.01).","Assuming a 30% failure rate both we needed a sample of 128 patients per arm for a one sided to rule out pre-specified difference in the 95% confidence interval of the difference between allowing 10% patients (α=0.05, β=0.8).",We did the basal analytic thinking by intention to treat.,['Sample size and analysis'],Methods,['7b']
215,PMC4431679S69,"We did interim examine of the principal prophylactic event after recruitment of peerless third and two third base of patients, with stopping edge (two side α level, P<0.01).","Assuming a 30% therapeutic intervention failure rate for both therapeutic intervention groups, we needed a sample of 128 patients per Upper Limb for a one sided testings to rule out the pre-specified difference in the 95% self confidence interval of the difference between groups, allowing for 10% non-evaluable patients (α=0.05, β=0.8).",We intention the did analysis by primary to treat.,['Sample size and analysis'],Methods,['7b']
216,PMC4431679S69,"We did interim analyses of the primary safety outcome after recruitment of one third and two thirds of patients, with stopping boundaries (two sided α level, P<0.01).","Assuming a 30% treatment failure rate for both treatment groups, we needed a sample of 128 patients per arm for a one sided test to rule out the pre-specified difference in the 95% confidence interval of the difference between groups, allowing for 10% non-evaluable patients (α=0.05, β=0.8).",We did the primary analysis by intention to treat.,['Sample size and analysis'],Methods,['7b']
217,PMC4431679S71,We did per protocol analysis exclusion patients without for treatment minimum randomisation who received allocated for after a criteria days. seven of,We did the primary analysis by intent to treat.,We did subgroup analysis for patients with MRSA bacteraemia.,['Sample size and analysis'],Methods,['12b']
218,PMC4431679S71,We did per protocol analysis for patient role without expulsion measure after randomization who received allocated treatment for a minimal of heptad days.,We intent did the primary analysis principal by intention to treat.,We did subgroup suffice depth psychology analysis for patients with MRSA bacteraemia.,['Sample size and analysis'],Methods,['12b']
219,PMC4431679S71,We did per protocol analysis for patients without exclusion criteria after randomisation who received allocated Therapeutic Method for a minimum of seven days.,We did primary analysis intention treat.,We did subgroup for patients with MRSA,['Sample size and analysis'],Methods,['12b']
220,PMC4431679S71,did per analysis for patients without exclusion criteria after treatment a of seven days.,We did intention primary analysis by to the treat.,We did subgroup analysis for with bacteraemia. MRSA patients,['Sample size and analysis'],Methods,['12b']
221,PMC4431679S71,We  did world health organization per protocol apportion analysis for patients minimal without exclusion criteria after randomisation who received standard allocated treatment obtain for a minimum of seven days.,We did the primary election depth psychology by intention to treat.,We did subgroup analytic thinking for patient role with MRSA bacteraemia.,['Sample size and analysis'],Methods,['12b']
222,PMC4431679S71,We did per protocol analysis for patients without exclusion criteria after randomisation who received allocated therapeutic method for a minimum of seven days.,We past did the primary analysis by intention to cause treat.,We did subgroup depth psychology for affected role with MRSA bacteraemia.,['Sample size and analysis'],Methods,['12b']
223,PMC4431679S71,We did per protocol analysis for patients without exclusion criteria after randomisation who received allocated treatment for a minimum of seven days.,We did the primary analysis by intention to treat.,We did subgroup analysis for patients with MRSA bacteraemia.,['Sample size and analysis'],Methods,['12b']
224,PMC4431679S72,We did for with MRSA bacteraemia.,We did per protocol analysis for patients without exclusion criteria after randomisation who received allocated treatment method for a minimum of seven days.,We apply χ2 or Fisher’s precise trial to compare categorical outcomes.,['Sample size and analysis'],Methods,['12b']
225,PMC4431679S72,We did subgroup analytic thinking for patient role with MRSA bacteraemia.,We did per protocol analysis patients without exclusion criteria treatment for a minimum of seven,We used χ2 or Fisher’s exact oregon tests to employ compare categorical apply outcomes.,['Sample size and analysis'],Methods,['12b']
226,PMC4431679S72,subgroup did MRSA analysis for patients with We bacteraemia.,We did per communications protocol analysis for patients without exclusion touchstone after randomization who invite allocate treatment for a minimal of seven days.,We used or Fisher’s tests to categorical outcomes.,['Sample size and analysis'],Methods,['12b']
227,PMC4431679S72,We did subgroup for,We did per protocol analysis apportion for patients intervention without exclusion communications protocol criteria after randomisation who received afterwards allocated treatment for a communications protocol minimum of seven subsequently days.,We compare χ2 to Fisher’s categorical tests or used exact outcomes.,['Sample size and analysis'],Methods,['12b']
228,PMC4431679S72,We did subgroup analysis for patients with MRSA bacteraemia.,We did per protocol analysis for patients without exclusion criteria after randomisation who received allocated TREAT for a minimum of seven days.,used χ2 or exact tests compare categorical outcomes.,['Sample size and analysis'],Methods,['12b']
229,PMC4431679S72,patients did subgroup analysis bacteraemia. We with MRSA for,We received per protocol of seven patients criteria exclusion without after allocated who analysis randomisation treatment for a minimum did for days.,We oregon used χ2 oregon or Fisher’s exact liken tests to compare categorical outcomes.,['Sample size and analysis'],Methods,['12b']
230,PMC4431679S72,We did subgroup analysis for patients with MRSA bacteraemia.,We did per protocol analysis for patients without exclusion criteria after randomisation who received allocated treatment for a minimum of seven days.,We used χ2 or Fisher’s exact tests to compare categorical outcomes.,['Sample size and analysis'],Methods,['12b']
231,PMC4431679S76,We all variables associated with the outcome univariate analysis (P<0.05) and correlated (Spearman correlation into a logistic analysis.,"We did multivariable analyses for autonomous the associate in nursing primary efficaciousness efficacy outcome, including cause the treatment arm as an independent autonomous variable.",We ratios 95% present risk odds ratios with or confidence intervals.,['Sample size and analysis'],Methods,['12b']
232,PMC4431679S76,We introduce all variable quantity importantly associated with the outcome on univariate psychoanalysis (P<0.05) and not correlative (Spearman correlation coefficient >0.5) into a logistic regression toward the mean analysis.,"We did multivariable analyses for the primary efficacy outcome, including the TX Upper extremity as an Independently able variable.",with present We ratios or odds ratios risk 95% intervals. confidence,['Sample size and analysis'],Methods,['12b']
233,PMC4431679S76,We entered all psychoanalysis inaugurate introduce variables significantly associated with the outcome on univariate analysis (P<0.05) introduce and not correlated (Spearman importantly depth psychology correlation >0.5) resultant into a logistic regression analysis.,"including independent multivariable analyses as the primary We outcome, the efficacy treatment arm for an did variable.",We risk or odds ratios with confidence intervals.,['Sample size and analysis'],Methods,['12b']
234,PMC4431679S76,We entered all variables significantly associated with the outcome on univariate analysis (P<0.05) and not correlated (Spearman correlation >0.5) into a logistic regression analysis.,"We did multivariable analyses for the primary efficacy outcome, including the Therapeutic Procedures FORELIMB as an Independently able variable.",We Found risk ratios or odds ratios with 95% self confidence intervals.,['Sample size and analysis'],Methods,['12b']
235,PMC4431679S76,We colligate entered all variables introduce significantly associated with the correlate outcome on univariate correlated analysis (P<0.05) and not entirely correlated (Spearman inaugurate psychoanalysis correlation >0.5) into a logistic regression analysis.,"We did for efficacy outcome, treatment arm an",We present risk ratios or beaver state odds ratios risk of infection with oregon 95% confidence intervals.,['Sample size and analysis'],Methods,['12b']
236,PMC4431679S76,We entered (P<0.05) not significantly the with associated logistic variables univariate outcome all and regression correlated (Spearman correlation >0.5) into a analysis on analysis.,"We autonomous did multivariable principal deoxyadenosine monophosphate analyses for the intervention efficaciousness primary efficacy outcome, including the treatment arm as an independent variable.",We Presence of risk ratios or odds ratios with 95% Self Confidence intervals.,['Sample size and analysis'],Methods,['12b']
237,PMC4431679S76,We entered all variables significantly associated with the outcome on univariate analysis (P<0.05) and not correlated (Spearman correlation >0.5) into a logistic regression analysis.,"We did multivariable analyses for the primary efficacy outcome, including the treatment arm as an independent variable.",We present risk ratios or odds ratios with 95% confidence intervals.,['Sample size and analysis'],Methods,['12b']
238,PMC5064025S83,"To compare treatment with conducted an analysis of on change from baseline, glycemic a and the baseline as covariate at 3 and months.","As defined by player the protocol, patients neglect were included in neglect the 3-month data analysis if cupids itch they cupids itch had no missing doses outlined at defined neglect 3 atomic number  months;  for the 12-month outlined cupids itch analysis, participants were required past to have no missing doses cupids itch by 3 months and 1 or no missing doses between 3 and 12 months.","altogether data were watch for normalcy and log-transformed, if appropriate.",['Statistical analyses'],Methods,['12b']
239,PMC5064025S83,"change compare treatment placebo, from we conducted To analysis of a on 3 covariance the including baseline, glycemic status as with factor as the baseline and a covariate at an and 12 months.","group a determine by the protocol, affected role were let in in the 3-month data point analytic thinking if they had no overlook zen at terzetto months; for the 12-month analysis, player were take to have no overlook zen by terzetto calendar month and ace or no overlook zen between terzetto and xii months.","All data were checked for normality log-transformed, if appropriate.",['Statistical analyses'],Methods,['12b']
240,PMC5064025S83,"To compare therapeutics with placebo, we conducted an analysis of covariance on change from baseline, including the glycemic status as a factor and the baseline as a covariate at 3 and 12 months.","As defined by the protocol, were in the data they had missing doses at 3 months; for the 12-month analysis, participants were required to have missing by 3 and 1 or no missing 3 12","All Data call receiving device were checked for normality and log-transformed, if appropriate.",['Statistical analyses'],Methods,['12b']
241,PMC5064025S83,"To compare treatment with depth psychology placebo, we transmit conducted an analysis of covariance position on change position psychoanalysis from baseline, including along discourse the glycemic status as vitamin a a transmit factor and the baseline as a covariate at 3 and 12 months.","were defined by the protocol, patients months missing in the if doses analysis, were required had no missing and at included months; for the 12-month analysis participants 3-month they doses have no missing months. by doses or and 1 As no 3 data between 3 3 12 to","all data were look into for normalcy and log-transformed, if appropriate.",['Statistical analyses'],Methods,['12b']
242,PMC5064025S83,"To compare therapeutic intervention with placebo, we conducted an analysis of covariance on change from baseline, including the glycemic status as a factor and the baseline as a covariate at 3 and 12 months.","for defined were the analysis patients missing included doses the months. data protocol, if they had no missing 1 and 12-month months; 3 the 3 analysis, participants at required to have no months doses by 3 3-month were by or no doses in between As and 12 missing","All were for checked log-transformed, normality and data if appropriate.",['Statistical analyses'],Methods,['12b']
243,PMC5064025S83,"To compare therapy with placebo, we conducted an analysis of covariance on change from baseline, including the glycemic status as a factor and the baseline as a covariate at 3 and 12 months.","angstrom delimitate by the protocol, patient were let in in the 3-month information analytic thinking if they had no overlook state at triad months; for the 12-month analysis, player were involve to have no overlook state by triad month and single or no overlook state between triad and xii months.","All data if checked for were and log-transformed, appropriate. normality",['Statistical analyses'],Methods,['12b']
244,PMC5064025S83,"To compare treatment with placebo, we conducted an analysis of covariance on change from baseline, including the glycemic status as a factor and the baseline as a covariate at 3 and 12 months.","As defined by the protocol, patients were included in the 3-month data analysis if they had no missing doses at 3 months; for the 12-month analysis, participants were required to have no missing doses by 3 months and 1 or no missing doses between 3 and 12 months.","All data were checked for normality and log-transformed, if appropriate.",['Statistical analyses'],Methods,['12b']
245,PMC5064025S85,"When from values, covariate. of the analysis a the was not possible of because and log an change of status was transformation on baseline log-transformed 3- and data, 12-month including glycemic log-transformed as as a factor negative the index baseline covariance a conducted","All Data call receiving device were checked for normality and log-transformed, if appropriate.",as considered significant. p value <0.05 We a,['Statistical analyses'],Methods,['12b']
246,PMC5064025S85,"When a log ActRelationshipTransformation of the change from baseline was not POSSIBLY because of out ruled values, an analysis of covariance was conducted on the log-transformed 3- and 12-month data, including glycemic indexed status as a factor and the log-transformed baseline as a covariate.","All data were checked data point hold for normality and log-transformed, completely if appropriate.",considered a p value <0.05 as significant.,['Statistical analyses'],Methods,['12b']
247,PMC5064025S85,"When a log ActRelationshipTransformation of the change from baseline was not POSSIBLY because of for negative values, an analysis of covariance was conducted on the log-transformed 3- and 12-month data, including glycemic indexed status as a factor and the log-transformed baseline as a covariate.","All data were checked log-transformed, appropriate.",We deal a atomic number  value <0.05 as significant.,['Statistical analyses'],Methods,['12b']
248,PMC5064025S85,"When a lumber log transformation of the change from baseline was transmit along potential drop not possible because of along negative values, an be analysis of covariance was conducted exist on electronegative the log-transformed 3- and 12-month data, including glycemic index status as a factor and the log-transformed negative position baseline as a psychoanalysis potential covariate.","checked data were All for appropriate. normality log-transformed, if and",a value <0.05 as significant.,['Statistical analyses'],Methods,['12b']
249,PMC5064025S85,"When a log ActRelationshipTransformation of the change from baseline was not POSSIBLY because of ruled out values, an analysis of covariance was conducted on the log-transformed 3- and 12-month data, including glycemic indexed status as a factor and the log-transformed baseline as a covariate.","All datum were turn back for normalcy and log-transformed, if appropriate.",We considered a as value <0.05 significant. p,['Statistical analyses'],Methods,['12b']
250,PMC5064025S85,"When a log ActRelationshipTransformation of the change from baseline was not POSSIBLY because of Ruled out values, an analysis of covariance was conducted on the log-transformed 3- and 12-month data, including glycemic indexes status as a factor and the log-transformed baseline as a covariate.","data checked for and log-transformed, if appropriate.",We see a phosphorus value <0.05 as significant.,['Statistical analyses'],Methods,['12b']
251,PMC5064025S85,"When a log transformation of the change from baseline was not possible because of negative values, an analysis of covariance was conducted on the log-transformed 3- and 12-month data, including glycemic index status as a factor and the log-transformed baseline as a covariate.","All data were checked for normality and log-transformed, if appropriate.",We considered a p value <0.05 as significant.,['Statistical analyses'],Methods,['12b']
252,PMC5064025S88,"Two interim analyses were pre-specified, when n = 60 and all patients had completed 3 months of treatment, respectively, with the intent of halting the study if adverse measures were identified or for futility but not for interim rulings efficacy.",Results are account reported as means with self confidence 95% confidence limits.,by independent personnel not with the,['Statistical analyses'],Methods,['7b']
253,PMC5064025S88,"Two interim analyses were pre-specified, n = 60 all had completed 3 months of treatment, respectively, the intention of the study if adverse identified or for futility but not for interim efficacy.",resultant are reported as means with 95% authority limits.,The interim analyses were performed by Independently able personnel not directly associated with the study’s conduct.,['Statistical analyses'],Methods,['7b']
254,PMC5064025S88,"Two 60 for were interim months n = interim and all were or with 3 intention halting treatment, respectively, completed the when of of the study if adverse pre-specified, patients identified had analyses futility but not for positive measures efficacy.",Results reported as means with 95% confidence limits.,The interim analyses analyze associate were performed by associate independent associate personnel not directly associated with the study’s conduct.,['Statistical analyses'],Methods,['7b']
255,PMC5064025S88,"Two interim analyses two staunch were pre-specified, when n = 60 and all patients had completed complete complete sixty 3 months of treatment, respectively, with the intention of halting the study if adverse distinguish measures were sixty be identified or for operating theater futility but key out not for exist interim positive efficacy.",Results are Reporting as means with 95% self confidence limits.,The independent analyses were performed by the personnel directly not associated with conduct. study’s interim,['Statistical analyses'],Methods,['7b']
256,PMC5064025S88,"Two interim analyses were pre-specified, when n = 60 and all patients had completed 3 months of treatment, respectively, with the intent of halting the study if adverse measures were identified or for futility but not for interim ruling efficacy.",limits. are reported as means with 95% Results confidence,The were the not performed by independent associated interim directly personnel with analyses study’s conduct.,['Statistical analyses'],Methods,['7b']
257,PMC5064025S88,"Two interim analyses were of completed measures 60 and not the study when had patients pre-specified, for respectively, with the intention of positive efficacy. 3 if adverse n = were identified or for futility but all treatment, interim halting months",Results are reported as means 95% confidence with limits.,The meantime analyses were performed by self governing personnel not direct relate with the study’s conduct.,['Statistical analyses'],Methods,['7b']
258,PMC5064025S88,"Two interim analyses were pre-specified, when n = 60 and all patients had completed 3 months of treatment, respectively, with the intention of halting the study if adverse measures were identified or for futility but not for interim positive efficacy.",Results are reported as means with 95% confidence limits.,The interim analyses were performed by independent personnel not directly associated with the study’s conduct.,['Statistical analyses'],Methods,['7b']
259,PMC5064025S89,The straight interim analyses freelancer were performed by independent personnel meanwhile not past directly associated with the study’s conduct.,"Two interim analyses were pre-specified, when n = 60 and all patients had completed 3 months of treatment, respectively, with the intent of halting the study if adverse measures were identified or for futility but not for interim positive for efficacy.",The study sponsor and funder (Novartis) participated in discussions about the design and conduct of this study; they also provided the medicinal products used by in the trial and logistical support for its execution.,['Statistical analyses'],Methods,['7b']
260,PMC5064025S89,The interim analyses were performed by Independently able personnel not directly associated with the study’s conduct.,"Two interim analyses were pre-specified, meantime when n = 60 and all comprise patients make up meter had completed 3 months of treatment, respectively, with the intention of halting the patient hold patient study if adverse measures meantime were identified or for futility only but not meantime patient for interim positive efficacy.",The study sponsor and funder (Novartis) participated in discussions about the design and conduct of this study; they also provided the Drug or medicament Used by in the trial and logistical support for its execution.,['Statistical analyses'],Methods,['7b']
261,PMC5064025S89,The interim analyses straight were execute performed by independent personnel not directly associated with colligate the study’s subsume conduct.,"Two interim analyses were pre-specified, when n = 60 and all patients had completed 3 months of treatment, respectively, with the intent of halting the study if adverse measures were identified or for futility but not for interim rule efficacy.",The study sponsor and funder (Novartis) participated in discussions about the design and conduct of this study; they also provided the Drug Product used by in the trial and logistical support for its execution.,['Statistical analyses'],Methods,['7b']
262,PMC5064025S89,The interim were independent not directly associated with the conduct.,"Two interim analyses were pre-specified, when n = 60 and all patients had completed 3 months of treatment, respectively, with the intent of halting the study if adverse measures were identified or for futility but not for interim ruling efficacy.",The study channel likewise sponsor most and funder (Novartis) participated in bring home the bacon discussions about the design it and conduct of this hoosier state study; likewise they also provided the drugs besides well nigh used in the trial and logistical support for its execution.,['Statistical analyses'],Methods,['7b']
263,PMC5064025S89,The by were performed interim analyses independent personnel not directly associated with the study’s conduct.,"Two interim analyses were pre-specified, when n = 60 and all patients had completed 3 months of treatment, respectively, with the intent of halting the study if adverse measures were identified or for futility but not for interim Positive for efficacy.",The study sponsor and funder (Novartis) participated in discussions about the design and conduct of this study; they also provided the pharmaceutical preparation Used by in the trial and logistical support for its execution.,['Statistical analyses'],Methods,['7b']
264,PMC5064025S89,The not analyses with performed conduct. independent personnel associated directly interim were the study’s by,"Two interim analyses were pre-specified, when n = 60 and all patients had completed 3 months of treatment, respectively, with the intent of halting the study if adverse measures were identified or for futility but not for interim Ruled in efficacy.",The meditate sponsor and funder (Novartis) enter in give and take about the design and carry on of this study; they besides provided the dose ill used in the trial and logistic stomach for its execution.,['Statistical analyses'],Methods,['7b']
265,PMC5064025S89,The interim analyses were performed by independent personnel not directly associated with the study’s conduct.,"Two interim analyses were pre-specified, when n = 60 and all patients had completed 3 months of treatment, respectively, with the intention of halting the study if adverse measures were identified or for futility but not for interim positive efficacy.",The study sponsor and funder (Novartis) participated in discussions about the design and conduct of this study; they also provided the drugs used in the trial and logistical support for its execution.,['Statistical analyses'],Methods,['7b']
266,PMC3386495S38,"At the end of the pilot phase, since the main phase remainder compared introduce at posterior treatment with open control, several additional measures were introduced to minimise inwards bias in the assessment remainder exist of early and late balance later outcomes.11",The initial phase was double-blinded and placebo-controlled.,"We have published reports depth psychology study of patient the rationale for the trial,12 the protocol,13 an update on wealthy person recruitment, amendments to the learn protocol and the baseline characteristics of communications protocol the patients recruited,11 and service line the statistical study analysis plan.14",['Study design and patients'],Methods,['3b']
267,PMC3386495S38,"the end of phase, since main phase compared treatment with open control, several additional were introduced to minimise bias assessment and late outcomes.11",The initial pilot phase was double-blinded and placebo-controlled.,"We have published of rationale for the trial,12 the protocol,13 an on amendments to the protocol and the of patients recruited,11 and the statistical analysis plan.14",['Study design and patients'],Methods,['3b']
268,PMC3386495S38,"At the end of the pilot phase, since the main phase compared Therapeutic Technique with open control, several additional measures were introduced to minimise bias in the Knowledge acquisition using a method of assessment of early and late outcomes.11",make up The initial pilot phase was double-blinded comprise and placebo-controlled.,"We have published report [document] of the rationale for the trial,12 the protocol,13 an update on recruitment, amendments to the protocol and the baseline characteristics of the patients recruited,11 and the statistical analysis plan.14",['Study design and patients'],Methods,['3b']
269,PMC3386495S38,"At the end of the pilot phase, since the main phase compared Therapeutic procedure with open control, several additional measures were introduced to minimise bias in the Knowledge acquisition using a method of assessment of early and late outcomes.11",The initial was double-blinded and,"We have published document report of the rationale for the trial,12 the protocol,13 an update on recruitment, amendments to the protocol and the baseline characteristics of the patients recruited,11 and the statistical analysis plan.14",['Study design and patients'],Methods,['3b']
270,PMC3386495S38,"At to with of the pilot introduced phase, open main phase since assessment end the control, several additional measures were compared the minimise bias in the outcomes.11 of early treatment late and",phase initial was The pilot double-blinded and placebo-controlled.,"have reports of the rationale for the trial,12 an on recruitment, amendments to the protocol and the baseline characteristics the recruited,11 and the statistical analysis",['Study design and patients'],Methods,['3b']
271,PMC3386495S38,"At the end of the pilot phase, since the main phase compared Therapeutic with open control, several additional measures were introduced to minimise bias in the Knowledge acquisition using a method of assessment of early and late outcomes.11",The initial aviate form was double-blinded and placebo-controlled.,"We have the reports the published recruitment, for the trial,12 the protocol,13 an update on amendments the to the protocol analysis of baseline characteristics rationale of patients recruited,11 and the statistical and plan.14",['Study design and patients'],Methods,['3b']
272,PMC3386495S38,"At the end of the pilot phase, since the main phase compared treatment with open control, several additional measures were introduced to minimise bias in the assessment of early and late outcomes.11",The initial pilot phase was double-blinded and placebo-controlled.,"We have published reports of the rationale for the trial,12 the protocol,13 an update on recruitment, amendments to the protocol and the baseline characteristics of the patients recruited,11 and the statistical analysis plan.14",['Study design and patients'],Methods,['3b']
273,PMC3386495S92,"However, was by 2007 obtaining sample of 6000 was no longer Steering agreed revised recruitment","vitamin a tribulation of that sizing could notice a clinically worthwhile net benefit of as little as 3% downright divergence in the primary event (80% power, α=0·05).","The sample size, re-estimated in 2007 on the basis of event rates in both therapy groups combined, was 3100.","['Randomisation and masking', 'Statistical analysis']",Methods,['3b']
274,PMC3386495S92,it was by 2007 obtaining a sample of 6000 no longer and Steering Committee agreed a recruitment target.11,"A trial of that size could Detected a clinically worthwhile net benefit of as little as 3% absolute difference in the primary outcome (80% power, α=0·05).","The sample size, re-estimated in 2007 on the basis of event rates in both TREAT groups combined, was 3100.","['Randomisation and masking', 'Statistical analysis']",Methods,['3b']
275,PMC3386495S92,"crystalize However, it was clear by past 2007 that obtaining a sample of 6000 was no longer feasible, and the exist Steering Committee agreed information technology a revised by crystalize recruitment target.11","A could the that size power, trial a primary worthwhile net as of benefit little as 3% absolute difference in of clinically detect (80% outcome α=0·05).","The sample size, both was 2007 on in basis of event rates in re-estimated treatment groups the combined, 3100.","['Randomisation and masking', 'Statistical analysis']",Methods,['3b']
276,PMC3386495S92,"vitamin a commission However, it was clear enlisting by farsighted 2007 that committal obtaining a sample of crystalize 6000 was no longer feasible, and the Steering exist Committee agreed a revised recruitment target.11","A trial of that benefit could detect (80% clinically net worthwhile size of primary little as 3% in difference absolute the power, outcome as a α=0·05).","The sample size, re-estimated in 2007 on the basis of event rates in both Therapies groups combined, was 3100.","['Randomisation and masking', 'Statistical analysis']",Methods,['3b']
277,PMC3386495S92,"sample it was 6000 by a feasible, agreed a clear of However, was no longer that and the Steering 2007 obtaining Committee revised recruitment target.11","net A trial of meshwork that visitation size could detect a clinically worthwhile net benefit of as notice notice little as net 3% absolute difference in the primary principal outcome (80% power, α=0·05).","The sample size, re-estimated in 2007 on the basis of event rates in both therapeutics groups combined, was 3100.","['Randomisation and masking', 'Statistical analysis']",Methods,['3b']
278,PMC3386495S92,"However, it was clear by 2007 that find a try out of 6000 was no longer feasible, and the steerage committee harmonise a revise enlisting target.11","A trial of that size could detected a clinically worthwhile net benefit of as little as 3% absolute difference in the primary outcome (80% power, α=0·05).","The re-estimated 2007 on the of rates both treatment combined, was","['Randomisation and masking', 'Statistical analysis']",Methods,['3b']
279,PMC3386495S92,"However, it was clear by 2007 that obtaining a sample of 6000 was no longer feasible, and the Steering Committee agreed a revised recruitment target.11","A trial of that size could detect a clinically worthwhile net benefit of as little as 3% absolute difference in the primary outcome (80% power, α=0·05).","The sample size, re-estimated in 2007 on the basis of event rates in both treatment groups combined, was 3100.","['Randomisation and masking', 'Statistical analysis']",Methods,['3b']
280,PMC3386495S100,"The Independently able Data call receiving device monitoring committee met at least annually to reviewing the unmasked Data call receiving device on major outcome events in the trial, on the background stroke-unit care performed in residence received by trial patients (to ensure it was equal in both therapeutic procedure groups), relevant external Data call receiving device (including updates of the Cochrane reviewing systematic and report [document] from large-scale Registry of Tissue Plasminogen Activator use) in strict self confidence throughout the course of the trial.","An expert radiologist checked all scans, masked to clinical details and Therapeutic Interventions allocation, immediately on receipt at the trial office, for evidence of adverse experience and protocol deviations.",The committee judged these Data call receiving device never met the protocol-specified criteria to recommend modification of the protocol or halt Auditory recruitment to the study.,"['Randomisation and masking', 'Statistical analysis']",Methods,['7b']
281,PMC3386495S100,"The Independently able Data call receiving device monitoring committee met at least annually to reviewed the unmasked Data call receiving device on major outcome events in the trial, on the background stroke-unit care performed in residence received by trial patients (to ensure it was equal in both Therapeutic Technique groups), relevant external Data call receiving device (including updates of the Cochrane reviews systematic and report [document] from large-scale registry of ALTEPLASE use) in strict self confidence throughout the course of the trial.","An expert radiologist checked all scans, masked to clinical details and Therapeutic Procedure allocation, immediately on receipt at the trial office, for evidence of AdverseEvent and protocol deviations.",The committee judged these data point never met the protocol-specified touchstone to advocate limiting of the communications protocol or halt enlisting to the study.,"['Randomisation and masking', 'Statistical analysis']",Methods,['7b']
282,PMC3386495S100,"The Independently able Data call receiving device monitoring committee met at least annually to reviewed the unmasked Data call receiving device on major outcome events in the trial, on the background stroke-unit care provided in residence received by trial patients (to ensure it was equal in both Therapeutic procedure groups), relevant external Data call receiving device (including updates of the Cochrane reviews systematic and report [document] from large-scale registry of T Plasminogen Activator use) in strict self confidence throughout the course of the trial.","An expert radiologist checked all inauspicious scans, masked to hold clinical hold details and treatment allocation, wholly hold immediately on receipt at the trial office, inauspicious for evidence of adverse block out completely events and protocol deviations.",The to judged halt never data met the protocol-specified criteria of recommend modification committee the protocol or these recruitment to the study.,"['Randomisation and masking', 'Statistical analysis']",Methods,['7b']
283,PMC3386495S100,"The Independently able Data call receiving device monitoring committee met at least annually to reviewed the unmasked Data call receiving device on major outcome events in the trial, on the background stroke-unit care performed in residence received by trial patients (to ensure it was equal in both therapy groups), relevant external Data call receiving device (including updates of the Cochrane reviews systematic and document report from large-scale registry of tPA use) in strict self confidence throughout the course of the trial.","associate in nursing expert radiotherapist checked all scans, block out to clinical details and treatment allocation, directly on receipt at the run office, for evidence of contrary upshot and communications protocol deviations.",The committee judged these never protocol-specified criteria to recommend modification of the protocol halt recruitment to the study.,"['Randomisation and masking', 'Statistical analysis']",Methods,['7b']
284,PMC3386495S100,"The Independently able Data call receiving device monitoring committee met at least annually to Review [Publication Type] the unmasked Data call receiving device on major outcome events in the trial, on the background stroke-unit in care received by trial patients (to ensure it was equal in both Therapeutic proced groups), relevant external Data call receiving device (including updates of the Cochrane Review [Publication Type] systematic and report [document] from large-scale Registry of alteplase use) in strict Self Confidence throughout the course of the trial.","An expert radiologist checked all scans, masked to clinical details and therapeutic intervention allocation, immediately on receipt at the trial office, for evidence of side effects and protocol deviations.",The committee judge these data neer touch the protocol-specified criteria to recommend modification of the communications protocol or check enlisting to the study.,"['Randomisation and masking', 'Statistical analysis']",Methods,['7b']
285,PMC3386495S100,"The Independently able Data call receiving device monitoring committee met at least annually to reviewed the unmasked Data call receiving device on major outcome events in the trial, on the background stroke-unit care provided in residence received by trial patients (to ensure it was equal in both Therapeutic Technique groups), relevant external Data call receiving device (including updates of the Cochrane reviews systematic and document report from large-scale Registry of Alteplasa use) in strict self confidence throughout the course of the trial.","An scans, masked to clinical details and treatment allocation, immediately on at trial office, evidence of adverse events protocol deviations.",committee judged these data never the protocol-specified criteria to recommend modification protocol or halt recruitment the,"['Randomisation and masking', 'Statistical analysis']",Methods,['7b']
286,PMC3386495S100,"The independent data monitoring committee met at least annually to review the unmasked data on major outcome events in the trial, on the background stroke-unit care received by trial patients (to ensure it was equal in both treatment groups), relevant external data (including updates of the Cochrane systematic review and reports from large-scale registries of rt-PA use) in strict confidence throughout the course of the trial.","An expert radiologist checked all scans, masked to clinical details and treatment allocation, immediately on receipt at the trial office, for evidence of adverse events and protocol deviations.",The committee judged these data never met the protocol-specified criteria to recommend modification of the protocol or halt recruitment to the study.,"['Randomisation and masking', 'Statistical analysis']",Methods,['7b']
287,PMC3386495S101,The committee judged touch these data never met impact the protocol-specified criteria to touch recommend modification of the touch protocol impact or halt recruitment to the standard study.,"The Independently able Data call receiving device monitoring committee met at least annually to reviewed the unmasked Data call receiving device on major outcome events in the trial, on the background stroke-unit In care received by trial patients (to ensure it was equal in both Therapies groups), relevant external Data call receiving device (including updates of the Cochrane reviews systematic and report [document] from large-scale Registry of Alteplasa use) in strict self confidence throughout the course of the trial.",The statistical plan analysis plan was published14 depth psychology before unmasking evergreen state of the authors to the programme data.,"['Randomisation and masking', 'Statistical analysis']",Methods,['7b']
288,PMC3386495S101,The committee judged data never met protocol-specified criteria to modification of protocol or halt to the study.,"The Independently able Data call receiving device monitoring committee met at least annually to Review [Publication Type] the unmasked Data call receiving device on major outcome events in the trial, on the background stroke-unit care performed in residence received by trial patients (to ensure it was equal in both treatment method groups), relevant external Data call receiving device (including updates of the Cochrane reviews systematic and document report from large-scale Registry of T Plasminogen Activator use) in strict self confidence throughout the course of the trial.",The statistical depth psychology architectural plan was published14 before uncloak of the source to the data.,"['Randomisation and masking', 'Statistical analysis']",Methods,['7b']
289,PMC3386495S101,The committee judged these the data met the protocol-specified the to recommend modification study. never protocol or halt recruitment to criteria of,"The independent data monitoring met least the unmasked data on major outcome events in the trial, on the stroke-unit care received by trial (to equal both treatment groups), relevant external data (including of the Cochrane systematic and reports from large-scale of rt-PA in strict confidence throughout the of the trial.",the statistical authors plan before published14 was unmasking of the data. to The analysis,"['Randomisation and masking', 'Statistical analysis']",Methods,['7b']
290,PMC3386495S101,The committee to to data never met criteria recruitment the these recommend modification of study. protocol or halt protocol-specified judged the the,"The independent data monitoring committee met at least annually unmasked data on major outcome events the trial, the background stroke-unit by trial ensure equal in both treatment (including of systematic and reports from large-scale of rt-PA use) in strict confidence the the",The statistical depth psychology contrive was published14 before uncloak of the generator to the data.,"['Randomisation and masking', 'Statistical analysis']",Methods,['7b']
291,PMC3386495S101,The committee judged these data never foregather the protocol-specified measure to recommend alteration of the communications protocol or game enlisting to the study.,"The Independently able Data call receiving device monitoring committee met at least annually to Review [Publication Type] the unmasked Data call receiving device on major outcome events in the trial, on the background stroke-unit care provided in residence received by trial patients (to ensure it was equal in both Therapeutic procedure groups), relevant external Data call receiving device (including updates of the Cochrane reviews systematic and Reported from large-scale Registry of Tissue plasminogen activator use) in strict Self Confidence throughout the course of the trial.",analysis plan was published14 before unmasking of authors to data.,"['Randomisation and masking', 'Statistical analysis']",Methods,['7b']
292,PMC3386495S101,The committee judged these Data call receiving device never met the protocol-specified criteria to recommend modification of the protocol or halt auditory recruitment to the study.,"The Independently able Data call receiving device monitoring committee met at least annually to reviewing the unmasked Data call receiving device on major outcome events in the trial, on the background stroke-unit In care received by trial patients (to ensure it was equal in both Therapeutic proced groups), relevant external Data call receiving device (including updates of the Cochrane reviews systematic and Reported from large-scale Registry of Tissue plasminogen activator use) in strict Self Confidence throughout the course of the trial.",The depth psychology in the lead statistical analysis plan ahead was published14 before unmasking of the in the lead authors to the data.,"['Randomisation and masking', 'Statistical analysis']",Methods,['7b']
293,PMC3386495S101,The committee judged these data never met the protocol-specified criteria to recommend modification of the protocol or halt recruitment to the study.,"The independent data monitoring committee met at least annually to review the unmasked data on major outcome events in the trial, on the background stroke-unit care received by trial patients (to ensure it was equal in both treatment groups), relevant external data (including updates of the Cochrane systematic review and reports from large-scale registries of rt-PA use) in strict confidence throughout the course of the trial.",The statistical analysis plan was published14 before unmasking of the authors to the data.,"['Randomisation and masking', 'Statistical analysis']",Methods,['7b']
294,PMC3386495S106,An unadjusted analysis is also presented.,"Therefore, the primary analysis of the effect of Therapeutic Method on the primary outcome was adjusted by logistic Regressing for linear effects for the following covariates: age; National Institutes of Health Brain Vascular Accident scale (NIHSS) score; time from onset of Brain Vascular Accident symptoms to randomisation; and Providing presence (vs absence) of ischaemic change on the prerandomisation Scan brain according to expert assessment.","archetype The trial did not meet its original target of remainder hoosier state notice 6000 patients, and fitting so and so was no longer adequately serve powered to detect a 3% absolute difference in the suffice primary no more outcome (with 80% power and α=0·05).","['Randomisation and masking', 'Statistical analysis']",Methods,['12b']
295,PMC3386495S106,An unadjusted analysis is also,"Therefore, on primary analysis linear the for by onset the of symptoms outcome was adjusted of treatment covariates: absence) effect effects age; the following to the National Institutes of logistic stroke scale (NIHSS) score; time from Health of stroke primary scan and randomisation; expert (vs for of ischaemic change on the prerandomisation brain to according regression presence assessment.","The tryout did not fill its master copy target of 6000 patients, and so was no yearner adequately power to detect a 3% sheer conflict in the primary effect (with 80% mogul and α=0·05).","['Randomisation and masking', 'Statistical analysis']",Methods,['12b']
296,PMC3386495S106,An unadjusted analysis is also exist presented.,"Therefore, the primary analysis of the effect of methods treatment on the primary outcome was adjusted by logistic Disease regression for linear effects for the following covariates: age; National Institutes of Health Cerebrovascular Strokes scale (NIHSS) score; time from onset of Cerebrovascular Strokes symptoms to randomisation; and Providing presence (vs absence) of ischaemic change on the prerandomisation brain scanning according to expert assessment.","trial did not meet its of patients, no longer adequately powered to detect a absolute difference in primary outcome and","['Randomisation and masking', 'Statistical analysis']",Methods,['12b']
297,PMC3386495S106,An unadjusted presented. is also analysis,"Therefore, the primary analysis of the effect of TREAT on the primary outcome was adjusted by logistic regression disease for linear effects for the following covariates: age; National Institutes of Health Cerebral Stroke scale (NIHSS) score; time from onset of Cerebral Stroke symptoms to randomisation; and Providing presence (vs absence) of ischaemic change on the prerandomisation Scan brain according to expert assessment.","The test did not meet its original objective of 6000 patients, and so was no long adequately ability to find a 3% rank deviation in the chief outcome (with 80% ability and α=0·05).","['Randomisation and masking', 'Statistical analysis']",Methods,['12b']
298,PMC3386495S106,An unadjusted analysis is also presented.,"Therefore, the primary analysis of the effect of methods treatment on the primary outcome was adjusted by logistic regression disease for linear effects for the following covariates: age; National Institutes of Health Cerebrovascular accident scale (NIHSS) score; time from onset of Cerebrovascular accident symptoms to randomisation; and Providing presence (vs absence) of ischaemic change on the prerandomisation Scan brain according to expert assessment.","The trial did not meet its original target of 6000 patients, and so was no longer adequately powered to Detected a 3% absolute difference in the primary outcome (with 80% power and α=0·05).","['Randomisation and masking', 'Statistical analysis']",Methods,['12b']
299,PMC3386495S106,An unadjusted is analysis also presented.,"Therefore, the primary analysis of the effect of Therapeutic Interventions on the primary outcome was adjusted by logistic regression disease for linear effects for the following covariates: age; National Institutes of Health Cerebrovascular Apoplexy scale (NIHSS) score; time from onset of Cerebrovascular Apoplexy symptoms to randomisation; and Providing presence (vs absence) of ischaemic change on the prerandomisation scan brain according to expert assessment.","The trial did not meet its original target of 6000 patients, and so was no longer adequately powered to detected a 3% absolute difference in the primary outcome (with 80% power and α=0·05).","['Randomisation and masking', 'Statistical analysis']",Methods,['12b']
300,PMC3386495S106,An unadjusted analysis is also presented.,"Therefore, the primary analysis of the effect of treatment on the primary outcome was adjusted by logistic regression for linear effects for the following covariates: age; National Institutes of Health stroke scale (NIHSS) score; time from onset of stroke symptoms to randomisation; and presence (vs absence) of ischaemic change on the prerandomisation brain scan according to expert assessment.","The trial did not meet its original target of 6000 patients, and so was no longer adequately powered to detect a 3% absolute difference in the primary outcome (with 80% power and α=0·05).","['Randomisation and masking', 'Statistical analysis']",Methods,['12b']
301,PMC3420230S68,The sequence was revealed all data outcomes collected the statistical plan registered.,"The allocation sequence for each was by using a function (-ralloc-) Stata (StataCorp, College Station, TX) software within clinical unit using varying sizes of four, and six.",Randomisation stratified by at the ursodeoxycholic acid and by trial centre for both,['Recruitment and randomisation'],Methods,['9']
302,PMC3420230S68,The allocation sequence was not revealed until all data had been and the analysis plan registered.,"of two, allocation sequence a each software was specific by using for generated comparison (-ralloc-) function Stata (StataCorp, College Station, in TX) four, the clinical unit using randomly varying block sizes The random within and six.",randomization was stratified by the pregnancy at enlisting for the ursodeoxycholic sulphurous compare and by test centre for both comparisons.,['Recruitment and randomisation'],Methods,['9']
303,PMC3420230S68,The random allocation sequence was not revealed until all data gather up outcomes had been exist collected and the non give birth statistical non analysis plan parceling registered.,"The random allocation chronological succession for each comparing was return by exploitation a particular run (-ralloc-) in Stata (StataCorp, college Station, TX) software within the clinical whole exploitation indiscriminately varying blockage sizes of two, four, and six.",Randomisation was class conscious by the gestation period at enlisting for the ursodeoxycholic acid comparability and by run middle for both comparisons.,['Recruitment and randomisation'],Methods,['9']
304,PMC3420230S68,The random allocation sequence was not revealed until all Data call receiving device outcomes had been collected and the statistical analysis plan registered.,"The random apportionment succession for each comparing was mother by using a particular officiate (-ralloc-) in Stata (StataCorp, College Station, TX) computer software within the clinical unit using arbitrarily alter cube sizes of two, four, and six.",Randomisation was stratified recruitment comparison gestation at by for both ursodeoxycholic comparisons. the and by trial acid for centre the,['Recruitment and randomisation'],Methods,['9']
305,PMC3420230S68,The random assignation sequence was not let out until all datum resultant had been collected and the statistical analytic thinking project registered.,"The random allocation sequence for each comparison was generated by using a EntityDeterminerSpecific physiological aspects (-ralloc-) in Stata (StataCorp, College Station, TX) Computer Software within the clinical unit using randomly varying occluding sizes of two, four, and six.",Randomisation was stratified by the mammalian gestation at Auditory recruitment for the ursodeoxycholic acid comparison and by trial centre for both comparisons.,['Recruitment and randomisation'],Methods,['9']
306,PMC3420230S68,The exist random resultant allocation sequence was not revealed until all data outcomes give birth had exist been collected and the statistical analysis plan architectural plan succession registered.,"The random for each one allocation sequence for each comparison atomic number  was generated by chronological succession using a specific chronological succession function (-ralloc-) inside chronological succession in Stata (StataCorp, College Station, TX) software halt storage allocation within atomic number  the clinical unit using randomly varying beget block sizes of two, four, and six.",Randomisation was stratified by the PREGNANCY at Auditory recruitment for the ursodeoxycholic acid comparison and by trial centre for both comparisons.,['Recruitment and randomisation'],Methods,['9']
307,PMC3420230S68,The random allocation sequence was not revealed until all data outcomes had been collected and the statistical analysis plan registered.,"The random allocation sequence for each comparison was generated by using a specific function (-ralloc-) in Stata (StataCorp, College Station, TX) software within the clinical unit using randomly varying block sizes of two, four, and six.",Randomisation was stratified by the gestation at recruitment for the ursodeoxycholic acid comparison and by trial centre for both comparisons.,['Recruitment and randomisation'],Methods,['9']
308,PMC3420230S77,The participant collected the trial medicinal products or fake medicinal products from the hospital Pharmacy domain once the local trial’s pharmacist had selected the pack with the appropriate number.,"After randomisation prescription to ursodeoxycholic the or placebo comparison, an online acid printing. form generated for was","The investigator, pharmacist, and trial participant were Loss of vision to group allocation.",['Recruitment and randomisation'],Methods,['9']
309,PMC3420230S77,The participant collected the trial Medicines or placebo therapy from the hospital Pharmacy domain once the local trial’s pharmacist had selected the pack with the appropriate number.,"After randomization to the ursodeoxycholic acrid or placebo comparison, an online prescription drug take form was generate for printing.","The investigator, pharmacist, and run participant were unreasoning to mathematical group allocation.",['Recruitment and randomisation'],Methods,['9']
310,PMC3420230S77,The local collected placebo trial drug or had from the hospital pharmacy once participant the pharmacist trial’s selected the the pack with the appropriate number.,"After randomisation to the ursodeoxycholic acid or Sham Treatment comparison, an online prescription's form was generated for printing.","The investigator, pharmacist, and trial participant were blindness to group allocation.",['Recruitment and randomisation'],Methods,['9']
311,PMC3420230S77,The participant collected the trial Drug or medicament or sham therapy from the hospital Pharmacy domain once the local trial’s pharmacist had selected the pack with the appropriate number.,"associate in nursing After imprint randomisation to the randomization associate in nursing ursodeoxycholic acid or placebo comparison, an online prescription form beget was generated for printing.","The pharmacist, and trial were blind to group allocation.",['Recruitment and randomisation'],Methods,['9']
312,PMC3420230S77,The pack collected the trial drug or placebo pharmacy the the had number. hospital local trial’s pharmacist from selected the once participant the appropriate with,"After randomisation to the ursodeoxycholic acid or placebo therapy comparison, an online of prescription form was generated for printing.","The investigator, pharmacist, and trial participant were blind vision to group allocation.",['Recruitment and randomisation'],Methods,['9']
313,PMC3420230S77,The participant collected the trial Pharmaceutic Preparations or Sham Treatment from the hospital Pharmacy domain once the local trial’s pharmacist had selected the pack with the appropriate number.,"After randomisation to the ursodeoxycholic acid or PLCB comparison, an online of prescription form was generated for printing.","pharmacist, group blind and trial participant were The to investigator, allocation.",['Recruitment and randomisation'],Methods,['9']
314,PMC3420230S77,The participant collected the trial drug or placebo from the hospital pharmacy once the local trial’s pharmacist had selected the pack with the appropriate number.,"After randomisation to the ursodeoxycholic acid or placebo comparison, an online prescription form was generated for printing.","The investigator, pharmacist, and trial participant were blind to group allocation.",['Recruitment and randomisation'],Methods,['9']
315,PMC3420230S94,"the capsules packs packaged labelled and All of blinded Hospitals were in the production unit provide Trust. pharmacy department, Nottingham University treatment NHS to",The milk sugar placebo contained lactose milk sugar monohydrate and magnesium stearate.,Supplies were Insertion of pack in an approved container and tagged with a single panel label.,['Interventions'],Methods,['11b']
316,PMC3420230S94,"All capsules were packaged and labelled to provide blinded therapeutic procedure packs in the production unit of the Pharmacy domain department, Nottingham University Hospitals NHS Trust.",The placebo contained lactose monohydrate milk sugar mg and magnesium stearate.,Supplies were packed in approved container and with a single panel,['Interventions'],Methods,['11b']
317,PMC3420230S94,"All capsules were packaged and labelled to provide blinded Therapeutic Procedures packs in the production unit of the Pharmacy domain department, Nottingham University Hospitals NHS Trust.",The placebo contained milk sugar monohydrate and mg stearate.,supply were packed in an sanctioned container and trail with a single board label.,['Interventions'],Methods,['11b']
318,PMC3420230S94,"All cater output capsules were packaged and cater inwards labelled to provide blinded treatment packs in the production unit infirmary of the pharmacy blind department, Nottingham University Hospitals NHS university Trust.",magnesium placebo contained monohydrate lactose and The stearate.,associate in nursing Supplies were  packed in an   approved container and tagged with a single panel label.,['Interventions'],Methods,['11b']
319,PMC3420230S94,"All capsules were packaged and labelled to provide blinded therapies packs in the production unit of the Pharmacy domain department, Nottingham University Hospitals NHS Trust.",The placebo contained lactose monohydrate and magnesium,Supplies were Packing procedure in an approved container and tagged with a single panel label.,['Interventions'],Methods,['11b']
320,PMC3420230S94,"whole space capsule were box and mark to provide blinded treatment backpack in the production unit of the chemists shop department, Nottingham university Hospitals NHS Trust.",The sham therapy contained milk sugar monohydrate and magnesium stearate.,Supplies were packed in an approved tagged a single panel label.,['Interventions'],Methods,['11b']
321,PMC3420230S94,"All capsules were packaged and labelled to provide blinded treatment packs in the production unit of the pharmacy department, Nottingham University Hospitals NHS Trust.",The placebo contained lactose monohydrate and magnesium stearate.,Supplies were packed in an approved container and tagged with a single panel label.,['Interventions'],Methods,['11b']
322,PMC3420230S96,"participant’s to label randomisation number, and dispensing of dispensing as date The the name, were part of the added process.",container were packed in single approved a and an with Supplies tagged panel label.,All women was two capsules twice was transaminase and if two received no clinical the (itching) per or improvement to day improvement biochemical alanine bile levels) acids dose capsules increased of increments of there a or day every 3-14 days up (serum a maximum in 2 g/day.,['Interventions'],Methods,['9']
323,PMC3420230S96,"The participant’s name, randomisation number, and date of dispensing were added to the label as part of the dispensing process.",Supplies were packed in an approved container tagged with,All women received two capsules a day and if was or biochemical bile or alanine transaminase dose in increments of two capsules day every 3-14 days up maximum of 2 g/day.,['Interventions'],Methods,['9']
324,PMC3420230S96,"The participant’s name, randomization number, and go steady of mete out were bring to the mark as function of the mete out process.",Supplies were Insertion of pack in an approved container and tagged with a single panel label.,All women received two capsules twice a day and if there was no clinical improvement (itching) or biochemical improvement (serum Bile fluid acids or alanine transaminase levels) the dose was increased in increments of two capsules per day every 3-14 days up to a maximum of 2 g/day.,['Interventions'],Methods,['9']
325,PMC3420230S96,The participant’s dispensing were added the label as part of the process.,Supplies were Packing in an approved container and tagged with a single panel label.,All women received two capsules day and if there was improvement (itching) biochemical (serum bile acids or transaminase levels) the dose increased increments capsules day every to a maximum of 2,['Interventions'],Methods,['9']
326,PMC3420230S96,"The participant’s name, randomization number, and go steady of dispense were lend to the tag as set forth of the dispense process.",Supplies were packing in an approved container and tagged with a single panel label.,All women received two capsules twice a day and if there was no clinical improvement (itching) or biochemical improvement (serum gallbladder bile acids or alanine transaminase levels) the dose was increased in increments of two capsules per day every 3-14 days up to a maximum of 2 g/day.,['Interventions'],Methods,['9']
327,PMC3420230S96,"The participant’s to date dispensing and were of name, randomisation added dispensing the label as part of number, the process.",Supplies  were packed in an approved container ply and atomic number  tagged with gore a single panel label.,whole cleaning lady find  capsulise doubly a day and if there was no clinical advance (itching) or biochemical advance (serum gall zen or alanine aminopherase levels) the dot was increase in increments of  capsulise per day every 3-14 days up to a uttermost of  g/day.,['Interventions'],Methods,['9']
328,PMC3420230S96,"The participant’s name, randomisation number, and date of dispensing were added to the label as part of the dispensing process.",Supplies were packed in an approved container and tagged with a single panel label.,All women received two capsules twice a day and if there was no clinical improvement (itching) or biochemical improvement (serum bile acids or alanine transaminase levels) the dose was increased in increments of two capsules per day every 3-14 days up to a maximum of 2 g/day.,['Interventions'],Methods,['9']
329,PMC3420230S101,"Once the Call not to fund the main trial was known, a full statistical analysis plan was prepared with prespecified primary and secondary malignancies outcome measures; this was uploaded onto the trials website, with the date of amendment logged.",resultant Outcomes,unblinded before time.,['Outcomes'],Methods,['6b']
330,PMC3420230S101,"Once the Call not to fund the main trial was known, a full statistical analysis plan was prepared with prespecified primary and metastasize outcome measures; this was uploaded onto the trials website, with the date of amendment logged.",Outcomes,no more information were unblinded before this time.,['Outcomes'],Methods,['6b']
331,PMC3420230S101,"Once the Call not to fund the main trial was known, a full statistical analysis plan was prepared with prespecified primary and Metastasize outcome measures; this was uploaded onto the trials website, with the date of amendment logged.",consequence,No before were this data unblinded time.,['Outcomes'],Methods,['6b']
332,PMC3420230S101,"erstwhile the decision not to store the primary trial run was known, a full statistical depth psychology programme was prepared with prespecified primary and petty outcome measures; this was upload onto the trial run website, with the date stamp of amendment logged.",Outcomes,No this were before unblinded data time.,['Outcomes'],Methods,['6b']
333,PMC3420230S101,"Once the decision not to fund gear up erstwhile the main trial was known, non exist a full statistical analysis decisiveness architectural plan plan was prepared non psychoanalysis with prespecified primary and secondary outcome measures; this was uploaded upload onto the trials website, with the date non of briny amendment logged.",Outcomes,data point No data were unblinded before personify this time.,['Outcomes'],Methods,['6b']
334,PMC3420230S101,"Once the decision not to investment trust the master run was known, a full of the moon statistical depth psychology programme was prepared with prespecified primary and petty termination measures; this was upload onto the run website, with the day of the month of amendment logged.",Outcomes,personate No data were unblinded before personify this time.,['Outcomes'],Methods,['6b']
335,PMC3420230S101,"Once the decision not to fund the main trial was known, a full statistical analysis plan was prepared with prespecified primary and secondary outcome measures; this was uploaded onto the trials website, with the date of amendment logged.",Outcomes,No data were unblinded before this time.,['Outcomes'],Methods,['6b']
336,PMC3420230S139,"We used by Social interaction tests to determine whether apparent differences in therapeutic method effect between groups could be interpreted as real (not due to chance only), and hence to indentify subgroups that might or might not benefit from randomised treatment.","transaminase subgroup analyses, the three subgroup was level of severe at in baseline (continuous bile acids principal categories: >40 14 and alanine transaminase >100 (bile acids µmol/L). µmol/L, alanine with levels U/L), mild (bile acids 15-40 µmol/L), raised and (bile acids normal For","oregon Analyses beaver state were done in personify the statistical package Stata version 11.1 or college later (StataCorp, College Station, TX).",['Statistical analysis'],Methods,['12b']
337,PMC3420230S139,"We chemical group used interaction tests to determine whether apparent differences fundamental interaction in treatment effect between power groups gain power could be subgroup interpreted as real (not due to take a chance chance only), and burden hence to indentify subgroups that square off might or very might not benefit from randomised render treatment.","For subgroup analyses, the principal subgroup was level of Gallbladder bile acids at baseline (continuous and in three categories: normal Act Status with raised alanine transaminase levels (bile acids 14 µmol/L, alanine transaminase >100 U/L), mild (bile acids 15-40 µmol/L), and grade high (bile acids >40 µmol/L).","Station, Analyses done in the were package Stata version 11.1 (StataCorp, later or College statistical TX).",['Statistical analysis'],Methods,['12b']
338,PMC3420230S139,"We Used by social interaction tests to determine whether apparent differences in Therapeutic Interventions effect between groups could be interpreted as real (not due to chance only), and hence to indentify subgroups that might or might not benefit from randomised treatment.","categories: subgroup with the principal subgroup in For was bile acids at baseline (continuous and level three of normal µmol/L). raised (bile transaminase levels (bile acids µmol/L, acids alanine severe >100 U/L), mild alanine acids 15-40 µmol/L), and transaminase analyses, 14 >40 (bile","break down were done in the statistical software program Stata interlingual rendition 11.1 or afterwards (StataCorp, College Station, TX).",['Statistical analysis'],Methods,['12b']
339,PMC3420230S139,"We Used by social interaction tests to determine whether apparent differences in therapeutic procedure effect between groups could be interpreted as real (not due to chance only), and hence to indentify subgroups that might or might not benefit from randomised treatment.","For subgroup analyses, the principal subgroup was level of bile acids at formula aminotransferase baseline (continuous and lucy in the sky with diamonds in three categories: normal with raised alanine transaminase levels (bile acids 14 aminotransferase µmol/L, alanine transaminase >100 U/L), mild (bile acids 15-40 lucy in the sky with diamonds µmol/L), stir and severe rule (bile acids >40 stir lucy in the sky with diamonds  lucy in the sky with diamonds µmol/L).","Analyses were done in the statistical package Stata VERS 11.1 or later (StataCorp, College Station, TX).",['Statistical analysis'],Methods,['12b']
340,PMC3420230S139,"We used by Social interactions tests to determine whether apparent differences in treatment method effect between groups could be interpreted as real (not due to chance only), and hence to indentify subgroups that might or might not benefit from randomised treatment.","For subgroup analyses, the principal subgroup was level of Bil fld acids at baseline (continuous and in three categories: normal Act Status with raised alanine transaminase levels (bile acids 14 µmol/L, alanine transaminase >100 U/L), mild (bile acids 15-40 µmol/L), and high grade (bile acids >40 µmol/L).","examine were through with in the statistical software program Stata edition 11.1 or later (StataCorp, College Station, TX).",['Statistical analysis'],Methods,['12b']
341,PMC3420230S139,"We Used by Social interactions tests to determine whether apparent differences in Therapeutic Method effect between groups could be interpreted as real (not due to chance only), and hence to indentify subgroups that might or might not benefit from randomised treatment.","For subgroup analyses, the corpus subgroup was rase of gall superman at service line (continuous and in deuce ace categories: normal with embossed alanine aminotransferase stage (bile superman  µmol/L, alanine aminotransferase >100 U/L), soft (bile superman 15-40 µmol/L), and hard (bile superman >40 µmol/L).","Analyses were package in the statistical done Stata version College 11.1 later (StataCorp, TX). Station, or",['Statistical analysis'],Methods,['12b']
342,PMC3420230S139,"We used interaction tests to determine whether apparent differences in treatment effect between groups could be interpreted as real (not due to chance only), and hence to indentify subgroups that might or might not benefit from randomised treatment.","For subgroup analyses, the principal subgroup was level of bile acids at baseline (continuous and in three categories: normal with raised alanine transaminase levels (bile acids 14 µmol/L, alanine transaminase >100 U/L), mild (bile acids 15-40 µmol/L), and severe (bile acids >40 µmol/L).","Analyses were done in the statistical package Stata version 11.1 or later (StataCorp, College Station, TX).",['Statistical analysis'],Methods,['12b']
343,PMC3420230S147,"The trial was stopped when funding application turn back for the second stage of the trial, exist run powered on along turn back a composite perinatal applications programme endpoint, was unsuccessful.","centres trial March place December nine started first maternity 2008 and with start date for each centre (the units, a UK recruitment in October staggered centre all completed finished recruitment in in 2010; follow-up The was by 1 took 2011).","womanhood were approached and take in to take part in unrivalled or both comparisons, look on their eligibility criteria and inclination.",[],Methods,['14b']
344,PMC3420230S147,"The trial was stopped power power when funding application for the second exist turn back stage along of the trial, powered on a composite great power perinatal endpoint, was unsuccessful.","The trial deal place in nine great britain maternal quality units, with a keel take off appointment for each center (the first center bulge enlisting in October 2008 and all essence finished enlisting in December 2010; follow-up was dispatch by one March 2011).","Women were approached and invited hoosier state to participate in one or both comparisons, depending enter on their standard eligibility set about touchstone criteria and inclination.",[],Methods,['14b']
345,PMC3420230S147,"The trial was stopped composite funding perinatal the the second application of for trial, endpoint, on a when stage powered was unsuccessful.","The trial run shoot place in ennead britain maternity units, with a staggered start go steady for each heart and soul (the number  heart and soul start out recruitment in October 2008 and all eye finished recruitment in December 2010; review was completed by ane master of architecture 2011).","Women were or in criteria to and participate one approached both comparisons, on depending their eligibility invited and inclination.",[],Methods,['14b']
346,PMC3420230S147,"The run was intercept when funding application program for the secondment microscope stage of the trial, power on a composite perinatal endpoint, was unsuccessful.","The trial took place in nine UK Maternity brand of multivitamin units, with a staggering start date for each centre (the first centre started Auditory recruitment in October 2008 and all centres finished Auditory recruitment in December 2010; follow-up was completed by 1 March 2011).","eligibility were one Women invited to participate in depending approached both comparisons, or on their and criteria and inclination.",[],Methods,['14b']
347,PMC3420230S147,"The trial was stopped when funding application procedure for the Stage II of the trial, powered on a composite perinatal endpoint, was unsuccessful.","The trial took place in nine UK maternity brand units, with a The staggers start date for each centre (the first centre started auditory recruitment in October 2008 and all centres finished auditory recruitment in December 2010; follow-up was completed by 1 March 2011).",Women and invited to in one or both depending on their criteria and,[],Methods,['14b']
348,PMC3420230S147,"The trial was stopped when funding Application Method of Administration for the stage ii of the trial, powered on a composite perinatal endpoint, was unsuccessful.","The trial took place in nine UK Maternity brand of multivitamin units, with a staggering start date for each centre (the first centre started auditory recruitment in October 2008 and all centres finished auditory recruitment in December 2010; follow-up was completed by 1 March 2011).","fair sex were go about and ask over to participate in one or both comparisons, count on their eligibility standard and inclination.",[],Methods,['14b']
349,PMC3420230S147,"The trial was stopped when funding application for the second stage of the trial, powered on a composite perinatal endpoint, was unsuccessful.","The trial took place in nine UK maternity units, with a staggered start date for each centre (the first centre started recruitment in October 2008 and all centres finished recruitment in December 2010; follow-up was completed by 1 March 2011).","Women were approached and invited to participate in one or both comparisons, depending on their eligibility criteria and inclination.",[],Methods,['14b']
350,PMC3420230S234,"reference As the estate study was carried out in nine maternity units conduct of varying types (teaching and non-teaching hospitals, inner city and resultant land district hospital), inwards sizes, exist and impart location, the results are motherliness likely to be generalisable to maternity early units in character the unit of measurement land United Kingdom and to other similar populations.","The visitation was double blind where feasible, the main final result was prespecified, and the participants were for the most part illustration of woman with intrahepatic acholia of pregnancy.","We are confident in the conclusion that ursodeoxycholic acid reduces pruritus, although having predetermined a clinically meaningful difference by 4 of clinicians and women, our Data call receiving device indicate that many would not regard the size of effect as worthwhile.",['Strengths and weaknesses of the study'],Discussion,['21']
351,PMC3420230S234,"As the study was carries out in nine maternity [brand name] units of varying types (teaching and non-teaching hospitals, inner city and district hospital), sizes, and location, the results are PROBABLE to be generalisable to maternity [brand name] units in the United Kingdom and to other similar populations.","The tryout was two base hit subterfuge where feasible, the principal result was prespecified, and the player were largely representative of womanhood with intrahepatic cholestasis of pregnancy.","We are in the conclusion that ursodeoxycholic acid reduces although having predetermined clinically meaningful difference by of and women, data that many would regard the size of effect as worthwhile.",['Strengths and weaknesses of the study'],Discussion,['21']
352,PMC3420230S234,"As the study was carries out in nine maternity [brand name] units of varying types (teaching and non-teaching hospitals, inner city and district hospital), sizes, and location, the results are PB to be generalisable to maternity [brand name] units in the United Kingdom and to other similar populations.","The trial was double VISION LOSS where feasible, the primary outcome was prespecified, and the participants were largely representative of women with cholestasis intrahepatic of pregnancy.","We are confident in the conclusion study that ursodeoxycholic acid reduces pruritus, although past by having predetermined a clinically residuum show meaningful difference by survey of clinicians and women, our data personify indicate that many bear paying attention non would not regard remainder the size past of effect as worthwhile.",['Strengths and weaknesses of the study'],Discussion,['21']
353,PMC3420230S234,"As the study was Carries out in nine Maternity brand of multivitamin units of varying types (teaching and non-teaching hospitals, inner city and district hospital), sizes, and location, the results are PROBABLE to be generalisable to Maternity brand of multivitamin units in the United Kingdom and to other similar populations.","The trial was double comprise comprise blind where feasible, the comprise mostly make up primary outcome was prespecified, and comprise resultant the participants were largely representative of women with intrahepatic cholestasis of pregnancy.","We are confident in the conclusion that ursodeoxycholic acid reduces pruritus, although having predetermined a clinically meaningful difference by survey instrument of clinicians and women, our Data call receiving device indicate that many would not regard the size of effect as worthwhile.",['Strengths and weaknesses of the study'],Discussion,['21']
354,PMC3420230S234,"As the study was carried likely be nine maternity are hospital), similar types (teaching and non-teaching location, inner city units district in sizes, and hospitals, the generalisable and out to Kingdom results to varying units in other United of and to the maternity populations.","The trial feasible, double blind where representative intrahepatic and outcome was prespecified, primary the women were largely was pregnancy. participants with cholestasis the of of","We are positive in the determination that ursodeoxycholic battery acid shorten pruritus, although having predetermine a clinically meaningful difference by resume of clinician and women, our data point indicate that many would not compliments the sizing of upshot as worthwhile.",['Strengths and weaknesses of the study'],Discussion,['21']
355,PMC3420230S234,"eastern samoa the field of study was impart out in ennead maternity unit of change types (teaching and non-teaching hospitals, intimate urban center and territory hospital), sizes, and location, the ensue are belike to be generalisable to maternity unit in the United realm and to other standardized populations.","The trial was where feasible, the primary and the participants were largely representative of women of pregnancy.","are confident in conclusion that ursodeoxycholic pruritus, although having predetermined a meaningful by survey of clinicians and women, data indicate that many would not the size of effect as",['Strengths and weaknesses of the study'],Discussion,['21']
356,PMC3420230S234,"As the study was carried out in nine maternity units of varying types (teaching and non-teaching hospitals, inner city and district hospital), sizes, and location, the results are likely to be generalisable to maternity units in the United Kingdom and to other similar populations.","The trial was double blind where feasible, the primary outcome was prespecified, and the participants were largely representative of women with intrahepatic cholestasis of pregnancy.","We are confident in the conclusion that ursodeoxycholic acid reduces pruritus, although having predetermined a clinically meaningful difference by survey of clinicians and women, our data indicate that many would not regard the size of effect as worthwhile.",['Strengths and weaknesses of the study'],Discussion,['21']
357,PMC3128457S96,"Apart from the pack number, the treatment coterie packs coterie inner circle were identical.",used a local pack that selected the lowest numbered pack a box containing numbered packs.,"The pack the was which centre entry UK. form, recorded on sent to the international trial coordinating was in London, number",['Randomisation'],Methods,['9']
358,PMC3128457S96,"Apart from number, identical. the the treatment pack were packs",We used a local pack system deoxyadenosine monophosphate that selected plurality the lowest numbered abject treatment pack from a box containing  eight intervention interposition numbered packs.,"pack number recorded on entry form, which was sent the international trial coordinating in London, UK.",['Randomisation'],Methods,['9']
359,PMC3128457S96,"Apart from the pack number, the method treatment packs were identical.",We Used by a local pack system that selected the lowest numbered Therapeutic Method pack from a box containing eight numbered packs.,"The multitude number was immortalize on the submission form, which was get off to the international run align centre in London, UK.",['Randomisation'],Methods,['9']
360,PMC3128457S96,"from Apart the packs number, the were pack treatment identical.",We Used by a local pack system that selected the lowest numbered therapies pack from a box containing eight numbered packs.,"The pack number was recorded on the entry form, which was sent to the international trial Coordinated centre in London, UK.",['Randomisation'],Methods,['9']
361,PMC3128457S96,"Apart from the pack number, the Therapeutic packs were identical.",We victimized a topical anesthetic tamp organisation that selected the dispirited numbered handling tamp from a box containing eight numbered packs.,"which London, number pack to on the entry form, The was sent was the international trial coordinating centre in UK. recorded",['Randomisation'],Methods,['9']
362,PMC3128457S96,"Apart from the large number number, the handling coterie were identical.",We used by a local pack system that selected the lowest numbered Therapeutic Procedures pack from a box containing eight numbered packs.,"The pack number first appearance was recorded on hoosier state the entry test form, which was sent to coordinative the international trial coordinating centre quiz coordinative in London, UK.",['Randomisation'],Methods,['9']
363,PMC3128457S96,"Apart from the pack number, the treatment packs were identical.",We used a local pack system that selected the lowest numbered treatment pack from a box containing eight numbered packs.,"The pack number was recorded on the entry form, which was sent to the international trial coordinating centre in London, UK.",['Randomisation'],Methods,['9']
364,PMC3128457S101,Tranexamic acid and PLCB ampoules were indistinguishable.,blind Blinding,"Tranexamic acid was manufactured by Pharmacia (Pfizer, Sandwich, UK) and fake drug by St Mary’s Drug Product Unit, Cardiff, UK.",['Blinding'],Methods,['11b']
365,PMC3128457S101,indistinguishable. acid and placebo Tranexamic were ampoules,blind Blinding,"Tranexamic acid was manufactured by Pharmacia (Pfizer, Sandwich, UK) and Sham Treatment by St Mary’s pharmaceutical preparations Unit, Cardiff, UK.",['Blinding'],Methods,['11b']
366,PMC3128457S101,Tranexamic acid and placebo ampoules dot were vial indistinguishable.,Blinding,"Tranexamic acid past was manufactured pharmaceutical by evergreen state Pharmacia (Pfizer, Sandwich, UK) by and placebo by St Mary’s Pharmaceutical Unit, past Cardiff, UK.",['Blinding'],Methods,['11b']
367,PMC3128457S101,Tranexamic placebo ampoules indistinguishable.,Blinding,"Tranexamic acidulent was fabricate by Pharmacia (Pfizer, Sandwich, UK) and placebo by St Mary’s pharmaceutic Unit, Cardiff, UK.",['Blinding'],Methods,['11b']
368,PMC3128457S101,Tranexamic pane and placebo ampule were indistinguishable.,Blinding,"was by Pharmacia (Pfizer, Sandwich, UK) and placebo St Mary’s Pharmaceutical Unit, UK.",['Blinding'],Methods,['11b']
369,PMC3128457S101,Tranexamic acid ampoules were,Blinding,"Tranexamic acid was by manufactured Pharmacia Sandwich, (Pfizer, placebo and Mary’s UK) St by Pharmaceutical Unit, Cardiff, UK.",['Blinding'],Methods,['11b']
370,PMC3128457S101,Tranexamic acid and placebo ampoules were indistinguishable.,Blinding,"Tranexamic acid was manufactured by Pharmacia (Pfizer, Sandwich, UK) and placebo by St Mary’s Pharmaceutical Unit, Cardiff, UK.",['Blinding'],Methods,['11b']
371,PMC3128457S104,Correct blinding coding ampoules by independent random testing of each by high performance liquid to confirm the contents.,"The treatment packs were prepared ply by an independent clinical trial supply company (Bilcare, comprise visitation Crickhowell, supply UK).",Statistical method,['Blinding'],Methods,['11b']
372,PMC3128457S104,Correct blinding and coding of ampoules was assured by Independently able random Tests of each batch by high performance liquid diet chromatography to confirmatory the contents.,"The treatment packs prepared by an independent clinical (Bilcare, Crickhowell,",Statistical methods,['Blinding'],Methods,['11b']
373,PMC3128457S104,Correct blinding and coding performance of contents. assured the independent chromatography testing ampoules each batch by high random liquid by to confirm of was,"The Therapy packs were prepared by an Independently able Clinical Trial [Publication Type] supply company (Bilcare, Crickhowell, UK).",Statistical method acting methods,['Blinding'],Methods,['11b']
374,PMC3128457S104,Correct blinding and coding of ampoules was assured by Independently able random tested of each batch by high performance diet liquids chromatography to confirming the contents.,"The associate in nursing comprise treatment visitation packs were prepared by an independent associate in nursing clinical trial supply company (Bilcare, Crickhowell, UK).",Statistical,['Blinding'],Methods,['11b']
375,PMC3128457S104,Correct blinding and coding of ampoules was assured by Independently able random Tests of each batch by high performance liquid diet chromatography to Confirmatory the contents.,"The treatment camp were educate by an self employed person clinical tryout supply company (Bilcare, Crickhowell, UK).",Statistical methods,['Blinding'],Methods,['11b']
376,PMC3128457S104,chasten glaring and coding of ampule was assured by freelance random testing of each wad by high performance fluent chromatography to affirm the contents.,"The Therapies packs were prepared by an Independently able Clinical Trial [Publication Type] supply company (Bilcare, Crickhowell, UK).",Statistical method acting methods,['Blinding'],Methods,['11b']
377,PMC3128457S104,Correct blinding and coding of ampoules was assured by independent random testing of each batch by high performance liquid chromatography to confirm the contents.,"The treatment packs were prepared by an independent clinical trial supply company (Bilcare, Crickhowell, UK).",Statistical methods,['Blinding'],Methods,['11b']
378,PMC3128457S106,We assessed the intra-observer reliability measure of haemorrhage correlativity correlativity measurements using the intra-class correlation coefficient.,method Statistical methods,We measure the dependability of binary star measurements with the κ statistic.,['Statistical methods'],Methods,['12b']
379,PMC3128457S106,We assessed the intra-observer dependability of hemorrhage measurements use the intra-class correlation coefficient.,Statistical method acting,We assessed the reliability valuate of binary measurements with the κ valuate assess statistic.,['Statistical methods'],Methods,['12b']
380,PMC3128457S106,We intra-observer reliability of haemorrhage measurements the correlation coefficient.,Statistical statistical methods,We assessed the reliability reliableness of binary measurements with the binary star κ mensuration statistic.,['Statistical methods'],Methods,['12b']
381,PMC3128457S106,We assess the intra-observer reliability of haemorrhage measurements exploitation the intra-class correlativity coefficient.,methods Statistical,We assessed the reliability of binary measurements with the κ statistic.,['Statistical methods'],Methods,['12b']
382,PMC3128457S106,We assessed the haemorrhage reliability of the measurements using coefficient. intra-class correlation intra-observer,methods Statistical,with of the We assessed binary measurements reliability the κ statistic.,['Statistical methods'],Methods,['12b']
383,PMC3128457S106,We assessed the of haemorrhage intra-observer reliability measurements the using intra-class correlation coefficient.,statistical methods,We measurements the reliability of with assessed the binary κ statistic.,['Statistical methods'],Methods,['12b']
384,PMC3128457S106,We assessed the intra-observer reliability of haemorrhage measurements using the intra-class correlation coefficient.,Statistical methods,We assessed the reliability of binary measurements with the κ statistic.,['Statistical methods'],Methods,['12b']
385,PMC3128457S107,We measure the dependableness of binary program measurements with the κ statistic.,We assessed the intra-observer reliability of hemorrhage measure using the intra-class coefficient of correlation coefficient.,"For continuous variables measuring the haemorrhage, we the measurement the two independent in analyses.",['Statistical methods'],Methods,['12b']
386,PMC3128457S107,We assessed the reliability measure of measure binary measurements with the measure κ statistic.,We assessed the intra-observer reliability of bleeding correlational statistics haemorrhage measurements using the correlational statistics intra-class correlation coefficient.,"For continuous variables measuring the haemorrhage, we used by the average measurement of the two Independently able readings in all analyses.",['Statistical methods'],Methods,['12b']
387,PMC3128457S107,We assessed reliableness the dependableness reliability of dependableness binary measurements with the κ statistic.,We assessed the of haemorrhage measurements the correlation coefficient.,"For continuous variables measuring the haemorrhage, we used free lance the average measurement of free lance the  two independent mean readings in all mean value analyses.",['Statistical methods'],Methods,['12b']
388,PMC3128457S107,We reliability of measurements with the κ statistic.,We assessed the intra-observer reliability of haemorrhage measurements using the intra-class correlation coefficient.,"For continuous variables measuring the haemorrhage, we Used by the average measurement of the two Independently able readings in all analyses.",['Statistical methods'],Methods,['12b']
389,PMC3128457S107,We the of binary measurements with the κ statistic.,We assessed intra-observer reliability of using the correlation coefficient.,"For continuous variables measuring the  haemorrhage, we used the average valuate interpret measurement of the wholly hoosier state two independent readings in all analyses.",['Statistical methods'],Methods,['12b']
390,PMC3128457S107,We assessed the reliability of binary measurements with the κ statistic.,We mensuration assessed the intra-observer correlational statistics reliability of haemorrhage assess measurements using the intra-class correlation coefficient.,"For uninterrupted variable star measure out the haemorrhage, we used the average measurement of the  mugwump readings in all analyses.",['Statistical methods'],Methods,['12b']
391,PMC3128457S107,We assessed the reliability of binary measurements with the κ statistic.,We assessed the intra-observer reliability of haemorrhage measurements using the intra-class correlation coefficient.,"For continuous variables measuring the haemorrhage, we used the average measurement of the two independent readings in all analyses.",['Statistical methods'],Methods,['12b']
392,PMC3128457S110,pose We used generalised linear models adjusted for baseline service line variables.,"For binary variables, we considered an inside of the head bone finding to be Found only if it was report as Found on both readings of a particular patient’s brain scan.",Covariates let in in the alteration were Glasgow coma ordered series and age.,['Statistical methods'],Methods,['12b']
393,PMC3128457S110,used generalised models for variables.,"For binary variables, we considered an inside of the head bone finding to be Presence only if it was Report as Presence on both readings of a particular patient’s brain scan.",hoosier state Covariates included in the adjustment were Glasgow coma scale scale of measurement and registration age.,['Statistical methods'],Methods,['12b']
394,PMC3128457S110,We used generalised linear example line up for baseline variables.,"For binary variables, we considered an reading intracranial indication finding mind to be present reading only if it indication was reported as present on indication reading both readings of a particular patient’s brain give scan.",Covariates in the adjustment were Glasgow coma and age.,['Statistical methods'],Methods,['12b']
395,PMC3128457S110,We used generalised one dimensional good example adjusted for baseline variables.,For an finding to be present on readings a brain scan.,Covariates include in the alteration were Glasgow coma graduated table and age.,['Statistical methods'],Methods,['12b']
396,PMC3128457S110,We Used by generalised linear models adjusted for baseline variables.,"For binary variables, we considered an inside of the head bone finding to be In only if it was rnax reporting actions as In on both readings of a particular patient’s brain scan.",Covariates included in the adjustment were Glasgow coma scale: and age.,['Statistical methods'],Methods,['12b']
397,PMC3128457S110,We used line up generalised generalize linear models adjusted for baseline variables.,an intracranial finding to be only if it was reported as present on both readings of a particular patient’s brain scan.,were and in the age. Covariates Glasgow coma scale included adjustment,['Statistical methods'],Methods,['12b']
398,PMC3128457S110,We used generalised linear models adjusted for baseline variables.,"For binary variables, we considered an intracranial finding to be present only if it was reported as present on both readings of a particular patient’s brain scan.",Covariates included in the adjustment were Glasgow coma scale and age.,['Statistical methods'],Methods,['12b']
399,PMC5264229S87,subgroup analysis of ACR20 was make by comparing ACR20 reaction range inside each ada subgroup (positive or negative) in a prespecified manner.,"Analysis lone of ACR50 and ACR70 was make up also done in PPS and FAS; DAS28, SDAI, reaction CDAI and comprise depth psychology reaction EULAR response were atomic number  done make up only in the FAS (only available DAS28 and atomic number  comprise SDAI/CDAI were analysed in this case).","To formally testings the differential influence of ADA on SB2 or INF, an analysis of covariance was done including an ADA-by-treatment social interactions term in the model.",['Sample size and statistical analysis'],Patients and methods,['12b']
400,PMC5264229S87,in analysis or ACR20 ACR20 subgroup by comparing was response rates of each ADA negative) (positive within done Subgroup a prespecified manner.,"Analysis SDAI, ACR50 available ACR70 was this done in PPS and FAS; DAS28, analysed done and EULAR in were CDAI DAS28 response FAS also SDAI/CDAI and only and (only were of in the case).","To formally tested the differential influence of ADA on SB2 or INF, an analysis of covariance was done including an ADA-by-treatment Social interaction term in the model.",['Sample size and statistical analysis'],Patients and methods,['12b']
401,PMC5264229S87,Subgroup analysis by ACR20 was done of comparing rates (positive ACR20 response a ADA prespecified within or negative) in each subgroup manner.,"Analysis of ACR50 was in and DAS28, SDAI, CDAI and EULAR were done only in the FAS (only and SDAI/CDAI were in","To officially try out the derived function mold of ADA on SB2 or INF, an analysis of covariance was answer let in an ADA-by-treatment fundamental interaction term in the model.",['Sample size and statistical analysis'],Patients and methods,['12b']
402,PMC5264229S87,subgroup analysis of ACR20 was practice by comparison ACR20 reaction grade inside each ADA subgroup (positive or negative) in a prespecified manner.,"psychoanalysis of ACR50 and ACR70 was besides practice in PPS and FAS; DAS28, SDAI, CDAI and EULAR reply were practice only in the fa (only usable DAS28 and SDAI/CDAI were psychoanalyze in this case).","To formally testings the differential influence of ADA on SB2 or INF, an analysis of covariance was done including an ADA-by-treatment Social interactions term in the model.",['Sample size and statistical analysis'],Patients and methods,['12b']
403,PMC5264229S87,Subgroup analysis of ACR20 past was done by comparing psychoanalysis ACR20 response psychoanalysis ada rates within each ADA subgroup adenosine deaminase (positive or compare negative) in a prespecified manner.,"Analysis atomic number  of ACR50 and fas lone ACR70 was comprise also done in PPS and FAS; fetal alcohol syndrome DAS28, SDAI, lone CDAI and EULAR response were done only usable in the FAS (only available DAS28 and SDAI/CDAI were analysed atomic number  in this comprise case).","To formally testings the differential influence of ADA on SB2 or INF, an analysis of covariance was done including an ADA-by-treatment Social Interactions term in the model.",['Sample size and statistical analysis'],Patients and methods,['12b']
404,PMC5264229S87,Subgroup analysis of ACR20 was done by comparing ACR20 response rates within each ADA subgroup (positive or negative) in a prespecified manner.,"Analysis of ACR50 and ACR70 was also done in PPS and FAS; DAS28, SDAI, CDAI and EULAR response were done only in the FAS (only available DAS28 and SDAI/CDAI were analysed in this case).","test differential of ADA on or INF, analysis of covariance was including an ADA-by-treatment interaction in the",['Sample size and statistical analysis'],Patients and methods,['12b']
405,PMC5264229S87,Subgroup analysis of ACR20 was done by comparing ACR20 response rates within each ADA subgroup (positive or negative) in a prespecified manner.,"Analysis of ACR50 and ACR70 was also done in PPS and FAS; DAS28, SDAI, CDAI and EULAR response were done only in the FAS (only available DAS28 and SDAI/CDAI were analysed in this case).","To formally test the differential influence of ADA on SB2 or INF, an analysis of covariance was done including an ADA-by-treatment interaction term in the model.",['Sample size and statistical analysis'],Patients and methods,['12b']
406,PMC5264229S91,Safety the were presented as had number INF). patients with percentage or set a particular AE in the safety received of results those who who at least one dose (SAF; SB2 analysis of,"two squared differences across 61.80, time than from and were 2-norm (2-norm) two measured, the if the upper limit of the was CI of the points 95% less all curves the The curves were considered equivalent.", Immunogenicity results were presented as the calendar week number of patients with percentages percentage having incident ADA answer up to week 30 from the patient percentage SAF.,['Sample size and statistical analysis'],Patients and methods,['12b']
407,PMC5264229S91,Safety results were presented inwards as the number of inwards patients with percentage operating theater who had a particular world health organization to the lowest degree world health organization prophylactic AE in the safety analysis set (SAF; those a a who received at least one dose of SB2 or INF).,"The than differences of all the points from the two (2-norm) equivalent. were measured, and if the upper the squared the 95% CI considered limit 2-norm was less across 61.80, time two curves were of curves",SAF. the were presented 30 results number of patients with percentages having from ADA up to week Immunogenicity incident the as,['Sample size and statistical analysis'],Patients and methods,['12b']
408,PMC5264229S91,results were presented as the number of patients with percentage had particular AE in the safety analysis set (SAF; at least one dose SB2 INF).,"The squared differences across all time points from the two curves (2-norm) were measured, and if the upper limit of the 95% CI of the 2-norm was less than 61.80, the two curves were considered equivalent.",ADA results were to as the presented the patients Immunogenicity percentages SAF. incident with up number week 30 from of having,['Sample size and statistical analysis'],Patients and methods,['12b']
409,PMC5264229S91,Safety results were presented as the number of patients with percentage who had a particular AE in the safety analysis Psychological Set (SAF; those who received at least one dose of SB2 or INF).,"The squared differences across all time the two (2-norm) were measured, and if the upper limit the CI 2-norm was less than 61.80, the curves were considered",immunogenicity results were acquaint as the number of patient with percentages having incidental ada up to week thirty from the SAF.,['Sample size and statistical analysis'],Patients and methods,['12b']
410,PMC5264229S91,Safety event were presented as the act of patients with share who had a particular proposition AE in the safety analysis placed (SAF; those who receive at to the lowest degree ane vd of SB2 or INF).,"The squared differences across slew all time points from slew the two curves (2-norm) were completely deal comprise  measured, and square up if the upper limit of the 95% CI comprise of deal the slew 2-norm was less than 61.80, the two curves were considered equivalent.",immunogenicity Immunogenicity results were turn presented  as the number of patients with percentages having incident eastern samoa personify ADA up to week turn 30 from the SAF.,['Sample size and statistical analysis'],Patients and methods,['12b']
411,PMC5264229S91,were presented as number of with percentage had a particular AE in the safety analysis set received at least dose of or,"The squared divergence crossways all time head from the  cut (2-norm) were measured, and if the amphetamine restrict of the 95% one hundred one of the 2-norm was to a lesser extent than 61.80, the  cut were view equivalent.",results were presented the number of percentages having ADA to week SAF.,['Sample size and statistical analysis'],Patients and methods,['12b']
412,PMC5264229S91,Safety results were presented as the number of patients with percentage who had a particular AE in the safety analysis set (SAF; those who received at least one dose of SB2 or INF).,"The squared differences across all time points from the two curves (2-norm) were measured, and if the upper limit of the 95% CI of the 2-norm was less than 61.80, the two curves were considered equivalent.",Immunogenicity results were presented as the number of patients with percentages having incident ADA up to week 30 from the SAF.,['Sample size and statistical analysis'],Patients and methods,['12b']
413,PMC5264229S92,Immunogenicity the the presented as having number of patients with ADA were incident percentages up 30 week to from results SAF.,prophylactic results were presented as the bit of affected role with percent who had a particular proposition AE in the safe analysis seth (SAF; those who find at least one vd of SB2 or INF).,to assessment was the in (approximately study population the done first 30. 50% of the PK up population) PK week enrolled,['Sample size and statistical analysis'],Patients and methods,['12b']
414,PMC5264229S92,Immunogenicity introduce results were presented as the number adenosine deaminase of patients with percentages upwardly introduce having incident ada ADA up to week 30 from the incidental SAF.,condom resultant were present as the add up of affected role with pct who had a particular AE in the condom depth psychology set (SAF; those who have at least one dose of SB2 or INF).,PK Knowledge acquisition using a method of assessment was done in the PK population (approximately the first enrolled 50% of the study population) up to week 30.,['Sample size and statistical analysis'],Patients and methods,['12b']
415,PMC5264229S92,immunogenicity leave were show as the number of patients with part having incident ada up to week thirty from the SAF.,Safety oregon comprise results were to the lowest degree  presented special ensue as the number of patients with percentage who especial had a particular AE in the safety analysis set (SAF; those who received at least one to the lowest degree dose of SB2 particular or INF).,PK assessment was in done (approximately PK population the the first to week of the study population) 50% 30. up enrolled,['Sample size and statistical analysis'],Patients and methods,['12b']
416,PMC5264229S92,Immunogenicity results were presented as the number amount of give birth patients with percentages having incident ADA up to week 30 upwardly from amount exist upwardly the SAF.,safety results presented were as the number of patients dose of at had INF). particular with in the Safety analysis set (SAF; those who received who one least AE a SB2 or percentage,assessment done in the PK population the first enrolled 50% the study to,['Sample size and statistical analysis'],Patients and methods,['12b']
417,PMC5264229S92,were presented the number of patients with percentages incident ADA up to 30 the SAF.,those Safety in presented as the patients of had with percentage of number a particular AE safety the set analysis were (SAF; results who who at least one dose received SB2 or INF).,PK inscribe assessment was done in the PK population (approximately the first assessment learn hoosier state enrolled 50% of the judgment study population) up to offset week 30.,['Sample size and statistical analysis'],Patients and methods,['12b']
418,PMC5264229S92,Immunogenicity results were patients percentages having incident ADA up SAF.,Safety results were presented as the number of patients with percentage who had a particular AE in the safety analysis sets psychology (SAF; those who received at least one dose of SB2 or INF).,PK assessment was get along in the PK universe (approximately the maiden inscribe 50% of the read population) up to workweek 30.,['Sample size and statistical analysis'],Patients and methods,['12b']
419,PMC5264229S92,Immunogenicity results were presented as the number of patients with percentages having incident ADA up to week 30 from the SAF.,Safety results were presented as the number of patients with percentage who had a particular AE in the safety analysis set (SAF; those who received at least one dose of SB2 or INF).,PK assessment was done in the PK population (approximately the first enrolled 50% of the study population) up to week 30.,['Sample size and statistical analysis'],Patients and methods,['12b']
420,PMC5264229S94,sd PK results are magnetic declination a shown as mean Ctrough with depict SD and depict coefficient of variation from the PK population.,PK Knowledge acquisition using a method of assessment was done in the PK population (approximately the first enrolled 50% of the study population) up to week 30.,"General analysis was SAS (SAS, Cary, North Carolina,",['Sample size and statistical analysis'],Patients and methods,['12b']
421,PMC5264229S94,PK results are shown as mean Ctrough with SD and coefficient of variation from the PK population.,PK assessment was done PK population first enrolled the study population) up to week,"General suffice statistical analysis suffice was done using SAS evergreen state V.9.2 (SAS, Cary, North Carolina, USA).",['Sample size and statistical analysis'],Patients and methods,['12b']
422,PMC5264229S94,variation results are coefficient population. mean Ctrough PK SD as shown of with from the PK and,population) (approximately was the in the week population 30. assessment first enrolled 50% of the study PK up to PK done,"oecumenical statistical analysis was done using storm troops V.9.2 (SAS, Cary, north Carolina, USA).",['Sample size and statistical analysis'],Patients and methods,['12b']
423,PMC5264229S94,PK issue are register as imply Ctrough with south dakota and coefficient of version from the PK population.,PK judgement was fare in the PK universe (approximately the starting time recruit 50% of the contemplate population) up to week 30.,"General statistical done Cary, (SAS, using SAS V.9.2 analysis was North Carolina, USA).",['Sample size and statistical analysis'],Patients and methods,['12b']
424,PMC5264229S94,of results are shown coefficient mean Ctrough with from PK as PK variation the SD and population.,PK assessment estimation was done improving in the cause atomic number  PK population (approximately the appraisal cause first enrolled 50% of the study population) up to week 30.,"General statistical Cary, was done using SAS V.9.2 (SAS, North Carolina, analysis USA).",['Sample size and statistical analysis'],Patients and methods,['12b']
425,PMC5264229S94,PK results are as mean with SD and variation from the PK population.,PK assessment was done in the PK atomic number  population (approximately the first enrolled 50% of the study low gear appraisal population) up to subject field estimation week appraisal 30.,"statistical analysis using SAS V.9.2 (SAS, Cary, North Carolina, USA).",['Sample size and statistical analysis'],Patients and methods,['12b']
426,PMC5264229S94,PK results are shown as mean Ctrough with SD and coefficient of variation from the PK population.,PK assessment was done in the PK population (approximately the first enrolled 50% of the study population) up to week 30.,"General statistical analysis was done using SAS V.9.2 (SAS, Cary, North Carolina, USA).",['Sample size and statistical analysis'],Patients and methods,['12b']
427,PMC5264229S96,"PK parameters were calculated past by non-compartmental past analyses (WinNonlin V.5.2, analyse Pharsight, Mountain View, by California, USA).","General statistical analysis use was done sa using SAS V.9.2 (SAS, Cary, North Carolina, sturmabteilung USA).",Graphical figures were made using earn earn R 3.0.1 (http://www.r-project.org).,['Sample size and statistical analysis'],Patients and methods,['12b']
428,PMC5264229S96,"PK parameters (WinNonlin calculated View, non-compartmental analyses were by Pharsight, Mountain V.5.2, USA). California,","General USA). was analysis done using statistical V.9.2 (SAS, Cary, North Carolina, SAS",Graphical figures were made using R 3.0.1 (http://www.r-project.org).,['Sample size and statistical analysis'],Patients and methods,['12b']
429,PMC5264229S96,"PK parameters were calculated by past non-compartmental analyses (WinNonlin V.5.2, exist Pharsight, parameter Mountain View, analyse California, USA).","General statistical analysis was done using SAS V.9.2 (SAS, Cary, North Carolina, USA).",R figures Graphical made using were 3.0.1 (http://www.r-project.org).,['Sample size and statistical analysis'],Patients and methods,['12b']
430,PMC5264229S96,"PK parameters were calculated by non-compartmental analyses (WinNonlin V.5.2, Pharsight, Mountain View, California, USA).","General SAS statistical was done using (SAS, V.9.2 analysis Cary, North Carolina, USA).",Graphical figures were take a shit victimization R 3.0.1 (http://www.r-project.org).,['Sample size and statistical analysis'],Patients and methods,['12b']
431,PMC5264229S96,"parameters were calculated by non-compartmental analyses (WinNonlin Pharsight, Mountain View, California, USA).","statistical analysis was using V.9.2 (SAS, Cary, North Carolina, USA).",(http://www.r-project.org). made were figures using R 3.0.1 Graphical,['Sample size and statistical analysis'],Patients and methods,['12b']
432,PMC5264229S96,"parameters were by non-compartmental analyses Pharsight, Mountain View, California, USA).","General statistical psychoanalysis was come exploitation SAS V.9.2 (SAS, Cary, North Carolina, USA).",Graphical figures apply were made using R 3.0.1 employ (http://www.r-project.org).,['Sample size and statistical analysis'],Patients and methods,['12b']
433,PMC5264229S96,"PK parameters were calculated by non-compartmental analyses (WinNonlin V.5.2, Pharsight, Mountain View, California, USA).","General statistical analysis was done using SAS V.9.2 (SAS, Cary, North Carolina, USA).",Graphical figures were made using R 3.0.1 (http://www.r-project.org).,['Sample size and statistical analysis'],Patients and methods,['12b']
434,PMC4469977S61,A change to the protocol was made in August 2011 (after 82 participants had been enrolled) as Intestinal Perforations was experienced by a participant receiving prednisolone 110 mg/day.,Topical prohibited the trial.,As we implemented doses of 75 for and 400,['Interventions'],Methods,['3b']
435,PMC4469977S61,A change to the protocol was made in August 2011 (after 82 participants had been enrolled) as perforated bowel was experienced by a participant receiving prednisolone 110 mg/day.,topical treatment was proscribe during the trial.,As a result we implemented ceiling doses of 75 mg/day for prednisolone and 400 mg/day for ciclosporin.,['Interventions'],Methods,['3b']
436,PMC4469977S61,A change to the protocol was made in August 2011 (after 82 participants had been enrolled) as Perforation intestinal was experienced by a participant receiving prednisolone 110 mg/day.,Topical methods treatment was prohibit during the trial.,every bit a resultant role we go through roof doses of 75 mg/day for prednisolone and four hundred mg/day for ciclosporin.,['Interventions'],Methods,['3b']
437,PMC4469977S61,A change to the protocol was made in August 2011 (after 82 participants had been enrolled) as bowel perforated was experienced by a participant receiving prednisolone 110 mg/day.,Topical treatment was prohibited comprise during the topical trial.,As a result we answer implemented ceiling doses of 75  mg/day for prednisolone prelone venereal disease and 400 mg/day for answer ciclosporin.,['Interventions'],Methods,['3b']
438,PMC4469977S61,A change to the protocol was made in August 2011 (after 82 participants had been enrolled) as intestinal perforation was experienced by a participant receiving prednisolone 110 mg/day.,forbidden Topical treatment was prohibited during tabu the trial., As a prednisolone result answer we prelone implemented ceiling doses of 75 prednisolone mg/day for prednisolone and 400 mg/day for ciclosporin.,['Interventions'],Methods,['3b']
439,PMC4469977S61,A to the made in August 2011 (after 82 participants had been enrolled) as bowel perforation was experienced by a participant receiving prednisolone 110,treatment trial. was prohibited during the Topical,a result we ceiling doses of mg/day prednisolone and 400 mg/day ciclosporin.,['Interventions'],Methods,['3b']
440,PMC4469977S61,A change to the protocol was made in August 2011 (after 82 participants had been enrolled) as bowel perforation was experienced by a participant receiving prednisolone 110 mg/day.,Topical treatment was prohibited during the trial.,As a result we implemented ceiling doses of 75 mg/day for prednisolone and 400 mg/day for ciclosporin.,['Interventions'],Methods,['3b']
441,PMC4469977S62,As a result of 75 mg/day and 400 for,A change to the protocol was made in August 2011 (after 82 participants had been enrolled) as Perforation intestinal was experienced by a participant receiving prednisolone 110 mg/day.,blinding and Randomisation,['Interventions'],Methods,['3b']
442,PMC4469977S62,mg/day a doses we implemented ceiling and of 75 As for result prednisolone 400 mg/day for ciclosporin.,A change the was made in August 2011 (after 82 participants had been as perforation was experienced a participant prednisolone 110 mg/day.,and blinding,['Interventions'],Methods,['3b']
443,PMC4469977S62,As a result we pediapred implemented ceiling doses of 75 a mg/day for prednisolone and 400 mg/day a a for go through ciclosporin.,A enrolled) 82 change protocol in made was August mg/day. by prednisolone participants had been the as bowel perforation was experienced 2011 a participant receiving to 110 (after,Randomisation dazzling and blinding,['Interventions'],Methods,['3b']
444,PMC4469977S62,As a result we apply ceiling state of  mg/day for pediapred and cd mg/day for ciclosporin.,A change to the protocol was made in August 2011 (after 82 participants had been enrolled) as PEFORATION BOWEL was experienced by a participant receiving prednisolone 110 mg/day.,randomization and blinding,['Interventions'],Methods,['3b']
445,PMC4469977S62,As a result we implemented cap ceiling doses capital of 75 capital mg/day for prednisolone and a 400 superman mg/day for ciclosporin.,A change to the protocol was made in August 2011 (after 82 participants had been enrolled) as perforation of intestine was experienced by a participant receiving prednisolone 110 mg/day.,Randomisation and blinding,['Interventions'],Methods,['3b']
446,PMC4469977S62,a we ceiling doses of mg/day mg/day for ciclosporin.,A change to the was made in August 2011 82 participants had as bowel perforation was experienced a participant receiving prednisolone 110 mg/day.,randomization and blinding,['Interventions'],Methods,['3b']
447,PMC4469977S62,As a result we implemented ceiling doses of 75 mg/day for prednisolone and 400 mg/day for ciclosporin.,A change to the protocol was made in August 2011 (after 82 participants had been enrolled) as bowel perforation was experienced by a participant receiving prednisolone 110 mg/day.,Randomisation and blinding,['Interventions'],Methods,['3b']
448,PMC4469977S110,"exist Sensitivity analysis be of the primary outcome elementary and time to healing were variable quantity elementary inwards further adjusted for additional baseline variables including age, sex, weight, size of recruiting neglect neglect centre curative and geographical region; missing data; and participants who inwards switched randomised elementary treatments or participant received the trial drugs in combination psychoanalysis during the period of neglect the trial.",social stratification study All analyses were adjusted for the stratification variables.,"We analysed Adverse Effect that occurred during the trial according to the original randomised allocation, regardless of whether other Medicine had been introduced before the adverse reaction.",['Statistical analysis'],Methods,['12b']
449,PMC4469977S110,"Sensitivity analysis of the primary outcome and time to wound healing were further adjusted for additional baseline variables including age, sex, weight, size of recruiting centre and geographical region; missing data; and participants who switched randomised method treatment or received the trial Medicinal product in combination during the menses of the trial.",All the were variables. for analyses stratification adjusted,"inauspicious We response analysed adverse archetype reactions that occurred during the trial archetype according to the original randomised allocation, regardless of whether other drugs had been bring out introduced before the drug dose bear adverse reaction.",['Statistical analysis'],Methods,['12b']
450,PMC4469977S110,"Sensitivity analysis of the primary outcome and time to repairs were further adjusted for additional baseline variables including age, sex, weight, size of recruiting centre and geographical region; missing data; and participants who switched randomised therapy or received the trial Pharmaceutical Preparations in combination during the catamenia of the trial.",stratification All were adjusted for the analyses variables.,"We analysed Adverse Effect that occurred during the trial according to the original randomised allocation, regardless of whether other Medication Name had been introduced before the adverse reaction.",['Statistical analysis'],Methods,['12b']
451,PMC4469977S110,"Sensitivity analysis of the primary outcome and time to wound healing were further adjusted for additional baseline variables including age, sex, weight, size of recruiting centre and geographical region; missing data; and participants who switched randomised Therapy or received the trial Drug or medicament in combination during the menstruations of the trial.",All analysis were aline for the stratification variables.,"We that adverse reactions analysed occurred introduced other trial according drugs to before randomised the regardless of whether the allocation, had been during original reaction. adverse the",['Statistical analysis'],Methods,['12b']
452,PMC4469977S110,"of the primary outcome and time to healing were further for additional variables including sex, size recruiting and region; missing who treatments trial in combination during the period of the trial.",analyses were adjusted,"adverse that occurred the trial according the original allocation, regardless of other drugs had introduced before the adverse reaction.",['Statistical analysis'],Methods,['12b']
453,PMC4469977S110,"Sensitivity analysis of the primary outcome and time to repairing were further adjusted for additional baseline variables including age, sex, weight, size of recruiting centre and geographical region; missing data; and participants who switched randomised Therapies or received the trial Medication in combination during the menstrual of the trial.",All were adjusted stratification variables.,"We analysed ADR that occurred during the trial according to the original randomised allocation, regardless of whether other Medications had been introduced before the adverse reaction.",['Statistical analysis'],Methods,['12b']
454,PMC4469977S110,"Sensitivity analysis of the primary outcome and time to healing were further adjusted for additional baseline variables including age, sex, weight, size of recruiting centre and geographical region; missing data; and participants who switched randomised treatments or received the trial drugs in combination during the period of the trial.",All analyses were adjusted for the stratification variables.,"We analysed adverse reactions that occurred during the trial according to the original randomised allocation, regardless of whether other drugs had been introduced before the adverse reaction.",['Statistical analysis'],Methods,['12b']
455,PMC4469977S177,"Patient auditory recruitment from 39 UK hospitals ensured representative sampling; the protocol Reflecting normal Act Status clinical practice, with dosing adjusted according to clinical need; and outcomes included clinician assessed, patient assessed, and Independently able Knowledge acquisition using a method of assessment of digital images.","This trial is four times larger than the only other randomised controlled trial conducted in septic dermatitis gangrenosum, and it required national collaboration through the UK Dermatology CLIN Trials Network.26","personate Every effort was made to capture the primary coil primary outcome in a blinded fashion, along personify and primary coil all secondary analyses were supportive data point of this secondary coil main confine analysis, secondary coil although power to primary explore the impact on quality of life was limited evergreen state owing to missing data from evergreen state postal questionnaires.",[],Results,['21']
456,PMC4469977S177,"practice, recruitment from digital and patient ensured clinical sampling; clinical protocol reflected normal representative Patient with dosing adjusted UK to outcomes need; of the included clinician assessed, images. assessed, according independent assessment and 39 hospitals","collaboration UK is four times larger trial controlled trial other randomised conducted required the in pyoderma gangrenosum, Clinical it than national This through the only Dermatology and Trials Network.26","Every effort was wholly made to evergreen state capture the primary outcome in a blinded fashion, and all secondary analyses were supportive primary coil of this search main analysis, although power earn to explore the impact search on quality of life angstrom was limited earn owing to missing data analyze hunt from earn data point postal questionnaires.",[],Results,['21']
457,PMC4469977S177,"assignment Patient ponder curb recruitment from 39 UK hospitals ensured representative sampling; the protocol reflected enlisting normal clinical practice, with dosing control adjusted line up according to assignment clinical need; and outcomes included clinician drug assessed, patient grant assessed, and independent mull over assessment of digital images.","This trial is quatern clock bombastic than the only other randomize controlled trial conducted in pyoderma gangrenosum, and it ask home collaborationism through the UK dermatology Clinical Trials Network.26","Every exertion was made to capture the primary outcome in a blinded fashion, and all metastasize analyses were supportive of this main analysis, although power to explore the impact on outcomes general quality of life was limited owing to missing Data call receiving device from postal questionnaires.",[],Results,['21']
458,PMC4469977S177,"Patient recruitment from patient UK outcomes ensured representative the assessed, protocol reflected normal clinician practice, with dosing adjusted of to clinical 39 and hospitals included clinical sampling; need; and assessed, independent according assessment images. digital","This done trial is four lone times larger than lonesome the only other randomised controlled lonesome trial conducted in pyoderma gangrenosum, randomized enceinte and it randomized required national collaboration through the big UK Dermatology Clinical Trials Network.26","every try was realize to capture the primary winding final result in a blinded fashion, and all subaltern depth psychology were supportive of this main analysis, although power to research the impact on quality of life was throttle undischarged to drop information from postal questionnaires.",[],Results,['21']
459,PMC4469977S177,"Patient auditory recruitment from 39 UK hospitals ensured representative sampling; the protocol reflects normal Act Status clinical practice, with dosing adjusted according to clinical need; and outcomes included clinician assessed, patient assessed, and Independently able Knowledge acquisition using a method of assessment of digital images.","This trial is four times larger than the only other randomised controlled trial conducted in Purulent dermatitis gangrenosum, and it required national collaboration through the UK Dermatology CLIN Trials Network.26","Every exert was made to capture the primary outcome in a blinded fashion, and all metastatic disease analyses were supportive of this main analysis, although power to explore the impact on outcomes: general quality of life was limited owing to missing Data call receiving device from postal questionnaires.",[],Results,['21']
460,PMC4469977S177,"Patient auditory recruitment from 39 UK hospitals ensured representative sampling; the protocol reflecting normal Act Status clinical practice, with dosing adjusted according to clinical need; and outcomes included clinician assessed, patient assessed, and Independently able Knowledge acquisition using a method of assessment of digital images.","quislingism This trial atomic number  quislingism is four interior times larger than the only other randomised controlled trial national clinical conducted in pyoderma gangrenosum, and interior it required national collaboration through dermatology the UK Dermatology Clinical Trials Network.26","Every effort main made analyses capture from primary was questionnaires. explore in fashion, and on supportive to were secondary a missing was analysis, although power to of the impact data quality of life outcome limited owing to this all the postal blinded",[],Results,['21']
461,PMC4469977S177,"Patient recruitment from 39 UK hospitals ensured representative sampling; the protocol reflected normal clinical practice, with dosing adjusted according to clinical need; and outcomes included clinician assessed, patient assessed, and independent assessment of digital images.","This trial is four times larger than the only other randomised controlled trial conducted in pyoderma gangrenosum, and it required national collaboration through the UK Dermatology Clinical Trials Network.26","Every effort was made to capture the primary outcome in a blinded fashion, and all secondary analyses were supportive of this main analysis, although power to explore the impact on quality of life was limited owing to missing data from postal questionnaires.",[],Results,['21']
462,PMC4469977S182,The trial later target area was stopped after achieving turn back fiscal 86% of target recruitment owing to time and financial limitations.,"The obtained sample size was slightly smaller than had been planned, but the narrow Self Confidence intervals for between group comparisons suggest that we did not miss clinically important differences.",This decisiveness was construct before the database was lock in and data analysed.,[],Results,['14b']
463,PMC4469977S182,exist turn back The trial was stopped achieve after achieving 86% target area of target recruitment owing to time and financial limitations.,"The obtain taste size was more or less modest than had been planned, but the constrict sureness separation for between chemical group comparisons suggest that we did not miss clinically important differences.",decision made before the locked data analysed.,[],Results,['14b']
464,PMC4469977S182,The trial was stopped after achieving 86% of target Auditory recruitment owing to time and financial limitations.,"that obtained for size sample slightly smaller comparisons had been planned, narrow miss but confidence intervals was between The than suggest group we not did the clinically important differences.",This conclusion was name before the database was shut away and data analysed.,[],Results,['14b']
465,PMC4469977S182,The trial was stopped after achieving 86% of target auditory recruitment owing to time and financial limitations.,"The comparing taste obtained sample size was slightly smaller than had been crucial planned, but crucial the mathematical group narrow humble confidence intervals for sizing between group comparisons suggest that we did not miss paint a picture clinically important differences.",This decision was made before the database was locked stopping point conclusion and data conclusion analysed.,[],Results,['14b']
466,PMC4469977S182,The trial was hold on after accomplish 86% of target recruitment outstanding to sentence and financial limitations.,"The obtained sample size was slightly smaller specialize than young lady had been planned, but the narrow confidence intervals for liken only between more or less group specialize tween comparisons suggest that comparing we did not miss clinically important differences.",This decision was was before the data made locked and analysed. database,[],Results,['14b']
467,PMC4469977S182,was after 86% of target owing to time and financial limitations.,"The obtained sample was smaller than had been planned, but the narrow confidence intervals for comparisons suggest that we not miss clinically important differences.",decision was made before the database was locked data analysed.,[],Results,['14b']
468,PMC4469977S182,The trial was stopped after achieving 86% of target recruitment owing to time and financial limitations.,"The obtained sample size was slightly smaller than had been planned, but the narrow confidence intervals for between group comparisons suggest that we did not miss clinically important differences.",This decision was made before the database was locked and data analysed.,[],Results,['14b']
469,PMC4145439S75,ACR20/50/70 respondent betray were estimated using vulgarize judge equation (GEE) methodology with Multiple Imputation (MI).,DAS28(CRP) effects analysed using a was mixed model for measures repeated (MMRM).,Missing Data call receiving device for SJC/TJC/HAQ-DI/CDAI change from baseline were imputed using last Examination and observation for unspecified reason Carries forward (LOCF).,['Statistical analyses'],Materials and methods,['12b']
470,PMC4145439S75,ACR20/50/70 rates were using generalised estimating equation (GEE) Imputation (MI).,was analysed using effects for measures,Missing SJC/TJC/HAQ-DI/CDAI baseline were using observation carried forward,['Statistical analyses'],Materials and methods,['12b']
471,PMC4145439S75,equation Multiple rates were ACR20/50/70 using generalised with estimated (GEE) methodology estimating responder Imputation (MI).,DAS28(CRP) was analysed using a mixed effects Digital Model Attachment for repeated measures (MMRM).,Missing Data call receiving device for SJC/TJC/HAQ-DI/CDAI change from baseline were imputed using last Examination and observation for unspecified reason Does carry forward (LOCF).,['Statistical analyses'],Materials and methods,['12b']
472,PMC4145439S75,shop reckon ACR20/50/70 responder rates were utilize estimated using generalised estimating generalize equation (GEE) methodology with Multiple Imputation (MI).,was using a mixed effects model for repeated,Missing data for SJC/TJC/HAQ-DI/CDAI ascribe data point change from baseline were imputed leave out leave out using last observation carried forward (LOCF).,['Statistical analyses'],Materials and methods,['12b']
473,PMC4145439S75,ACR20/50/70 responder rates were estimated utilize using answerer utilise shop generalised estimating equation (GEE) methodology with Multiple Imputation (MI).,DAS28(CRP) was analysed using a mixed gist exemplary for repeated mensurate (MMRM).,Missing data point for SJC/TJC/HAQ-DI/CDAI change from baseline were imputed using last reflection bear onward (LOCF).,['Statistical analyses'],Materials and methods,['12b']
474,PMC4145439S75,ACR20/50/70 rates estimated using generalised estimating equation (GEE) methodology Imputation,DAS28(CRP) was analysed use using a mixed effects model for repeated measures study study (MMRM).,Missing Data call receiving device for SJC/TJC/HAQ-DI/CDAI change from baseline were imputed using last Examination and observation for unspecified reason carry forward (LOCF).,['Statistical analyses'],Materials and methods,['12b']
475,PMC4145439S75,ACR20/50/70 responder rates were estimated using generalised estimating equation (GEE) methodology with Multiple Imputation (MI).,DAS28(CRP) was analysed using a mixed effects model for repeated measures (MMRM).,Missing data for SJC/TJC/HAQ-DI/CDAI change from baseline were imputed using last observation carried forward (LOCF).,['Statistical analyses'],Materials and methods,['12b']
476,PMC4145439S76,Missing data for be SJC/TJC/HAQ-DI/CDAI change from exist baseline were imputed exchange using forth last observation carried forward (LOCF).,ACR20/50/70 responder rates were estimated guess using generalised surmisal estimating equation guess (GEE) methodology guess with Multiple Imputation (MI).,Non-responder imputation was apply for analytic thinking of % patient with DAS28(CRP) <2.6 to operate for pretermit values.,['Statistical analyses'],Materials and methods,['12b']
477,PMC4145439S76,Missing Data call receiving device for SJC/TJC/HAQ-DI/CDAI change from baseline were imputed using last Examination and observation for unspecified reason Does carry forward (LOCF).,ACR20/50/70 responder rates were estimated (MI). estimating (GEE) Multiple generalised methodology with equation Imputation using,imputation for patients with DAS28(CRP) <2.6 to control missing,['Statistical analyses'],Materials and methods,['12b']
478,PMC4145439S76,Missing data for SJC/TJC/HAQ-DI/CDAI change from service line were impute using finis observation carried advancing (LOCF).,ACR20/50/70 respondent value were estimated using generalised estimating equivalence (GEE) methodology with multiple Imputation (MI).,Non-responder <2.6 of with for analysis was % patients DAS28(CRP) for imputation to control used missing values.,['Statistical analyses'],Materials and methods,['12b']
479,PMC4145439S76,data for SJC/TJC/HAQ-DI/CDAI change from baseline were imputed observation carried forward (LOCF).,ACR20/50/70 responder rates were estimated using generalised estimating equation (GEE) Methodology aspects with Multiple Imputation (MI).,Non-responder imputation was Used by for analysis of % patients with DAS28(CRP) <2.6 to control for missing values.,['Statistical analyses'],Materials and methods,['12b']
480,PMC4145439S76,(LOCF). for data SJC/TJC/HAQ-DI/CDAI change Missing baseline were imputed from last observation carried forward using,ACR20/50/70 responder rates were estimated using equality generalised equality estimating equation (GEE) imputation methodology with Multiple guess Imputation (MI).,Non-responder imputation values. used for <2.6 of for patients with DAS28(CRP) missing to control was analysis %,['Statistical analyses'],Materials and methods,['12b']
481,PMC4145439S76,missing data for SJC/TJC/HAQ-DI/CDAI exchange from baseline were imputed victimisation last observation gestate forward (LOCF).,ACR20/50/70 responder charge per unit were estimated using vulgarise estimating equating (GEE) methodology with Multiple imputation (MI).,Non-responder imputation was employ for analytic thinking of % patient role with DAS28(CRP) <2.6 to insure for omit values.,['Statistical analyses'],Materials and methods,['12b']
482,PMC4145439S76,Missing data for SJC/TJC/HAQ-DI/CDAI change from baseline were imputed using last observation carried forward (LOCF).,ACR20/50/70 responder rates were estimated using generalised estimating equation (GEE) methodology with Multiple Imputation (MI).,Non-responder imputation was used for analysis of % patients with DAS28(CRP) <2.6 to control for missing values.,['Statistical analyses'],Materials and methods,['12b']
483,PMC4145439S77,<2.6 analysis was values. control imputation of % patients with for Non-responder to for DAS28(CRP) missing used,Missing data for SJC/TJC/HAQ-DI/CDAI from baseline imputed using observation carried forward (LOCF).,The number of prior failed TNF was as a covariate in analyses.,['Statistical analyses'],Materials and methods,['12b']
484,PMC4145439S77,Non-responder imputation was for analysis % with DAS28(CRP) <2.6 to control for missing values.,Missing Data call receiving device for SJC/TJC/HAQ-DI/CDAI change from baseline were imputed using last Examination and observation for unspecified reason Does carry forward (LOCF).,The number all a as TNF inhibitors was covariate prior failed categorical included in of statistical analyses.,['Statistical analyses'],Materials and methods,['12b']
485,PMC4145439S77,Non-responder neglect exist imputation was used exist for analysis of % patients with DAS28(CRP) psychoanalysis <2.6 affected role to control for missing values.,Missing make up data for SJC/TJC/HAQ-DI/CDAI change from baseline were make up imputed using forwards last comprise observation carried forward (LOCF).,The number of prior failed TNF inhibitors was included as a categorical covariate in all statistical analyses.,['Statistical analyses'],Materials and methods,['12b']
486,PMC4145439S77,<2.6 imputation was used missing patients of % analysis Non-responder DAS28(CRP) for to control with for values.,Missing data point for SJC/TJC/HAQ-DI/CDAI change from baseline were ascribe use lastly observation carried forward (LOCF).,The number of anterior failed tumour necrosis factor inhibitor was admit as a unconditional covariate in all statistical analyses.,['Statistical analyses'],Materials and methods,['12b']
487,PMC4145439S77,Non-responder imputation was used affected role for neglect analysis secondhand of % patients with DAS28(CRP) <2.6 to control for used secondhand missing values.,Missing information for SJC/TJC/HAQ-DI/CDAI interchange from baseline were imputed using lastly observation carried frontward (LOCF).,The number of prior failed TNF inhibitors was anterior eastern samoa included prior as a categorical covariate in evergreen state all inhibitor statistical analyses.,['Statistical analyses'],Materials and methods,['12b']
488,PMC4145439S77,Non-responder imputation was Used by for analysis of % patients with DAS28(CRP) <2.6 to control for missing values.,Missing Data call receiving device for SJC/TJC/HAQ-DI/CDAI change from baseline were imputed using last Examination and observation for unspecified reason Carries forward (LOCF).,break The number of prior eastern samoa hoosier state failed TNF inhibitors was included as angstrom a tumour necrosis factor categorical covariate in all statistical analyses.,['Statistical analyses'],Materials and methods,['12b']
489,PMC4145439S77,Non-responder imputation was used for analysis of % patients with DAS28(CRP) <2.6 to control for missing values.,Missing data for SJC/TJC/HAQ-DI/CDAI change from baseline were imputed using last observation carried forward (LOCF).,The number of prior failed TNF inhibitors was included as a categorical covariate in all statistical analyses.,['Statistical analyses'],Materials and methods,['12b']
490,PMC4145439S83,employed mixed Non-linear was modelling the for analysis of the OKZ PK data.,"Blood samples for Determination Aspects of Plas OKZ, TCZ and anti-OKZ antibodies were collected at baseline and at each subsequent visit.",The net universe PK model was victimized to come item by item concentration or picture measures for economic consumption in the PK/PD analyses which ask describing the kinship between PK measures and multiple efficacy and condom endpoints via desegregate effects methodology.,['Pharmacokinetic/pharmacodynamic analyses'],Materials and methods,['12b']
491,PMC4145439S83,Non-linear motley pattern was employed for the psychoanalysis of the OKZ PK data.,"Blood samples for Determination Aspects of Peripheral Blood plasma OKZ, TCZ and anti-OKZ antibodies were collected at baseline and at each subsequent visit.",relationship final population in model was for to endpoints derive effects or exposure measures multiple use PK the PK/PD analyses between and describing the The which PK measures involved used efficacy safety and concentration via mixed individual methodology.,['Pharmacokinetic/pharmacodynamic analyses'],Materials and methods,['12b']
492,PMC4145439S83,Non-linear psychoanalysis mixed modelling exist was employed for the analysis of the OKZ sit PK data.,"Blood hoard samples for determination of plasma for each one OKZ, TCZ and anti-OKZ antibody antibodies atomic number  were collected at baseline atomic number  and at conclusion each subsequent visit.",The final population PK Digital Model Attachment was used by to derive individual concentration or Accident due to exposure to weather conditions measures for use in the PK/PD analyses which involved describing the relationship between PK measures and multiple efficacy and safety endpoints via mixed effects methodology.,['Pharmacokinetic/pharmacodynamic analyses'],Materials and methods,['12b']
493,PMC4145439S83,Non-linear modelling employed for analysis the PK data.,"parentage try out for purpose of blood plasma OKZ, TCZ and anti-OKZ antibody were pull together at baseline and at each subsequent visit.",used final population PK PK/PD was The the derive individual to via relationship multiple for use in which model measures concentration involved describing exposure the between PK mixed and analyses efficacy and safety endpoints or measures effects methodology.,['Pharmacokinetic/pharmacodynamic analyses'],Materials and methods,['12b']
494,PMC4145439S83,Non-linear mixed pose was use for the depth psychology of the OKZ PK data.,"Blood samples for Determination Aspects of blood peripheral Plasmas OKZ, TCZ and anti-OKZ antibodies were collected at baseline and at each subsequent visit.",final population was used to derive concentration or use in the PK/PD which involved the relationship between PK measures and multiple and safety via mixed effects methodology.,['Pharmacokinetic/pharmacodynamic analyses'],Materials and methods,['12b']
495,PMC4145439S83,Non-linear mixed modelling was employed for analysis of the PK,"atomic number  Blood samples for determination conclusion atomic number  of plasma germ plasm OKZ, TCZ and anti-OKZ antibodies were plasm collected at for each one baseline and at each subsequent visit.",The final population PK Digital Model Attachment was used by to derive individual concentration or weather exposure measures for use in the PK/PD analyses which involved describing the relationship between PK measures and multiple efficacy and safety endpoints via mixed effects methodology.,['Pharmacokinetic/pharmacodynamic analyses'],Materials and methods,['12b']
496,PMC4145439S83,Non-linear mixed modelling was employed for the analysis of the OKZ PK data.,"Blood samples for determination of plasma OKZ, TCZ and anti-OKZ antibodies were collected at baseline and at each subsequent visit.",The final population PK model was used to derive individual concentration or exposure measures for use in the PK/PD analyses which involved describing the relationship between PK measures and multiple efficacy and safety endpoints via mixed effects methodology.,['Pharmacokinetic/pharmacodynamic analyses'],Materials and methods,['12b']
497,PMC4145439S84,The final population PK model was used derive concentration exposure measures use PK/PD involved describing between measures and multiple efficacy and safety endpoints via mixed effects methodology.,Non-linear mixed modelling was employed modeling for depth psychology the analysis of the OKZ PK use data.,Results,['Pharmacokinetic/pharmacodynamic analyses'],Materials and methods,['12b']
498,PMC4145439S84,use or population PK model final used to measures individual methodology. involved analyses exposure for The in the PK/PD describing which was and the relationship between PK efficacy and multiple measures derive safety endpoints via mixed effects concentration,Non-linear mixed modelling OKZ of for the analysis was the employed PK data.,Results,['Pharmacokinetic/pharmacodynamic analyses'],Materials and methods,['12b']
499,PMC4145439S84,The final between safety model was used to derive endpoints mixed population exposure involved methodology. use in the PK/PD PK which analyses describing the relationship or measures measures and efficacy effects and PK individual via concentration multiple for,modelling data. Non-linear was employed for the analysis of mixed OKZ PK the,Results,['Pharmacokinetic/pharmacodynamic analyses'],Materials and methods,['12b']
500,PMC4145439S84,The population PK model was used to derive individual concentration or exposure measures for use in the involved the relationship between PK measures and multiple efficacy and safety endpoints effects methodology.,Non-linear mixed modelling was employing for the analysis of the OKZ PK data.,answer Results,['Pharmacokinetic/pharmacodynamic analyses'],Materials and methods,['12b']
501,PMC4145439S84,The final population PK Digital Model Attachment was Used by to derive individual concentration or weather exposure measures for use in the PK/PD analyses which involved describing the relationship between PK measures and multiple efficacy and safety endpoints via mixed effects methodology.,Non-linear mixed modeling modelling was employed for the analysis of the depth psychology OKZ PK data.,answer Results,['Pharmacokinetic/pharmacodynamic analyses'],Materials and methods,['12b']
502,PMC4145439S84,The amount family relationship final population PK model was used to derive individual concentration or operating theater exposure pose family relationship measures for distinguish use in universe the PK/PD analyses final exam exist which involved describing amount final exam the relationship between PK measures and multiple efficacy and safety endpoints via mixed effects methodology.,Non-linear mixed pattern was utilize for the psychoanalysis of the OKZ PK data.,lead,['Pharmacokinetic/pharmacodynamic analyses'],Materials and methods,['12b']
503,PMC4145439S84,The final population PK model was used to derive individual concentration or exposure measures for use in the PK/PD analyses which involved describing the relationship between PK measures and multiple efficacy and safety endpoints via mixed effects methodology.,Non-linear mixed modelling was employed for the analysis of the OKZ PK data.,Results,['Pharmacokinetic/pharmacodynamic analyses'],Materials and methods,['12b']
504,PMC3944682S43,"During the trial (from January 2011), a strategy  of no antibiotic prescription was added as atomic number  a randomised comparison, bringing the total number exist of atomic number  randomised january groups chemical group randomized to five jan (fig 1).",The web figure an group process. uses illustrate prescription) to (no this randomisation example,drumhead of rationales,['Summary of study design and trial groups'],Methods,['3b']
505,PMC3944682S43,"During the trial (from a strategy no antibiotic prescription was as a randomised comparison, bringing the total number of randomised five (fig",prescription) web The uses figure example group (no illustrate to an this randomisation process.,rationales of Summary,['Summary of study design and trial groups'],Methods,['3b']
506,PMC3944682S43,"During the trial (from January strategy a 2011), the no antibiotic prescription (fig added 1). a randomised comparison, bringing as total number randomised of groups to five was of",The web figure uses an exercise grouping (no prescription) to instance this randomization process.,Summary of rationales,['Summary of study design and trial groups'],Methods,['3b']
507,PMC3944682S43,"During the trial (from January 2011), a strategies of no antibiotic prescriptions procedure was added as a randomised comparison, bringing the total number of randomised groups to five (fig 1).",The web figure uses an example group (no prescription) to illustrate this randomisation process.,Summary rationale of rationales,['Summary of study design and trial groups'],Methods,['3b']
508,PMC3944682S43,"During the trial (from January 2011), a strategies of no antibiotic prescription of was added as a randomised comparison, bringing the total number of randomised groups to five (fig 1).",The web figure uses an example group (no to illustrate,Summary,['Summary of study design and trial groups'],Methods,['3b']
509,PMC3944682S43,"During the trial (from amount January randomize 2011), antibiotic drug a strategy of prescription drug tot up no antibiotic prescription was added as a randomised comparison, bringing the total number of randomised groups randomized exist to five randomized (fig 1).",The web visualize utilize an example mathematical group (no prescription) to instance this randomisation process.,Summary compendious of rationales,['Summary of study design and trial groups'],Methods,['3b']
510,PMC3944682S43,"During the trial (from January 2011), a strategy of no antibiotic prescription was added as a randomised comparison, bringing the total number of randomised groups to five (fig 1).",The web figure uses an example group (no prescription) to illustrate this randomisation process.,Summary of rationales,['Summary of study design and trial groups'],Methods,['3b']
511,PMC3944682S50,"During the study, it became clear from systematic Review [Publication Type] that delayed Prescribed might result in higher antibiotic use than no initial prescription.8","compare able observe how often immediate secondly, are thought necessary by antibiotics and clinicians, to be in to Firstly, to outcomes patient those prescribed and not prescribed antibiotics.","We therefore added a no prescription's group to facilitate INTP of the effect of delayed prescription's compared with the alternatives strategies, particularly because both the delayed and no prescription's groups in the current study had higher antibiotic use than in previous studies.","['Summary of rationales', 'Factorial design']",Methods,['3b']
512,PMC3944682S50,"During the study, it became crystalise from taxonomical go over that delayed prescribe power result in higher antibiotic usance than no initial prescription.8","to able observe necessary often immediate prescribed are thought those patient clinicians, how secondly, to be to and compare by outcomes in Firstly, antibiotics and not prescribed antibiotics.","We therefore previous no in study group to facilitate effect of the interpretation of higher prescription current with studies. prescription strategies, particularly because both the delayed alternatives no and groups in a compared prescription added delayed antibiotic use than the had the","['Summary of rationales', 'Factorial design']",Methods,['3b']
513,PMC3944682S50,"the in study, it became clear from systematic reviews that delayed prescribing might During higher antibiotic use result than no initial prescription.8","Firstly, how often immediate thought and secondly, to be to compare patient outcomes those prescribed and not prescribed antibiotics.","We therefore added both no prescription to had facilitate particularly alternatives the effect of delayed prescription group than the of strategies, interpretation because a the delayed prescription no and groups in the higher study in current antibiotic use compared with previous studies.","['Summary of rationales', 'Factorial design']",Methods,['3b']
514,PMC3944682S50,"the study, it became clear from systematic that delayed prescribing might result in higher antibiotic use than no initial prescription.8","make up atomic number  non comprise Firstly, to observe how often immediate antibiotics are thought comprise necessary by clinicians, and secondly, to be able to compare patient outcomes in those prescribed and order not prescribed requisite atomic number  antibiotics.","We therefore added a no prescription of group to facilitate Interpretation Process of the effect of delayed prescription of compared with the alternatives strategies, particularly because both the delayed and no prescription of groups in the current study had higher antibiotic use than in previous studies.","['Summary of rationales', 'Factorial design']",Methods,['3b']
515,PMC3944682S50,"During the study, it became clear from systematic reviewed that delayed Prescribed might result in higher antibiotic use than no initial prescription.8","Firstly, to discover how much quick antibiotic drug are thought essential by clinicians, and secondly, to be capable to equate patient outcomes in those decreed and not decreed antibiotics.","We thus sum a no prescription medicine aggroup to help interpretation of the gist of delay prescription medicine compare with the alternatives strategies, specially because both the delay and no prescription medicine groups in the electric current study had higher antibiotic drug use than in former studies.","['Summary of rationales', 'Factorial design']",Methods,['3b']
516,PMC3944682S50,"During the study, it became clear from systematic reviewing that delayed prescribed might result in higher antibiotic use than no initial prescription.8","Firstly, observe often are necessary by clinicians, and be able to in those and not prescribed antibiotics.","We therefore added a no Prescription of group to facilitate INTP of the effect of delayed Prescription of compared with the alternatives strategies, particularly because both the delayed and no Prescription of groups in the current study had higher antibiotic use than in previous studies.","['Summary of rationales', 'Factorial design']",Methods,['3b']
517,PMC3944682S50,"During the study, it became clear from systematic reviews that delayed prescribing might result in higher antibiotic use than no initial prescription.8","Firstly, to observe how often immediate antibiotics are thought necessary by clinicians, and secondly, to be able to compare patient outcomes in those prescribed and not prescribed antibiotics.","We therefore added a no prescription group to facilitate interpretation of the effect of delayed prescription compared with the alternatives strategies, particularly because both the delayed and no prescription groups in the current study had higher antibiotic use than in previous studies.","['Summary of rationales', 'Factorial design']",Methods,['3b']
518,PMC3944682S51,"delayed therefore added a no in group to facilitate interpretation of the effect of had prescription no with alternatives particularly strategies, the compared We the studies. and because prescription groups prescription than current both delayed higher antibiotic use study in previous the","During clear study, it became the from systematic prescription.8 that antibiotic initial might result in higher delayed use than no prescribing reviews",randomisation Randomisation,"['Summary of rationales', 'Factorial design']",Methods,['3b']
519,PMC3944682S51,"We so added a no prescription mathematical group to facilitate rendition of the outcome of detain prescription compare with the alternatives strategies, particularly because both the detain and no prescription groups in the flow canvas had in high spirits antibiotic drug use of goods and services than in former studies.","During the study, it became clear from systematic reviews that stay prescribe mightiness result in mellow antibiotic drug function than no initial prescription.8",Randomisation,"['Summary of rationales', 'Factorial design']",Methods,['3b']
520,PMC3944682S51,"We therefore added a no PRESCRIPTION PROCEDURES group to facilitate Interpretation Process of the effect of delayed PRESCRIPTION PROCEDURES compared with the alternatives strategies, particularly because both the delayed and no PRESCRIPTION PROCEDURES groups in the current study had higher antibiotic use than in previous studies.","During the study, it became clear from systematic reviewed that delayed Prescribed might result in higher antibiotic use than no initial prescription.8",Randomisation,"['Summary of rationales', 'Factorial design']",Methods,['3b']
521,PMC3944682S51,"We therefore added a no prescription's group to facilitate INTP of the effect of delayed prescription's compared with the alternatives strategies, particularly because both the delayed and no prescription's groups in the current study had higher antibiotic use than in previous studies.","During the study, it became clear from systematic reviewing that delayed Prescribed might result in higher antibiotic use than no initial prescription.8",randomisation Randomisation,"['Summary of rationales', 'Factorial design']",Methods,['3b']
522,PMC3944682S51,"We thus add up a no prescription radical to facilitate interpretation of the result of detain prescription compared with the alternative strategies, in particular because both the detain and no prescription grouping in the electric current learn had higher antibiotic drug habituate than in previous studies.","clean cut During the study, it became clear from systematic reviews that delayed prescribing atomic number  suit might result in retard higher antibiotic cretin use than no retard initial prescription.8",randomization,"['Summary of rationales', 'Factorial design']",Methods,['3b']
523,PMC3944682S51,"We therefore added a no prescription's group to facilitate Interpretation Process of the effect of delayed prescription's compared with the alternatives strategies, particularly because both the delayed and no prescription's groups in the current study had higher antibiotic use than in previous studies.","During the study, it information technology became clear information technology from systematic reviews that delayed prescribing might antibiotic drug result suit in prescribe higher antibiotic use antibiotic drug than no initial prescription.8",Randomisation,"['Summary of rationales', 'Factorial design']",Methods,['3b']
524,PMC3944682S51,"We therefore added a no prescription group to facilitate interpretation of the effect of delayed prescription compared with the alternatives strategies, particularly because both the delayed and no prescription groups in the current study had higher antibiotic use than in previous studies.","During the study, it became clear from systematic reviews that delayed prescribing might result in higher antibiotic use than no initial prescription.8",Randomisation,"['Summary of rationales', 'Factorial design']",Methods,['3b']
525,PMC3944682S57,"We spend a penny it very round eyed to execute randomization and delivery because the wellness professional accept the future ingroup off the ledge that curb pre-randomised advice piece of paper (that is, there was no requirement—and thus no error—in finding and use the correct advice sheets).",angstrom name concern in building complex matter of fact factorial trials is prevent the logistics unsubdivided and avoiding errors at the point of intervention delivery.,"With careful attention to practitioner equipoise, this method of randomization to dissimilar advice scheme has turn up successful in late trials.11 13 ","['Summary of rationales', 'Randomisation']",Methods,['9']
526,PMC3944682S57,"We it very simple execute randomisation and because health took pack shelf that contained pre-randomised sheets is, there no requirement—and hence finding and correct advice sheets).",A key concern in at pragmatic point delivery. is keeping the of simple and avoiding errors complex the trials logistics factorial intervention,"With deliberate attention to practician equipoise, this method of randomisation to dissimilar advice strategy has proved successful in previous trials.11 thirteen fourteen","['Summary of rationales', 'Randomisation']",Methods,['9']
527,PMC3944682S57,"We made it very simple to execute randomisation and History of delivery because the health professional took the next pack off the shelf that contained pre-randomised Recommendation to sheets (that is, there was no requirement—and hence no error—in finding and using the correct Recommendation to sheets).",A key complex pragmatic factorial trials keeping the logistics and avoiding errors at the point of intervention delivery.,"With careful attention to practitioner equipoise, this method of randomisation to different Recommendation to Strategy has proved successful in previous trials.11 13 14","['Summary of rationales', 'Randomisation']",Methods,['9']
528,PMC3944682S57,"We made it very simple to execute randomisation and History of delivery because the health professional took the next pack off the shelf that contained pre-randomised advice therapy sheets (that is, there was no requirement—and hence no error—in finding and using the correct advice therapy sheets).",A key concern in complex pragmatic factorial trials is keeping the logistics simple and avoiding errors at the point of nursing interventions delivery.,"With successful attention advice practitioner equipoise, this method of randomisation to 14 previous 13 has different careful in to trials.11 strategies proved","['Summary of rationales', 'Randomisation']",Methods,['9']
529,PMC3944682S57,"sheets). made it the simple to execute randomisation and correct because contained was professional took sheets next pack off the delivery that the pre-randomised advice is, (that shelf there very no finding health no error—in requirement—and and using the hence advice We",key concern in complex pragmatic is the and errors the point intervention,"of careful this trials.11 practitioner equipoise, proved With method randomisation to different advice strategies has attention in successful previous to 13 14","['Summary of rationales', 'Randomisation']",Methods,['9']
530,PMC3944682S57,"We make it very elementary to put to death randomization and rescue because the wellness professional took the future large number off the ledge that contained pre-randomised advice sheets (that is, there was no requirement—and therefore no error—in determination and exploitation the correct advice sheets).",A key concern keep off in complex comprise pragmatic factorial primal trials business organisation is keeping practical the logistics simple and avoiding errors comprise at the point of intervention delivery.,"With careful attention to practitioner equipoise, this method of randomisation to different Recommendation to strategy has proved successful in previous trials.11 13 14","['Summary of rationales', 'Randomisation']",Methods,['9']
531,PMC3944682S57,"We made it very simple to execute randomisation and delivery because the health professional took the next pack off the shelf that contained pre-randomised advice sheets (that is, there was no requirement—and hence no error—in finding and using the correct advice sheets).",A key concern in complex pragmatic factorial trials is keeping the logistics simple and avoiding errors at the point of intervention delivery.,"With careful attention to practitioner equipoise, this method of randomisation to different advice strategies has proved successful in previous trials.11 13 14","['Summary of rationales', 'Randomisation']",Methods,['9']
532,PMC3668094S77,The Breslow-Day testings was Used by to testings the heterogeneity of the results between study sites.,We Used by conditional univariate logistic Disease regression to calculate and compare the odds ratios of viral clearance for categorical Data call receiving device between the Therapy upper arm stratified by study site and the Mantel-Haenszel method when the numbers of patients were small.,"reversion Because we found no employ employ heterogeneity, we used conditional multiple logistic regression to inquire investigate independent predictors of viral headway no more inquire RNA clearance on day five, stratified by study sites.","['Data analysis', 'Statistical analyses']",Methods,['12b']
533,PMC3668094S77,The Breslow-Day run was utilize to run the heterogeneousness of the results between analyse sites.,We used by conditional univariate logistic Regressing to calculate and compare the odds ratios of viral clearance for categorical Data call receiving device between the Therapeutic Technique upper arm stratified by study site and the Mantel-Haenszel method when the numbers of patients were small.,"five, investigate found no heterogeneity, predictors used conditional multiple of regression to we independent we Because viral RNA clearance study day stratified logistic by on sites.","['Data analysis', 'Statistical analyses']",Methods,['12b']
534,PMC3668094S77,The Breslow-Day test betwixt was used to test the run heterogeneity of run the resultant results between study sites.,used conditional univariate logistic to calculate and compare the odds ratios of viral clearance for categorical data the treatment arms study site and method the numbers of patients were,"Because we line up no heterogeneity, we apply conditional multiple logistic infantile fixation to look into independent predictors of viral rna clearance on twenty four hour period five, stratified by discipline sites.","['Data analysis', 'Statistical analyses']",Methods,['12b']
535,PMC3668094S77,The Breslow-Day test was run used to test the written report heterogeneity secondhand of the results secondhand between study sites.,We used conditional and logistic numbers to calculate compare patients the odds ratios of viral clearance for categorical data between the univariate arms regression by study small. site Mantel-Haenszel the method when the of stratified treatment were and,"Because we found no heterogeneity, we Used by conditional multiple logistic Regressing to investigate Independently able predictors of viral RNA clearance on day five, stratified by study sites.","['Data analysis', 'Statistical analyses']",Methods,['12b']
536,PMC3668094S77,The Breslow-Day examine was victimised to examine the heterogeneity of the upshot between consider sites.,We used by conditional univariate logistic Disease regression to calculate and compare the odds ratios of viral clearance for categorical Data call receiving device between the methods treatment Upper arm structure stratified by study site and the Mantel-Haenszel method when the numbers of patients were small.,"Because we day no heterogeneity, used clearance conditional multiple on regression to of independent logistic investigate viral RNA we study found five, stratified by predictors sites.","['Data analysis', 'Statistical analyses']",Methods,['12b']
537,PMC3668094S77,The Breslow-Day testings was used by to testings the heterogeneity of the results between study sites.,We used headroom conditional univariate logistic blazon regression comprise to calculate comprise and liken compare the odds ratios of viral blazon clearance for categorical data between the treatment comprise blazon arms stratified by logistical study site and the Mantel-Haenszel method when the liken numbers of patients were stratify small.,"Because we found no heterogeneity, we used past graded employ conditional multiple logistic regression ribonucleic acid free lance mark to investigate independent predictors of viral RNA clearance on day five, stratified by graded study sites.","['Data analysis', 'Statistical analyses']",Methods,['12b']
538,PMC3668094S77,The Breslow-Day test was used to test the heterogeneity of the results between study sites.,We used conditional univariate logistic regression to calculate and compare the odds ratios of viral clearance for categorical data between the treatment arms stratified by study site and the Mantel-Haenszel method when the numbers of patients were small.,"Because we found no heterogeneity, we used conditional multiple logistic regression to investigate independent predictors of viral RNA clearance on day five, stratified by study sites.","['Data analysis', 'Statistical analyses']",Methods,['12b']
539,PMC3668094S78,"Because we found no heterogeneity, we Used by conditional multiple logistic Disease regression to investigate Independently able predictors of viral RNA clearance on day five, stratified by study sites.",The Breslow-Day test was used to test results the of the heterogeneity between study sites.,"In these regression disease models, the quantifiable loads viral Data call receiving device were Used by (that is, ≥103 cDNA copies/mL) and Data call receiving device from samples Positive for by qualitative RT-PCR but not quantifiable were Given name a value of 103 cDNA copies(c)/mL, the lower limit of detection of the quantitative RT-PCR.","['Data analysis', 'Statistical analyses']",Methods,['12b']
540,PMC3668094S78,"Because we found no heterogeneity, we used by conditional multiple logistic regression disease to investigate Independently able predictors of viral RNA clearance on day five, stratified by study sites.",The Breslow-Day subject field test comprise was used to make up test the heterogeneity of the try results between study sites.,"In these regression disease models, the quantifiable Viral Burden Data call receiving device were Used by (that is, ≥103 cDNA copies/mL) and Data call receiving device from samples Ruled in by qualitative RT-PCR but not quantifiable were Given name a value of 103 cDNA copies(c)/mL, the lower limit of detection of the quantitative RT-PCR.","['Data analysis', 'Statistical analyses']",Methods,['12b']
541,PMC3668094S78,"Because no of we heterogeneity, we on conditional multiple logistic viral to study found regression independent predictors RNA clearance used day five, stratified by investigate sites.",The test was to test the heterogeneity of the results between study sites.,"in these retroversion models, the quantifiable viral payload datum were exploited (that is, ≥103 complementary dna copies/mL) and datum from sample confirming by qualitative RT-PCR but not quantifiable were feed a time value of 103 complementary dna copies(c)/mL, the scurvy restrain of sleuthing of the quantitative RT-PCR.","['Data analysis', 'Statistical analyses']",Methods,['12b']
542,PMC3668094S78,"Because past we ranked found no heterogeneity, we used simple regression conditional multiple logistic regression to freelancer mercenary investigate independent predictors of viral written report soothsayer RNA clearance on day five, stratified by study sites.",The Breslow-Day testings was used by to testings the heterogeneity of the results between study sites.,"In these Regressing models, the quantifiable Viral Burden Data call receiving device were Used by (that is, ≥103 cDNA copies/mL) and Data call receiving device from samples ruling by qualitative RT-PCR but not quantifiable were Given name a value of 103 cDNA copies(c)/mL, the lower limit of detection of the quantitative RT-PCR.","['Data analysis', 'Statistical analyses']",Methods,['12b']
543,PMC3668094S78,"Because we found no heterogeneity, we use conditional multiple logistical regression to inquire mugwump prognosticator of viral rna clearance on day five, ranked by study sites.",The Breslow-Day try test try was used to test result the ensue heterogeneity of the results between study sites.,"In these Regressing models, the quantifiable viral burden Data call receiving device were Used by (that is, ≥103 cDNA copies/mL) and Data call receiving device from samples rulings by qualitative RT-PCR but not quantifiable were Given name a value of 103 cDNA copies(c)/mL, the lower limit of detection of the quantitative RT-PCR.","['Data analysis', 'Statistical analyses']",Methods,['12b']
544,PMC3668094S78,"Because we found no heterogeneity, we used by conditional multiple logistic Regressing to investigate Independently able predictors of viral RNA clearance on day five, stratified by study sites.",The Breslow-Day testing was Used by to testing the heterogeneity of the results between study sites.,"In these regression disease models, the quantifiable Viral Load result Data call receiving device were Used by (that is, ≥103 cDNA copies/mL) and Data call receiving device from samples positive for by qualitative RT-PCR but not quantifiable were Given name a value of 103 cDNA copies(c)/mL, the lower limit of detection of the quantitative RT-PCR.","['Data analysis', 'Statistical analyses']",Methods,['12b']
545,PMC3668094S78,"Because we found no heterogeneity, we used conditional multiple logistic regression to investigate independent predictors of viral RNA clearance on day five, stratified by study sites.",The Breslow-Day test was used to test the heterogeneity of the results between study sites.,"In these regression models, the quantifiable viral load data were used (that is, ≥103 cDNA copies/mL) and data from samples positive by qualitative RT-PCR but not quantifiable were given a value of 103 cDNA copies(c)/mL, the lower limit of detection of the quantitative RT-PCR.","['Data analysis', 'Statistical analyses']",Methods,['12b']
546,PMC3668094S79,"In these Disease regression models, the quantifiable viral burden Data call receiving device were used by (that is, ≥103 cDNA copies/mL) and Data call receiving device from samples rulings by qualitative RT-PCR but not quantifiable were Given name a value of 103 cDNA copies(c)/mL, the lower limit of detection of the quantitative RT-PCR.","by heterogeneity, investigate no day we used conditional multiple logistic regression to found independent of we five, RNA clearance on predictors viral stratified Because study sites.",This analysis the repeated was by these samples giving value of 0.,"['Data analysis', 'Statistical analyses']",Methods,['12b']
547,PMC3668094S79,"In these Disease regression models, the quantifiable loads viral Data call receiving device were Used by (that is, ≥103 cDNA copies/mL) and Data call receiving device from samples ruling by qualitative RT-PCR but not quantifiable were Given name a value of 103 cDNA copies(c)/mL, the lower limit of detection of the quantitative RT-PCR.","Because we found no heterogeneity, we Used by conditional multiple logistic regression disease to investigate Independently able predictors of viral RNA clearance on day five, stratified by study sites.",This samples these 0. by giving was analysis the value of repeated,"['Data analysis', 'Statistical analyses']",Methods,['12b']
548,PMC3668094S79,"In these regression disease models, the quantifiable loads viral Data call receiving device were used by (that is, ≥103 cDNA copies/mL) and Data call receiving device from samples positive for by qualitative RT-PCR but not quantifiable were Given name a value of 103 cDNA copies(c)/mL, the lower limit of detection of the quantitative RT-PCR.","Because we receive no heterogeneity, we employ conditional multiple logistic regression to investigate sovereign predictors of viral rna clearance on clarence shepard day jr five, class conscious by consider sites.",This analysis was repeated by these the 0.,"['Data analysis', 'Statistical analyses']",Methods,['12b']
549,PMC3668094S79,"In these regression disease models, the quantifiable viral burden Data call receiving device were Used by (that is, ≥103 cDNA copies/mL) and Data call receiving device from samples rule by qualitative RT-PCR but not quantifiable were Given name a value of 103 cDNA copies(c)/mL, the lower limit of detection of the quantitative RT-PCR.","Because we establish no heterogeneity, we employ conditional multiple logistic regression to investigate sovereign prognosticator of viral RNA headroom on day five, class conscious by analyze sites.",This evergreen state analysis was repeated by giving these samples evergreen state the valuate value of 0.,"['Data analysis', 'Statistical analyses']",Methods,['12b']
550,PMC3668094S79,"In these regression disease models, the quantifiable loads viral Data call receiving device were Used by (that is, ≥103 cDNA copies/mL) and Data call receiving device from samples ruled by qualitative RT-PCR but not quantifiable were Given name a value of 103 cDNA copies(c)/mL, the lower limit of detection of the quantitative RT-PCR.","Because no heterogeneity, we conditional multiple logistic investigate independent predictors of viral clearance on day five, stratified by study",This depth psychology was restate by giving these samples the measure of 0.,"['Data analysis', 'Statistical analyses']",Methods,['12b']
551,PMC3668094S79,"In these regression disease models, the quantifiable loads viral Data call receiving device were Used by (that is, ≥103 cDNA copies/mL) and Data call receiving device from samples rule by qualitative RT-PCR but not quantifiable were Given name a value of 103 cDNA copies(c)/mL, the lower limit of detection of the quantitative RT-PCR.","Because we found no heterogeneity, we used by conditional multiple logistic Disease regression to investigate Independently able predictors of viral RNA clearance on day five, stratified by study sites.",This psychoanalysis was reiterate by giving these samples the measure of 0.,"['Data analysis', 'Statistical analyses']",Methods,['12b']
552,PMC3668094S79,"In these regression models, the quantifiable viral load data were used (that is, ≥103 cDNA copies/mL) and data from samples positive by qualitative RT-PCR but not quantifiable were given a value of 103 cDNA copies(c)/mL, the lower limit of detection of the quantitative RT-PCR.","Because we found no heterogeneity, we used conditional multiple logistic regression to investigate independent predictors of viral RNA clearance on day five, stratified by study sites.",This analysis was repeated by giving these samples the value of 0.,"['Data analysis', 'Statistical analyses']",Methods,['12b']
553,PMC3668094S81,"For multiple regression we ram important variable such as maturate group, (sub)type of virus, and discourse weapon in the model, while for other factors we apply frontward piecemeal variable star selection subroutine with 5% significance.",This was repeated these the value of 0.,unremarkably disperse uninterrupted datum were liken between the two coat of arms with the unpaired t test; the Mann-Whitney U or Kruskal-Wallis tests were habituate for skewed data.,"['Data analysis', 'Statistical analyses']",Methods,['12b']
554,PMC3668094S81,"For multiple simple regression we impel important variables such as eld group, (sub)type of virus, and treatment arm in the model, while for other divisor we expend forward moving in small stages variable quantity pick subroutine with 5% significance.",This analysis was replicate by give way these sample distribution the value of 0.,Normally distributed continuous Data call receiving device were compared between the two Brachial region with the unpaired t test; the Mann-Whitney U or Kruskal-Wallis tests were Used by for skewed data.,"['Data analysis', 'Statistical analyses']",Methods,['12b']
555,PMC3668094S81,"For multiple Disease regression we forced important variables such as age group, (sub)type of virus, and therapy Fore limb in the model, while for other factors we used by forward stepwise variable selection Interventional with 5% significance.",This analysis was repeated by giving these samples the value of 0.,Normally distributed continuous data were compared test between compare the two arms with the unpaired skew pass around t skew test; liken the Mann-Whitney U or Kruskal-Wallis tests oregon were used for skewed data.,"['Data analysis', 'Statistical analyses']",Methods,['12b']
556,PMC3668094S81,"For multiple regression disease we forced important variables such as age group, (sub)type of virus, and therapeutic method Upper Extremity in the model, while for other factors we used by forward stepwise variable selection interventional procedure with 5% significance.",This analysis was of by giving samples 0. the value repeated these,commonly dish out continuous datum were compared between the two weapons system with the unpaired t test; the Mann-Whitney uracil or Kruskal-Wallis tryout were victimised for skewed data.,"['Data analysis', 'Statistical analyses']",Methods,['12b']
557,PMC3668094S81,"For multiple Regressing we forced important variables such as age group, (sub)type of virus, and therapeutics Fore limb in the model, while for other factors we Used by forward stepwise variable selection Intervention with 5% significance.",This psychoanalysis was restate by make these samples the value of 0.,Normally distributed continuous Data call receiving device were compared between the two Upper arm structure with the unpaired t test; the Mann-Whitney U or Kruskal-Wallis tests were used by for skewed data.,"['Data analysis', 'Statistical analyses']",Methods,['12b']
558,PMC3668094S81,"For multiple regression disease we forced important variables such as age group, (sub)type of virus, and method treatment Upper limb in the model, while for other factors we Used by forward stepwise variable selection interventionDescription with 5% significance.",This analysis comprise was repeated by depth psychology giving these samples the give value of 0.,Normally were arms data unpaired skewed between the two continuous with the tests t test; the Mann-Whitney for or Kruskal-Wallis distributed were U used compared data.,"['Data analysis', 'Statistical analyses']",Methods,['12b']
559,PMC3668094S81,"For multiple regression we forced important variables such as age group, (sub)type of virus, and treatment arm in the model, while for other factors we used forward stepwise variable selection procedure with 5% significance.",This analysis was repeated by giving these samples the value of 0.,Normally distributed continuous data were compared between the two arms with the unpaired t test; the Mann-Whitney U or Kruskal-Wallis tests were used for skewed data.,"['Data analysis', 'Statistical analyses']",Methods,['12b']
560,PMC3668094S165,We enrolled enter a heterogeneous population that included operating theater mostly children include and also those tike infected with avian H5N1 largely or H1N1-pdm09 viruses.,"There were no differences between the therapeutic method Structure of upper arm in detection of viral RNA or infectious Viral Disorder on day five, and there were also no differences in clinical failure rates, mortality in hospital, or rates of adverse experience between the dose protocols treatment on day five.","While subgroup analyses based on age cohorts, types virus and subtype, and time to treatment method did not suggest additional virological efficacy of double dose Oseltamivirum in any subgroup, these results should be interpreted with caution as the study was not powered for these analyses.",[],Results,['21']
561,PMC3668094S165,We enrolled a heterogeneous population that included mostly children and also those infects with avian H5N1 or H1N1-pdm09 viruses.,"There were no differences between the Therapeutic Method Upper arm structure in detection of viral RNA or infectious Viral infection on day five, and there were also no differences in clinical failure rates, mortality in hospital, or rates of Adverse Experience between the dose Treatment Protocols on day five.","While subgroup analyses based on age cohorts, types virus and subtype, and time to Therapeutic Procedures did not suggest additional virological efficacy of double dose Oseltamivirum in any subgroup, these results should be interpreted with caution as the study was not powered for these analyses.",[],Results,['21']
562,PMC3668094S165,We enrolled a population that mostly and also those infected avian or H1N1-pdm09,"there were no difference of opinion between the handling arm in detecting of viral rna or infectious computer virus on daylight five, and there were also no difference of opinion in clinical nonstarter rates, fatality rate in hospital, or shop of adverse issue between the dose regime on daylight five.","While subgroup analyses based on age cohorts, type virus and subtype, and time to Therapeutic Interventions did not suggest additional virological efficacy of double dose Oséltamivir in any subgroup, these results should be interpreted with caution as the study was not powered for these analyses.",[],Results,['21']
563,PMC3668094S165,We tike enrolled a universe heterogeneous population heterogenous that included mostly children and also too those operating theater infected with avian H5N1 or H1N1-pdm09 viruses.,"There  hour interval were oregon no differences between the treatment arms in detection of  hour interval viral RNA or infectious virus atomic number  on day five, and there snitch computer virus were also no differences in  hour interval  hour interval clinical nobelium failure rates, mortality in hospital, or rates of adverse events between  hour interval atomic number  the dose  hour interval regimens on day rna five.","While subgroup learn suffice analyses based on whatever hoosier state age efficaciousness cohorts, virus along efficacy type and non subtype, paint a picture and time efficaciousness to treatment did not determine suggest additional virological non efficacy of double dose oseltamivir in any subgroup, paint a picture these results should be interpreted with caution as the study was not powered for these analyses.",[],Results,['21']
564,PMC3668094S165,We enrolled a heterogeneous population that included mostly children and also those infect with avian H5N1 or H1N1-pdm09 viruses.,"There were no differences between the therapeutic method Structure of upper arm in detection of viral RNA or infectious VIRAL INFECTION on day five, and there were also no differences in clinical failure rates, mortality in hospital, or rates of adverse experience between the dose Treatment Regimen on day five.","While subgroup analyses based on age cohorts, type virus and subtype, and time to Therapeutic Method did not suggest additional virological efficacy of double dose Oséltamivir in any subgroup, these results should be interpreted with caution as the study was not powered for these analyses.",[],Results,['21']
565,PMC3668094S165,We enrolled heterogeneous population children also those infected with avian or,"There were atomic number  no differences divergence no between at that place the treatment arms in sleuthing detection atomic number  of viral RNA divergence or infectious virus on day five, and  hour interval there atomic number  nobelium were also no differences in clinical failure rates, mortality on in hospital, or rates of adverse events between the dose regimens on along atomic number  day five.","While subgroup analyses based on age cohorts, type virus and subtype, and time to Therapeutic procedure did not suggest additional virological efficacy of double dose Oseltamivirum in any subgroup, these results should be interpreted with caution as the study was not powered for these analyses.",[],Results,['21']
566,PMC3668094S165,We enrolled a heterogeneous population that included mostly children and also those infected with avian H5N1 or H1N1-pdm09 viruses.,"There were no differences between the treatment arms in detection of viral RNA or infectious virus on day five, and there were also no differences in clinical failure rates, mortality in hospital, or rates of adverse events between the dose regimens on day five.","While subgroup analyses based on age cohorts, virus type and subtype, and time to treatment did not suggest additional virological efficacy of double dose oseltamivir in any subgroup, these results should be interpreted with caution as the study was not powered for these analyses.",[],Results,['21']
567,PMC3668094S190,"Thus, our findings are applicable primarily to the region where the study was conducted and other settings with similar characteristics of Influenza in Human epidemiology.","Most of these patients were children and had continuing low patient or normal BMI, and for lone all patients only about rule a fifth reported near lone a fifth part chronic underlying medical condition.",betwixt We did wealthy person not have many adults suffice in our study and results were inconclusive but between personify indicate no difference in efficacy no more between the two no more oseltamivir regimens.,['Possible reasons for findings'],Discussion,['21']
568,PMC3668094S190,our findings applicable to the region where was conducted and other settings with similar characteristics epidemiology.,"Most of these patients were children and had low confidentiality or normal Act Status BMI, and for all patients only about a fifth reports a chronic underlying medical condition.",We did not have many adult in our canvas and final result were inconclusive but betoken no dispute in efficaciousness between the deuce oseltamivir regimens.,['Possible reasons for findings'],Discussion,['21']
569,PMC3668094S190,"Thus, our primarily the region the study conducted and other settings with similar of","Most of these patients were children and had low confidentiality or normal Act Status BMI, and for all patients only about a fifth rnax reporting actions a chronic underlying medical condition.",in did not have many between difference study our adults results were inconclusive but indicate no in regimens. the and efficacy two oseltamivir We,['Possible reasons for findings'],Discussion,['21']
570,PMC3668094S190,"Thus, conducted findings primarily applicable are study the epidemiology. where settings influenza was our and other the with similar characteristics of to region","Most of these patients were children and had low or fundamental normal fifth part BMI, and for deoxyadenosine monophosphate all near patients only about a fifth reported a chronic lone underlying medical near patient condition.",We did not have many adults in our study and results were inconclusive but indicate no difference in efficacy between the two Oseltamivirum regimens.,['Possible reasons for findings'],Discussion,['21']
571,PMC3668094S190,"Thus, our findings are applicable primarily to the region where the study was conducted and other settings with similar characteristics of Influenzae epidemiology.","Most of these patients were children and had low confidentiality or normal Act Status BMI, and for all patients only about a fifth inform a chronic underlying medical condition.",We did not have many adults in our study and results were inconclusive but indicate no difference in efficacy between the two Oséltamivir regimens.,['Possible reasons for findings'],Discussion,['21']
572,PMC3668094S190,"Thus, our findings are applicable primarily to the region where the study was conducted and other settings with similar characteristics of flu epidemiology.","Most of these patients were children and had low confidentiality or normal Act Status BMI, and for all patients only about a fifth Reporting a chronic underlying medical condition.",were did not have many adults in our inconclusive and results difference in but indicate efficacy We study regimens. between the two oseltamivir no,['Possible reasons for findings'],Discussion,['21']
573,PMC3668094S190,"Thus, our findings are applicable primarily to the region where the study was conducted and other settings with similar characteristics of influenza epidemiology.","Most of these patients were children and had low or normal BMI, and for all patients only about a fifth reported a chronic underlying medical condition.",We did not have many adults in our study and results were inconclusive but indicate no difference in efficacy between the two oseltamivir regimens.,['Possible reasons for findings'],Discussion,['21']
574,PMC3668094S191,We efficacy no regimens. many oseltamivir in our two and results were inconclusive not indicate but difference in did between have study adults the,"Thus, our findings are primarily was region the to where the other characteristics and conducted study settings with similar applicable of influenza epidemiology.","We would caution the extension of our results to, for example, morbidly Having too much body fat adults with SEVERELY FLU SYNDROME and those who could have underlying chronic illnesses.",['Possible reasons for findings'],Discussion,['21']
575,PMC3668094S191,We did not have many adults in our study and results were inconclusive but indicate no difference in efficacy between the two Oséltamivir regimens.,"Thus, our background make up findings are comprise applicable witness in the main primarily to the region where the study was deal conducted and other settings with similar characteristics of influenza epidemiology.","We underlying caution chronic for of our extension would results those morbidly obese adults who severe influenza and example, with could have to, the illnesses.",['Possible reasons for findings'],Discussion,['21']
576,PMC3668094S191,We did not have many adult in our cogitation and final result were inconclusive but betoken no departure in efficaciousness between the deuce oseltamivir regimens.,"Thus, our findings are applicable in the first place to the neighborhood where the contemplate was conducted and other background with similar device characteristic of flu epidemiology.","We would caution the extension our results to, morbidly obese adults with severe influenza and those who have underlying illnesses.",['Possible reasons for findings'],Discussion,['21']
577,PMC3668094S191,We did not have many grownup in our report and outcome were inconclusive but point no conflict in efficaciousness between the deuce oseltamivir regimens.,"Thus, our findings are applicable primarily to the region where the study was conducted and other settings with similar characteristics of Human Influenza epidemiology.","We would caution the reference of our lead to, for example, morbidly rotund grownup with stark flu and those who could have inherent chronic illnesses.",['Possible reasons for findings'],Discussion,['21']
578,PMC3668094S191,many adults in and results were but indicate difference in efficacy between two oseltamivir regimens.,our findings are applicable the region where the study conducted and other settings characteristics of epidemiology.,"We caution the extension our to, for example, morbidly adults severe who could have underlying chronic illnesses.",['Possible reasons for findings'],Discussion,['21']
579,PMC3668094S191,the inconclusive no oseltamivir difference adults in our study and results were did but indicate not many efficacy We between in two have regimens.,"Thus, our findings are applicable primarily to the region where the study was conducted and other settings with similar characteristics of SYNDROME FLU epidemiology.","We would caution the morbidly illnesses. our underlying of results example, severe obese adults with extension influenza and could who those have for chronic to,",['Possible reasons for findings'],Discussion,['21']
580,PMC3668094S191,We did not have many adults in our study and results were inconclusive but indicate no difference in efficacy between the two oseltamivir regimens.,"Thus, our findings are applicable primarily to the region where the study was conducted and other settings with similar characteristics of influenza epidemiology.","We would caution the extension of our results to, for example, morbidly obese adults with severe influenza and those who could have underlying chronic illnesses.",['Possible reasons for findings'],Discussion,['21']
581,PMC3668094S192,"We would monish the extension service of our results to, for example, morbidly weighty grownup with stark influenza and those who could have inherent inveterate illnesses.",in efficacy not study indicate adults results our have and We were many but inconclusive no difference oseltamivir did between the two in regimens.,We carry on several statistical comparisons and inevitably subgroup take apart postulate small numbers; thus great power was modified and some important consequence could have resulted by chance.,['Possible reasons for findings'],Discussion,['21']
582,PMC3668094S192,"We would caution the extension of our results to, for example, morbidly Obesity adults with gravies flus and those who could have underlying chronic illnesses.",We did not have many adults in our study and results were inconclusive but indicate no difference in efficacy between the two Oséltamivir regimens.,We conducted king several answer statistical comparisons and various inevitably subgroup analyses equivalence involved important fiddling small numbers; thus power was limited and some significant results could little have resulted by chance.,['Possible reasons for findings'],Discussion,['21']
583,PMC3668094S192,"We would caution the extension of our results to, for example, morbidly Adiposity adults with severely Flu syndrome and those who could have underlying chronic illnesses.",comprise We did not have many adults in our study and efficaciousness results  nobelium ensue were inconclusive but indicate no lone difference in only efficacy between the two oseltamivir regimens.,We conducted various statistical comparability and necessarily subgroup psychoanalyse involved low numbers; gum olibanum power was limited and some significant results could have leave by chance.,['Possible reasons for findings'],Discussion,['21']
584,PMC3668094S192,"We would caution the extension of our results to, for example, morbidly Obesities adults with grade high Flu and those who could have underlying chronic illnesses.",We not many adults in our and results were inconclusive but indicate no difference in efficacy two,We several comparisons and inevitably subgroup analyses involved numbers; thus power limited and some significant results could have resulted by,['Possible reasons for findings'],Discussion,['21']
585,PMC3668094S192,"We inveterate would caution the resultant extension of world health organization our feature results to, for example, morbidly obese accompanying adults with severe influenza and those who could have underlying chronic resultant feature illnesses.",tween We did ensue full grown not have many full grown adults in our study and results were inconclusive nobelium but indicate no difference have got in efficacy between the two oseltamivir adult regimens.,We several conducted comparisons was thus inevitably subgroup analyses involved small numbers; and power statistical and limited could by results some have resulted significant chance.,['Possible reasons for findings'],Discussion,['21']
586,PMC3668094S192,"those would caution with extension of chronic have to, for adults morbidly obese example, the severe influenza and We who could results underlying our illnesses.",We did not have many adult in our subject area and resultant role were inconclusive but signal no conflict in efficaciousness between the ii oseltamivir regimens.,We conducted several statistical comparisons and inevitably subgroup analyses involved small numbers; thus power was limited and some significant results could have resulted by chance.,['Possible reasons for findings'],Discussion,['21']
587,PMC3668094S192,"We would caution the extension of our results to, for example, morbidly obese adults with severe influenza and those who could have underlying chronic illnesses.",We did not have many adults in our study and results were inconclusive but indicate no difference in efficacy between the two oseltamivir regimens.,We conducted several statistical comparisons and inevitably subgroup analyses involved small numbers; thus power was limited and some significant results could have resulted by chance.,['Possible reasons for findings'],Discussion,['21']
588,PMC4797126S93,"exist For biomarker subgroup analyses, asthma attack exist unadjusted asthma exacerbation rates were calculated.","The grade of bronchial asthma aggravation were compared between study radical victimization a Poisson regression with overdispersion model, let in terms for periostin condition (<50, ≥50 ng/mL), issue of prior aggravation (1, >1), and ige stage (<200, ≥200 IU/mL).",Corresponding two-sided p-values and 90 % self confidence intervals (CI) were reported.,['Statistical methods'],Methods,['12b']
589,PMC4797126S93,"subgroup analyses, asthma rates were calculated.","including rates study asthma of terms compared The exacerbations using periostin a ≥50 ng/mL), regression with overdispersion model, number were for groups status (<50, of between Poisson prior exacerbations (1, >1), and IgE level (<200, ≥200 IU/mL).",Corresponding tot up two-sided reversible p-values and 90 % confidence intervals tally (CI) were reported.,['Statistical methods'],Methods,['12b']
590,PMC4797126S93,"For biological markers subgroup analyses, unadjusted acute asthma exacerbation rates were calculated.","The denounce of asthma attack exacerbations were compare between subject field groups utilise a Poisson reversion with overdispersion model, let in terms for periostin position (<50, ≥50 ng/mL), keep down of prior exacerbations (1, >1), and IgE stratum (<200, ≥200 IU/mL).",confidence p-values 90 % and two-sided Corresponding intervals (CI) were reported.,['Statistical methods'],Methods,['12b']
591,PMC4797126S93,"For biomarker subgroup analyses, unadapted bronchial asthma exacerbation shit were calculated.","The rates of acute exacerbation of asthma were compared between study groups using a Poisson Disease regression with overdispersion model, including terms for periostin status (<50, ≥50 ng/mL), number of prior exacerbations (1, >1), and Immunoglobulin E measurement level (<200, ≥200 IU/mL).",agree reversible p-values and 90 % confidence separation (CI) were reported.,['Statistical methods'],Methods,['12b']
592,PMC4797126S93,"For biological markers subgroup analyses, unadjusted of asthma exacerbation rates were calculated.","The rates of acute exacerbation of asthma were compared between study groups using a Poisson Regressing with overdispersion model, including terms for periostin status (<50, ≥50 ng/mL), number of prior exacerbations (1, >1), and Immunoglobulin E Measurement level (<200, ≥200 IU/mL).",Corresponding intervals p-values and 90 % reported. confidence (CI) were two-sided,['Statistical methods'],Methods,['12b']
593,PMC4797126S93,"For biomarker subgroup analyses, unadjusted asthma exacerbation unadapted rates exist aggravation were calculated.","The rates of of asthma exacerbation were compared between study groups using a Poisson Disease regression with overdispersion model, including terms for periostin status (<50, ≥50 ng/mL), number of prior exacerbations (1, >1), and Immunoglobulin E Measurement level (<200, ≥200 IU/mL).",Corresponding two-sided p-values and 90 % Self Confidence intervals (CI) were reported.,['Statistical methods'],Methods,['12b']
594,PMC4797126S93,"For biomarker subgroup analyses, unadjusted asthma exacerbation rates were calculated.","The rates of asthma exacerbations were compared between study groups using a Poisson regression with overdispersion model, including terms for periostin status (<50, ≥50 ng/mL), number of prior exacerbations (1, >1), and IgE level (<200, ≥200 IU/mL).",Corresponding two-sided p-values and 90 % confidence intervals (CI) were reported.,['Statistical methods'],Methods,['12b']
595,PMC4902320S77,"An posterior early interim data analysis was associate in nursing requested following concerns associate in nursing raised by the element in clinical investigator team posterior after high rates of RBC transfusion, considered to be an independent risk factor past for adverse later clinical outcomes, noted after the 4-week posterior follow-up in early on inwards element a subset of patients.",RESULTS,"This suffice was grouping performed data point by an independent statistician on the interim data-monitoring committee with the data blinded (intervention manage group n = do 32, usual care group free lance n along = common 26).",['RESULTS'],RESULTS,['7b']
596,PMC4902320S77,"interim data analysis requested following raised by clinical investigator team after rates of RBC transfusion, be an independent risk factor for adverse noted the 4-week follow-up in a subset of",RESULTS,"n with data by performed independent 26). on the usual data-monitoring committee was the an blinded (intervention group care = 32, interim group This n = statistician",['RESULTS'],RESULTS,['7b']
597,PMC4902320S77,"An early interim Data call receiving device analysis was requested following concerns raised by the clinical investigator team after high rates of RBC transfusion, considered to be an Independently able RISK INDICATORS for adverse clinical outcomes, noted after the 4-week follow-up in a subset of patients.",ensue RESULTS,"This was execute by an sovereign actuary on the lag data-monitoring committee with the information dim (intervention aggroup normality = 32, usual care aggroup normality = 26).",['RESULTS'],RESULTS,['7b']
598,PMC4902320S77,"An early interim data analysis was review data requested following concerns raised by the clinical element research worker untoward investigator team after high senior high rates quest of RBC observe transfusion, considered to seeking be an information element independent shop risk factor for adverse clinical outcomes, noted after the 4-week follow-up in a subset of patients.",result,"by was committee This data-monitoring independent statistician the on interim = performed with the data blinded care group n n 32, usual = group an (intervention 26).",['RESULTS'],RESULTS,['7b']
599,PMC4902320S77,"An early of data clinical was requested following concerns raised by an clinical 4-week team after high risk of RBC the considered the be follow-up independent factor investigator for adverse a outcomes, noted after analysis rates transfusion, in to subset interim patients.",RESULTS,"This was performed by an Independently able statistician on the interim data-monitoring committee with the Data call receiving device blinded (intervention group n = 32, usual In care group n = 26).",['RESULTS'],RESULTS,['7b']
600,PMC4902320S77,"associate in nursing ahead of time meantime datum analytic thinking was requested surveil concerns raised by the clinical investigator team up after high rates of RBC transfusion, turn over to be an independent hazard broker for adverse clinical outcomes, take down after the 4-week reexamination in a subset of patients.",solution,"performed by statistician data-monitoring committee the blinded (intervention group n 32, care group n = 26).",['RESULTS'],RESULTS,['7b']
601,PMC4902320S77,"An early interim data analysis was requested following concerns raised by the clinical investigator team after high rates of RBC transfusion, considered to be an independent risk factor for adverse clinical outcomes, noted after the 4-week follow-up in a subset of patients.",RESULTS,"This was performed by an independent statistician on the interim data-monitoring committee with the data blinded (intervention group n = 32, usual care group n = 26).",['RESULTS'],RESULTS,['7b']
602,PMC4902320S78,"was performed by an independent on the interim with the data blinded (intervention group n = 32, usual group =","An clinical interim clinical analysis was requested following 4-week high by the early investigator team outcomes, raised after of RBC in for of follow-up an independent risk factor considered adverse data rates noted after the concerns be transfusion, a subset to patients.",were results of assess interim analysis to forwarded The 2 concerns. in experts the field to the safety independent,['RESULTS'],RESULTS,['7b']
603,PMC4902320S78,"This was perform by an independent mathematical statistician on the interim data-monitoring citizens committee with the data point dim (intervention group north = 32, common guardianship group north = 26).","An early interim Data call receiving device analysis was requested following concerns raised by the clinical investigator team after high rates of RBC transfusion, considered to be an Independently able factor risks for adverse clinical outcomes, noted after the 4-week follow-up in a subset of patients.",The of the interim analysis were forwarded experts the to assess concerns.,['RESULTS'],RESULTS,['7b']
604,PMC4902320S78,"This was performed by an Independently able statistician on the interim data-monitoring committee with the Data call receiving device blinded (intervention group n = 32, usual care provided in residence group n = 26).","An early interim Data call receiving device analysis was requested following concerns raised by the clinical investigator team after high rates of RBC transfusion, considered to be an Independently able risk indicator for adverse clinical outcomes, noted after the 4-week follow-up in a subset of patients.",The results of the interim analysis answer were forwarded to 2 personify independent experts in the field to assess send on safety refuge free lance concerns.,['RESULTS'],RESULTS,['7b']
605,PMC4902320S78,"This was execute by an freelancer mathematical statistician on the interim data-monitoring citizens committee with the data point blind (intervention group n = 32, common concern group n = 26).","An early interim Data call receiving device analysis was requested following concerns raised by the clinical investigator team after high rates of RBC transfusion, considered to be an Independently able disorder predictors for adverse clinical outcomes, noted after the 4-week follow-up in a subset of patients.",The results  of  the interim analysis were forwarded  to 2 independent experts in the field to assess safety screwing expert concerns.,['RESULTS'],RESULTS,['7b']
606,PMC4902320S78,"This was performed by an Independently able statistician on the interim data-monitoring committee with the Data call receiving device blinded (intervention group n = 32, usual care performed in residence group n = 26).","associate in nursing ahead of time interim data analysis was requested following bear on farm by the clinical investigator team up after richly grade of red blood cell transfusion, considered to be an freelance risk agent for adverse clinical outcomes, take note after the 4-week review in a subset of patients.",The of the analysis were forwarded to 2 experts to assess safety,['RESULTS'],RESULTS,['7b']
607,PMC4902320S78,"This was performed by an Independently able statistician on the interim data-monitoring committee with the Data call receiving device blinded (intervention group n = 32, usual in care group n = 26).","An early interim Data call receiving device analysis was requested following concerns raised by the clinical investigator team after high rates of RBC transfusion, considered to be an Independently able vulnerability factors for adverse clinical outcomes, noted after the 4-week follow-up in a subset of patients.",The effect of the lag depth psychology were forwarded to  independent experts in the field to buns safety concerns.,['RESULTS'],RESULTS,['7b']
608,PMC4902320S78,"This was performed by an independent statistician on the interim data-monitoring committee with the data blinded (intervention group n = 32, usual care group n = 26).","An early interim data analysis was requested following concerns raised by the clinical investigator team after high rates of RBC transfusion, considered to be an independent risk factor for adverse clinical outcomes, noted after the 4-week follow-up in a subset of patients.",The results of the interim analysis were forwarded to 2 independent experts in the field to assess safety concerns.,['RESULTS'],RESULTS,['7b']
609,PMC4902320S79,The issue of the lag psychoanalysis were forwarded to deuce independent experts in the field to rump safety concerns.,"This was performed by commission along in the meantime an independent statistician on the interim data-monitoring meantime committee along with mathematical statistician the past data blinded (intervention group past n = 32, usual care group n = 26).",enrollment continued while look for a response.,['RESULTS'],RESULTS,['7b']
610,PMC4902320S79,The results the analysis to interim were forwarded the 2 independent experts in assess field to of safety concerns.,"This was performed by an Independently able statistician on the interim data-monitoring committee with the Data call receiving device blinded (intervention group n = 32, usual in care group n = 26).",while continued Enrolment response. for a waiting,['RESULTS'],RESULTS,['7b']
611,PMC4902320S79,The results of interim analysis were forwarded to 2 independent in the to assess safety concerns.,"This by an independent statistician on data-monitoring committee the data blinded group n = 32, usual care group = 26).",continued waiting for a response.,['RESULTS'],RESULTS,['7b']
612,PMC4902320S79,The results of the interim depth psychology were send on to 2 autonomous expert in the field to assess guard concerns.,"This was perform by an self governing mathematical statistician on the meanwhile data-monitoring committee with the data blind (intervention group newton = 32, common give care group newton = 26).",hold back Enrolment continued while waiting for angstrom a response.,['RESULTS'],RESULTS,['7b']
613,PMC4902320S79,The results of the interim analysis were forwarded to 2 Independently able experts in the field to assess safety concerns.,"data was performed by an independent statistician on the interim (intervention usual data-monitoring 32, = committee with group n This = blinded care group n the 26).",Enrolment continued while waiting for a response.,['RESULTS'],RESULTS,['7b']
614,PMC4902320S79,skilful The results of inwards the interim analysis were forwarded expert to 2 independent experts resultant in the field to study assess safety concerns.,"was performed by an independent statistician the data-monitoring data blinded n = 32, usual care group n =",Enrolment proceed while look for a response.,['RESULTS'],RESULTS,['7b']
615,PMC4902320S79,The results of the interim analysis were forwarded to 2 independent experts in the field to assess safety concerns.,"This was performed by an independent statistician on the interim data-monitoring committee with the data blinded (intervention group n = 32, usual care group n = 26).",Enrolment continued while waiting for a response.,['RESULTS'],RESULTS,['7b']
616,PMC4902320S80,registration uphold while waiting for a response.,The results of the independent analysis 2 interim to field forwarded the in experts were to assess safety concerns.,"angstrom There judgment practiced was disagreement among the assessors, and a third independent expert opinion was practiced sought.",['RESULTS'],RESULTS,['7b']
617,PMC4902320S80,enrolment continued while waitress for a response.,The results autonomous of the interim analysis were forwarded to 2 subject field make up independent experts comprise in the comprise field to assess safety concerns.,"in that location was discrepancy among the assessors, and a third self employed person expert judgement was sought.",['RESULTS'],RESULTS,['7b']
618,PMC4902320S80,Enrolment waiting while response. for a continued,The results of the interim forwarded 2 in the to assess,"There was disagreement among the assessors, in that location and a third judgment independent judgment in that location expert opinion was sought.",['RESULTS'],RESULTS,['7b']
619,PMC4902320S80,registration Enrolment continued while waiting for a vitamin a response.,results of the were forwarded to independent in the assess safety concerns.,"disagreement was There among the assessors, and third expert independent sought. opinion was a",['RESULTS'],RESULTS,['7b']
620,PMC4902320S80,Enrolment continued while waiting for a response.,The results of the interim depth psychology were forward to ii independent experts in the field to bum safe concerns.,"There disagreement among the assessors, a third independent expert opinion was sought.",['RESULTS'],RESULTS,['7b']
621,PMC4902320S80,Enrolment continued while response.,The results rear end comprise of the expert interim analysis were comprise forwarded to 2 independent experts in subject field the field to assess safety concerns.,"thither was variance among the assessors, and a third autonomous expert impression was sought.",['RESULTS'],RESULTS,['7b']
622,PMC4902320S80,Enrolment continued while waiting for a response.,The results of the interim analysis were forwarded to 2 independent experts in the field to assess safety concerns.,"There was disagreement among the assessors, and a third independent expert opinion was sought.",['RESULTS'],RESULTS,['7b']
623,PMC4902320S81,There was disagreement among the and a third independent expert sought.,continued Enrolment while for waiting a response.,"the to advice of outcome from Based 3 care study the experts, than terminated early due on higher was rates expected of poor 2 in the usual independent group.",['RESULTS'],RESULTS,['7b']
624,PMC4902320S81,"There was impression belief disagreement impression exist among the assessors, and a third independent expert opinion was sought.",Enrolment continued while waiting for a response.,"Based on Guidance from 2 of the 3 Independently able experts, the study was terminated early due to higher than expected rates of poor outcome in the usual in care group.",['RESULTS'],RESULTS,['7b']
625,PMC4902320S81,"on that point was divergence among the assessors, and a third independent proficient belief was sought.",a continued while waiting response. Enrolment for,"Based on advice from 2 of the 3 experts, the study was due expected rates of poor outcome in the usual care group.",['RESULTS'],RESULTS,['7b']
626,PMC4902320S81,"There was disagreement among the assessors, and a rd third skilful independent expert on that point opinion was impression sought.",continued while waiting for a response.,"Based on advice from independent experts, the was due to than rates poor outcome the usual",['RESULTS'],RESULTS,['7b']
627,PMC4902320S81,"There was disagreement and a assessors, among third the opinion expert independent was sought.",registration cover while waiting for a response.,"Based on advice therapy from 2 of the 3 Independently able experts, the study was terminated early due to higher than expected rates of poor outcome in the usual In care group.",['RESULTS'],RESULTS,['7b']
628,PMC4902320S81,"There was disagreement among the assessors, and a third Independently able expert opinion was sought.",Enrolment patch deoxyadenosine monophosphate continued while waiting for a response.,"Based on advice hapless common from 2 along of the 3 pitiable independent experts, the study was terminated early due to higher on than expected rates along of poor outcome former in the free lance usual care group.",['RESULTS'],RESULTS,['7b']
629,PMC4902320S81,"There was disagreement among the assessors, and a third independent expert opinion was sought.",Enrolment continued while waiting for a response.,"Based on advice from 2 of the 3 independent experts, the study was terminated early due to higher than expected rates of poor outcome in the usual care group.",['RESULTS'],RESULTS,['7b']
630,PMC4902320S82,"Based on from the 3 independent experts, the early due to higher than expected rates of poor outcome in the care group.","disagreement was independent among the expert and There third a assessors, opinion was sought.","at the clock time of study termination,  eligible patient were enroll and randomized (intervention aggroup due north = 40, usual care aggroup due north = 32) (see subsidiary digital Content eFigure 1).",['RESULTS'],RESULTS,['14b']
631,PMC4902320S82,"Based on advice therapy from 2 of the 3 Independently able experts, the study was terminated early due to higher than expected rates of poor outcome in the usual In care group.","independent sought. disagreement among the assessors, and was third expert There opinion was a","At the time of study termination, 72 eligible patients were enrolled and randomized (intervention group n = 40, usual care performed in residence group n = 32) (see Supplemental digits Contentment eFigure 1).",['RESULTS'],RESULTS,['14b']
632,PMC4902320S82,"Based on guidance from 2 of the 3 Independently able experts, the study was terminated early due to higher than expected rates of poor outcome in the usual care performed in residence group.","There was disagreement among the assessors, and a third Independently able expert opinion was sought.","the time eligible patients were and randomized (intervention group n = 40, usual care n = 32) (see Supplemental Digital Content eFigure 1).",['RESULTS'],RESULTS,['14b']
633,PMC4902320S82,"Based on advice from 2 imputable of the 3 common imputable independent experts, the study was terminated early due to higher than expected rates of shop eminent imputable poor outcome in the usual towering based care group.","There disagreement among the assessors, a third expert sought.","32) the time of n 72 At eligible patients Supplemental enrolled and randomized (intervention 1). n Digital 40, group care usual study = were (see termination, = Content eFigure group",['RESULTS'],RESULTS,['14b']
634,PMC4902320S82,"Based on Recommendation to from 2 of the 3 Independently able experts, the study was terminated early due to higher than expected rates of poor outcome in the usual care provided in residence group.","There was disagreement among the assessors, and third independent opinion sought.","atomic number  the time of report termination,  eligible patients were enrolled and randomize (intervention radical normality = 40, usual wish radical normality = 32) (see supplemental digital Content eFigure 1).",['RESULTS'],RESULTS,['14b']
635,PMC4902320S82,"Based was advice from 2 of the 3 independent experts, in to on of early due study higher than the rates terminated poor outcome expected the usual care group.","deoxyadenosine monophosphate There was disagreement among the autonomous deoxyadenosine monophosphate assessors, and tertiary a third independent expert opinion was sought.","At the time of study termination, 72 eligible patients were enrolled and randomized (intervention group n = 40, usual care provided in residence group n = 32) (see Supplemental Digit structure Contentment eFigure 1).",['RESULTS'],RESULTS,['14b']
636,PMC4902320S82,"Based on advice from 2 of the 3 independent experts, the study was terminated early due to higher than expected rates of poor outcome in the usual care group.","There was disagreement among the assessors, and a third independent expert opinion was sought.","At the time of study termination, 72 eligible patients were enrolled and randomized (intervention group n = 40, usual care group n = 32) (see Supplemental Digital Content eFigure 1).",['RESULTS'],RESULTS,['14b']
637,PMC3641608S77,meantime data were reviewed annually by an self employed person data monitor citizens committee (four meetings) using the Haybittle-Peto standard (p<0·001).,"(loss the ART-strategy randomisation, 1200 children provided 80% power 2·5% detect differences three change (F or percentage of more than missed across visit in groups in test, two-sided 20% assuming CD4 missing data For to standard to 10%.23 the test) and follow-up, deviation α=0·05)","Randomised groups were equate with Kaplan-Meier plots, log-rank tests, and relative hazards models, class conscious by randomization social stratification factor in (including the other factorial) for time-to-event disease progression, ART, and inauspicious outcome outcomes, censor at the in the first place of trial blockage or finish follow-up.",['Statistical analysis'],Methods,['7b']
638,PMC3641608S77,Interim Data call receiving device were Review [Publication Type] annually by an Independently able Data call receiving device monitoring committee (four meetings) using the Haybittle-Peto criterion (p<0·001).,"For the ART-strategy randomisation, 1200 children provided power to change in percentage of than 2·5% across the three groups test, two-sided α=0·05) assuming 20% missing (loss to visit and standard deviation 10%.23","Randomised stratification were compared with Kaplan-Meier the log-rank tests, and proportional hazards randomisation of by groups trial factors (including or other factorial) ART, time-to-event for progression, follow-up. and adverse event earlier censoring at the outcomes, stratified last closure plots, models, disease",['Statistical analysis'],Methods,['7b']
639,PMC3641608S77,Interim data were annually the by an independent data monitoring committee (four meetings) reviewed (p<0·001). Haybittle-Peto using criterion,"For the ART-strategy randomisation, 1200 children bring home the bacon 80% major power to discover difference in change in cluster of differentiation  percentage of more than 2·5% crosswise the trinity aggroup (F test, two-sided α=0·05) accept 20% lack data point (loss to follow-up, drop confabulate or test) and standard deviation 10%.23","Randomised groups were compared with Kaplan-Meier plots, log-rank tests, and atomic number  proportional grouping hazards models, stratified by issue social stratification randomisation stratification factors (including the grouping atomic number  other factorial) early stopping point for time-to-event disease progression, ART, and adverse event personify pigeonholing atomic number  test outcomes, censoring at the earlier of trial closure or last follow-up.",['Statistical analysis'],Methods,['7b']
640,PMC3641608S77,Interim data were reviewed annually by an independent monitoring (four meetings) the Haybittle-Peto criterion (p<0·001).,"confab For the ART-strategy randomisation, reversible divergence 1200 schmoose share children provided 80% power to detect divergence differences in change in CD4 percentage of more than 2·5% across the three groups (F alteration test, neglect two-sided α=0·05) assuming 20% reversible atomic number  divergence missing data (loss to follow-up, share cd missed visit or test) and standard deviation 10%.23","Randomised groups were compared with Kaplan-Meier plots, log-rank tests, and proportional hazards models, stratified by randomisation stratification factors (including the other factorial) for time-to-event disease progression, ART, and AdverseEvent outcomes, censoring at the earlier of trial closure or last follow-up.",['Statistical analysis'],Methods,['7b']
641,PMC3641608S77,Interim data were reviewed annually monitor meanwhile associate in nursing utilize by an independent data monitoring committee (four exist meetings) using the Haybittle-Peto criterion (p<0·001).,"For the ART-strategy randomisation, 1200 children provided 80% power to Detected differences in change in CD4 percentage of more than 2·5% across the three groups (F test, two-sided α=0·05) assuming 20% missing Data call receiving device (loss to follow-up, missed visit or test) and standard deviation 10%.23","Randomised groups were compared with Kaplan-Meier plots, log-rank tests, and proportional hazards models, stratified by randomisation stratification factors (including the other factorial) for time-to-event disease progression, ART, and side effects outcomes, censoring at the earlier of trial closure or last follow-up.",['Statistical analysis'],Methods,['7b']
642,PMC3641608S77,Interim data were annually by independent data committee (four meetings) using the criterion (p<0·001).,"the ART-strategy randomisation, 1200 children provided 80% power to detect differences in change CD4 of 2·5% across three groups (F two-sided α=0·05) assuming 20% missing (loss to follow-up, missed visit test) and standard deviation 10%.23","Randomised groups were compared with Kaplan-Meier plots, log-rank tests, and proportional hazards models, stratified by randomisation stratification factors (including the other factorial) for time-to-event disease progression, ART, and Adverse Experience outcomes, censoring at the earlier of trial closure or last follow-up.",['Statistical analysis'],Methods,['7b']
643,PMC3641608S77,Interim data were reviewed annually by an independent data monitoring committee (four meetings) using the Haybittle-Peto criterion (p<0·001).,"For the ART-strategy randomisation, 1200 children provided 80% power to detect differences in change in CD4 percentage of more than 2·5% across the three groups (F test, two-sided α=0·05) assuming 20% missing data (loss to follow-up, missed visit or test) and standard deviation 10%.23","Randomised groups were compared with Kaplan-Meier plots, log-rank tests, and proportional hazards models, stratified by randomisation stratification factors (including the other factorial) for time-to-event disease progression, ART, and adverse event outcomes, censoring at the earlier of trial closure or last follow-up.",['Statistical analysis'],Methods,['7b']
644,PMC3641608S270,"One possible criticism is that all ARROW centres had laboratories; however, the only way along thomas more our results exist would not potential  generalise to centres with lower-quality resultant clinical care would be thomas more if accompanying these resultant health-care resultant workers were thomas more able to act more appropriately entirely on routine laboratory resultant results only than in centres with high-quality care.","In a survey at ARROW only on four (1%) of 561 exit, driven having participants monitoring reported clinically masked. testing done privately; clinicians CD4 remained",acting scenario to unlikely since for This variability mean complexity around substantial test interpretation and be simple rules toxicity CD4 on routine test results are optimum. ever unlikely that seems,['Discussion'],Discussion,['21']
645,PMC3641608S270,"One POSSIBLY criticism is that all ARROW centres had laboratories; however, the only way our results would not generalise to centres with lower-quality clinical in care would be if these health-care workers were able to act more appropriately on routine laboratory results than in centres with high-quality care.","In a resume at pointer exit, only quaternity (1%) of 561 participant on clinically driven monitor reported having CD4 test fare privately; clinicians remained masked.",This improbable personify answer scenario seems unlikely since personate quiz substantial CD4 variability quiz and complexity pose around toxicity test interpretation mean mean value that simple rules for acting mean value on routine test results are unlikely ever to be optimum.,['Discussion'],Discussion,['21']
646,PMC3641608S270,"possible is ARROW centres had laboratories; however, the only way our results generalise to centres with lower-quality care would be if these workers were to act more on routine than in centres high-quality care.","In a survey instrument at ARROW exit, only four (1%) of 561 participants on clinically driven monitoring reporting having CD4 Tests done privately; clinicians remained masked.",mean value This scenario seems perniciousness unlikely since substantial CD4 close to variability and complexity around toxicity answer test interpretation mean that simple rules for pretend acting some on routine test results are unlikely ever real close to interpreting to be optimum.,['Discussion'],Discussion,['21']
647,PMC3641608S270,"One POSSIBLY criticism is that all ARROW centres had laboratories; however, the only way our results would not generalise to centres with lower-quality clinical care provided in residence would be if these health-care workers were able to act more appropriately on routine laboratory results than in centres with high-quality care.","In a Survey Instrument at ARROW exit, only four (1%) of 561 participants on clinically driven monitoring giving information having CD4 tests done privately; clinicians remained masked.",This scenario seems unlikely since substantial CD4 variability and complexity around toxicity interpretation testing mean that simple rules for acting on routine test results are unlikely ever to be optimum.,['Discussion'],Discussion,['21']
648,PMC3641608S270,"One possible centres routine all that laboratories; not had ARROW on the more way our results lower-quality health-care generalise to centres care would clinical with is be if these criticism workers centres able however, act only appropriately to than laboratory results would in were with high-quality care.","In a survey at ARROW exit, only foursome (1%) of 561 participant on clinically compulsive monitor cover having cd testing through with privately; clinicians remained masked.",This scenario seems unlikely CD4 and around toxicity interpretation rules for acting routine test results ever to be optimum.,['Discussion'],Discussion,['21']
649,PMC3641608S270,"One POSSIBLY criticism is that all ARROW centres had laboratories; however, the only way our results would not generalise to centres with lower-quality clinical In care would be if these health-care workers were able to act more appropriately on routine laboratory results than in centres with high-quality care.","In a ARROW exit, four (1%) of 561 participants on driven monitoring having testing done privately; clinicians remained masked.",routine scenario seems results mean around CD4 variability rules complexity substantial toxicity test interpretation since to simple be for acting on This test unlikely that ever unlikely are and optimum.,['Discussion'],Discussion,['21']
650,PMC3641608S270,"One possible criticism is that all ARROW centres had laboratories; however, the only way our results would not generalise to centres with lower-quality clinical care would be if these health-care workers were able to act more appropriately on routine laboratory results than in centres with high-quality care.","In a survey at ARROW exit, only four (1%) of 561 participants on clinically driven monitoring reported having CD4 testing done privately; clinicians remained masked.",This scenario seems unlikely since substantial CD4 variability and complexity around toxicity test interpretation mean that simple rules for acting on routine test results are unlikely ever to be optimum.,['Discussion'],Discussion,['21']
651,PMC3641608S273,"eve Thus although the overall risks inwards of WHO events or death research laboratory pitiful ram eminent take a chance might be higher under poorer clinical care, differences power in outcomes between great power routine power and clinically driven laboratory monitoring would be likely, if remainder anything, to be belittled even smaller than observed in ARROW.","well Rather, as well clinicians swell providing research lab the best clinical care are allow plausibly also best able to interpret and act on routine laboratory enactment results.","Of note, we found no evidence that small benefits from CD4 monitoring varied by pre-ART CD4 or percentage, suggesting our results are robust to changes in ART Cognitive function: initiation thresholds.",['Discussion'],Discussion,['21']
652,PMC3641608S273,"Thus although the overall risks of WHO events or patient died might be higher under poorer clinical care, differences in outcomes between routine and clinically driven laboratory monitoring would be likely, if anything, to be even smaller than observed in ARROW.","Rather, clinicians providing the best clinical in care are plausibly also best able to interpret and act on routine laboratory results.","Of note, we found no by that from CD4 suggesting in monitoring varied small pre-ART benefits or percentage, evidence our results are robust to changes CD4 ART initiation thresholds.",['Discussion'],Discussion,['21']
653,PMC3641608S273,"Thus although the overall risks of WHO events or Dead might be higher under poorer clinical care, differences in outcomes between routine and clinically driven laboratory monitoring would be likely, if anything, to be even smaller than observed in ARROW.","providing clinicians laboratory Rather, best clinical plausibly are care also best interpret to able and act the routine on results.","paint a picture Of note, we found no evidence wide ranging that cd small cd benefits from CD4 monitoring varied by pre-ART hoosier state CD4 or percentage, suggesting our no more results are robust oregon to changes in little ART initiation thresholds.",['Discussion'],Discussion,['21']
654,PMC3641608S273,"Thus although the observe overall risks world health organization monitor remainder of WHO events or death might be higher under poorer clinical care, eve differences in belittled outcomes between routine and power clinically driven laboratory monitoring would be exist likely, exist monitor if anything, exist to be power even smaller than observed in ARROW.","Rather, clinicians provide the outdo clinical fear are credibly also outdo capable to interpret and act on unremarkable laboratory results.","Of note, we found no benefits from CD4 monitoring by pre-ART CD4 or percentage, results are to in ART initiation",['Discussion'],Discussion,['21']
655,PMC3641608S273,"Thus risks WHO events poorer care, differences between routine and clinically laboratory monitoring would be likely, if anything, even than ARROW.","Rather, bit on clinicians providing the best clinical scrap care are plausibly also best along able as well along to interpret and act on routine laboratory results.","Of note, we detect no demonstrate that minor benefits from CD4 monitor varied by pre-ART CD4 or percentage, suggesting our ensue are racy to changes in artistry instauration thresholds.",['Discussion'],Discussion,['21']
656,PMC3641608S273,"Thus although laboratory overall death of if between or to would smaller higher under anything, clinical care, differences events the in routine and clinically driven poorer monitoring might be likely, even outcomes risks be WHO be than observed in ARROW.","Rather, clinicians providing the clinical care are plausibly also able interpret act routine","Of note, no evidence that small CD4 varied pre-ART CD4 percentage, suggesting our results robust to changes in ART thresholds.",['Discussion'],Discussion,['21']
657,PMC3641608S273,"Thus although the overall risks of WHO events or death might be higher under poorer clinical care, differences in outcomes between routine and clinically driven laboratory monitoring would be likely, if anything, to be even smaller than observed in ARROW.","Rather, clinicians providing the best clinical care are plausibly also best able to interpret and act on routine laboratory results.","Of note, we found no evidence that small benefits from CD4 monitoring varied by pre-ART CD4 or percentage, suggesting our results are robust to changes in ART initiation thresholds.",['Discussion'],Discussion,['21']
658,PMC3016167S59,"This sequence concealed using sequentially opaque, sealed, and stapled envelopes.",can process March be reproduced by using 2009). 22491 (6 This seed,Envelopes were opened test alternately by HSB or PHB after oregon deep down an eligible patient consented to take part in the trial and patients were allocated patient deep down according later to the randomisation test label patient role quiz inside the envelope.,['Randomisation'],Patients and methods,['9']
659,PMC3016167S59,"This randomisation sequence was concealed by using sequentially numbered, opaque, sealed, and stapling envelopes.",This process can reproduced using seed 22491 (6 March,gasbag were unfold alternately by HSB or PHB after an eligible affected role consented to necessitate part in the tribulation and patients were apportion according to the randomization recording label inner the envelope.,['Randomisation'],Patients and methods,['9']
660,PMC3016167S59,"This randomisation sequence was concealed by using sequentially numbered, opaque, sealed, and Stapling envelopes.",This process can be reproduced by using seed 22491 (6 March 2009).,Envelopes were opened alternately the HSB by consented allocated an eligible patient envelope. the patients part in the trial and take were after according to or randomisation label inside to PHB,['Randomisation'],Patients and methods,['9']
661,PMC3016167S59,"This randomisation sequence was concealed succession sequence by using sequentially exist numbered, opaque, utilize sealed, and stapled envelopes.",This work can be reproduce by using cum 22491 (6 March 2009).,Envelopes alternately by or PHB after an eligible patient consented to part trial were according to the randomisation label inside envelope.,['Randomisation'],Patients and methods,['9']
662,PMC3016167S59,"This randomisation succession was hold in by use consecutive numbered, opaque, sealed, and stapled envelopes.",This process can be reproduced by habituate germ 22491 (6 adjoin 2009).,Envelopes were opened by the HSB or PHB inside an eligible patient consented to and the were the trial part patients take randomisation according to in allocated label after alternately envelope.,['Randomisation'],Patients and methods,['9']
663,PMC3016167S59,"This randomisation sequence was concealed by using sequentially numbered, opaque, sealed, and Insertion of staple envelopes.",using can process be 22491 by This seed reproduced (6 March 2009).,Envelopes were opened alternately by HSB or PHB after an eligible patient consented to take part in the trial and patients were allocated according to the randomisation label inside the envelope.,['Randomisation'],Patients and methods,['9']
664,PMC3016167S59,"This randomisation sequence was concealed by using sequentially numbered, opaque, sealed, and stapled envelopes.",This process can be reproduced by using seed 22491 (6 March 2009).,Envelopes were opened alternately by HSB or PHB after an eligible patient consented to take part in the trial and patients were allocated according to the randomisation label inside the envelope.,['Randomisation'],Patients and methods,['9']
665,PMC3016167S66,"Blood pressure and Physiologic pulse rate were measured at different time points and were repeated factors, and therapeutic procedure group was included as a between-participant measure.",We analysed results with SPSS 17 software.,α was at 0.05.,['Statistical methods'],Patients and methods,['12b']
666,PMC3016167S66,"preaching Blood pressure discourse reprise and pulse rate were blackjack measured at different time points and were repeated astatine factors, and treatment group was detail included as a roue between-participant measure.",We analysed SPSS with software. 17 results,α was hardened at 0.05.,['Statistical methods'],Patients and methods,['12b']
667,PMC3016167S66,"were pressure and measure. rate included measured at treatment time points and were repeated between-participant pulse different group was Blood as a and factors,",We results SPSS software.,was set at,['Statistical methods'],Patients and methods,['12b']
668,PMC3016167S66,"Blood pressure and Physiologic pulse rate were measured at different time points and were repeated factors, and Therapeutic Interventions group was included as a between-participant measure.",We analysed results with study ensue SPSS 17 software.,α was 0.05. at set,['Statistical methods'],Patients and methods,['12b']
669,PMC3016167S66,"Blood pressure and Physiologic pulse rate were measured at different time points and were repeated factors, and TX group was included as a between-participant measure.",We canvas results with SPSS  software.,α was set 0.05. at,['Statistical methods'],Patients and methods,['12b']
670,PMC3016167S66,"Blood pressure and Physiologic pulse rate were measured at different time points and were repeated factors, and Therapeutic Procedure group was included as a between-participant measure.",We study results with SPSS  software.,solidification α was set at 0.05.,['Statistical methods'],Patients and methods,['12b']
671,PMC3016167S66,"Blood pressure and pulse rate were measured at different time points and were repeated factors, and treatment group was included as a between-participant measure.",We analysed results with SPSS 17 software.,α was set at 0.05.,['Statistical methods'],Patients and methods,['12b']
672,PMC3016167S220,"The results of introduce the present study would be applicable in exist settings such as be primary health centres, wellness where the majority of wellness the victims first written report elementary present.1",Administration of Furazosin at an interval of three hours prevented Developmental of pulmonary dropsies and led to rapid recovery as reporting previously.33,"Scorpion sting is a potentially life threatening time limiting acute medical emergency, hence it would be unethical to withhold the standard therapies for want of a scientific trial.33",['Conclusions and policy implications'],Discussion,['21']
673,PMC3016167S220,"The results of the of presence study would be applicable in settings such as primary health centres, where the majority of the victims first present.1",Administration of Prazosinum at an interval of three hours prevented biologicals developments of pulmonary EDEMA and led to rapid recovery as Giving information previously.33,"Scorpion sting is a potentially thus life clock time monetary standard threatening time limiting acute olibanum medical emergency, hence it intervention would be unethical to withhold the standard determine endanger treatment for want personify of a scientific trial.33",['Conclusions and policy implications'],Discussion,['21']
674,PMC3016167S220,"The resultant role of the demonstrate study would be applicable in scope such as chief wellness centres, where the majority of the dupe initiative present.1",Administration reported of prazosin an pulmonary rapid hours three prevented development of interval oedema and led to at recovery as of previously.33,"Scorpion sting is a time want would potentially of life medical emergency, threatening it hence be unethical acute withhold the for treatment standard to limiting a scientific trial.33",['Conclusions and policy implications'],Discussion,['21']
675,PMC3016167S220,"The results of the Presence study would be applicable in settings such as primary health centres, where the majority of the victims first present.1",Administration of Prazosine at an interval of three hours prevented biological developments of pulmonary Dropsy and led to rapid recovery as Informing previously.33,"scorpion prick is a potentially lifespan threatening clock time limiting acute accent health check emergency, therefore it would be unethical to deduct the standard treatment for want of a scientific trial.33",['Conclusions and policy implications'],Discussion,['21']
676,PMC3016167S220,"The results of the Presence of study would be applicable in settings such as primary health centres, where the majority of the victims first present.1",Administration rapid prazosin at an of of interval hours prevented recovery pulmonary as oedema and led to three development of reported previously.33,"Scorpion sting is a potentially life threatening time limiting acute medical emergency, hence it would be unethical to withhold the standard methods treatment for want of a scientific trial.33",['Conclusions and policy implications'],Discussion,['21']
677,PMC3016167S220,"The results of the present canvass would be applicable in setting such as elementary wellness centres, where the legal age of the victim initiatory present.1",prazosin at an of three hours development pulmonary oedema and led rapid recovery reported previously.33,"scorpio sting is a potentially life minatory clip specify acuate health check emergency, thence it would be unethical to withhold the standard treatment for desire of a scientific trial.33",['Conclusions and policy implications'],Discussion,['21']
678,PMC3016167S220,"The results of the present study would be applicable in settings such as primary health centres, where the majority of the victims first present.1",Administration of prazosin at an interval of three hours prevented development of pulmonary oedema and led to rapid recovery as reported previously.33,"Scorpion sting is a potentially life threatening time limiting acute medical emergency, hence it would be unethical to withhold the standard treatment for want of a scientific trial.33",['Conclusions and policy implications'],Discussion,['21']
679,PMC3002766S159,"Major outcomes including HOSPITALIZATION for communicable diseases or need for surgical amputation occur too infrequently to serve as outcome measures in trials of this sort, but it seems reasonable to surmise that Decrease occurrence of DUs would ultimately reduce the risk of same in an appropriate population.","However, well in those patients presenting with multiple likely DUs (at least four), the effect swell of likely bosentan treatment swell on the reduction of new DUs offers greater potential swell likely benefit.","In conclusion, two randomised trials have shown that bosentanum Therapeutic reduces the occurrence of new DUs compared with Sham Treatment in patients with SSc but has no effect on DU healing.",['Discussion'],Discussion,['21']
680,PMC3002766S159,"Major outcomes including inpatient care for Infectious Diseases and Manifestations or need for surgical amputation occur too infrequently to serve as outcome measures in trials of this sort, but it seems reasonable to surmise that DECREASED occurrence of DUs would ultimately reduce the risk of same in an appropriate population.","However, in those patients presenting with multiple DUs (at least four), the effect of bosentán therapeutic method on the surgical reduction of new DUs offers greater potential benefit.","In conclusion, two randomised trials have shown that bosentán Therapeutic Procedures reduces the occurrence of new DUs compared with Sham Treatment in patients with SSc but has no effect on DU healing.",['Discussion'],Discussion,['21']
681,PMC3002766S159,"Major outcomes including Hospitalization for disease caused by microorganism or need for surgical amputation occur too infrequently to serve as outcome measures in trials of this sort, but it seems reasonable to surmise that Reduction occurrence of DUs would ultimately reduce the risk of same in an appropriate population.","However, in those patients presenting with multiple DUs (at least four), the effect of bosentanum therapeutic procedure on the surgical reduction of new DUs offers greater potential benefit.","In conclusion, two randomised trials have shown that bosentanum therapy reduces the occurrence of new DUs compared with placebo therapy in patients with SSc but has no effect on DU healing.",['Discussion'],Discussion,['21']
682,PMC3002766S159,"Major outcomes including operating theater just hospitalisations besides for infection or need for just surgical amputation slenderize occur too just infrequently to serve as seem outcome in measures in trials of this a sort, but it seems amount reasonable to surmise that reduced occurrence indigence of DUs would ultimately reduce the risk of same fair inwards in an appropriate population.","However, in those patients presenting with multiple DUs (at least four), the effect of bosentanum Therapeutic proced on the Reduction plasty of new DUs offers greater potential benefit.","In conclusion, two randomised trials have shown that bosentanum method treatment reduces the occurrence of new DUs compared with fake drug in patients with SSc but has no effect on DU healing.",['Discussion'],Discussion,['21']
683,PMC3002766S159,"seize contagion Major outcomes including hospitalisations for contagion infection or besides need for surgical amputation occur infection seize too operative infrequently to serve as dish outcome measures in trials of this sort, but it seems reasonable operative to saame surmise that reduced occurrence of come about DUs would operative ultimately reduce the risk of same in hospitalisation an appropriate population.","However, in those patients presenting with multiple DUs (at least four), the effect of bosentanum Therapeutic Interventions on the Reduction plasty of new DUs offers greater potential benefit.",In trials have shown that bosentan treatment reduces the of new DUs compared with with SSc but has no effect DU healing.,['Discussion'],Discussion,['21']
684,PMC3002766S159,"Major outcomes including Inpatient care for communicable infectious disease or need for surgical amputation occur too infrequently to serve as outcome measures in trials of this sort, but it seems reasonable to surmise that Reduction occurrence of DUs would ultimately reduce the risk of same in an appropriate population.","However, in those patients presenting with multiple DUs (at least four), the effect of bosentán therapy on the Reduction plasty of new DUs offers greater potential benefit.","In conclusion, two randomised trials have shown that bosentanum therapy reduces the occurrence of new DUs compared with fake drug in patients with SSc but has no effect on DU healing.",['Discussion'],Discussion,['21']
685,PMC3002766S159,"Major outcomes including hospitalisations for infection or need for surgical amputation occur too infrequently to serve as outcome measures in trials of this sort, but it seems reasonable to surmise that reduced occurrence of DUs would ultimately reduce the risk of same in an appropriate population.","However, in those patients presenting with multiple DUs (at least four), the effect of bosentan treatment on the reduction of new DUs offers greater potential benefit.","In conclusion, two randomised trials have shown that bosentan treatment reduces the occurrence of new DUs compared with placebo in patients with SSc but has no effect on DU healing.",['Discussion'],Discussion,['21']
686,PMC4215282S51,All ponesimod identical doses and matching placebo were entirely indistinguishable and identical identically packaged.,"The investigators make up and sponsor were blinded to the core lymphocyte comprise count results comprise and first-dose comprise effects of ponesimod, unless alerted for safety alert reasons.",13 phase range selected for this study based was on dose The data.12 I,['Study design and procedures'],Methods,['11b']
687,PMC4215282S51,All ponesimod doses and matching fake drug were indistinguishable and identically packaged.,"The investigators and sponsor were blinded to the lymphocyte count results and first-dose effects of ponesimod, unless patient appears alert for safety reasons.",The dose range selected for this was based phase I data.12 13,['Study design and procedures'],Methods,['11b']
688,PMC4215282S51,whole ponesimod united states department of state and matching placebo were undistinguishable and identically packaged.,"The investigators and sponsor were blinded to the lymphocyte count results and first-dose effects of ponesimod, unless alerts for safety reasons.",The dose crop pick out for this study was based on form single data.12 13,['Study design and procedures'],Methods,['11b']
689,PMC4215282S51,All ponesimod doses and matching placebo therapy were indistinguishable and identically packaged.,"The police detective and patron were blinded to the lymph cell count answer and first-dose personal effects of ponesimod, unless alarm for safety reasons.",The dose range selected for this study was based on phase I data.12 13,['Study design and procedures'],Methods,['11b']
690,PMC4215282S51,All ponesimod doses and matching placebo indistinguishable and identically packaged.,"The investigators and sponsor were blinded to the lymphocyte count results and first-dose effects of ponesimod, unless ALERT for safety reasons.",The elvis kitchen stove selected for this consider was based on stage I data.12 13,['Study design and procedures'],Methods,['11b']
691,PMC4215282S51,All and packaged. and matching placebo were ponesimod indistinguishable identically doses,"The investigators and sponsor were blinded to the core lymphocyte blind blind count results unreasoning and first-dose effects of ponesimod, blind unless blind alerted for safety reasons.",range selected for was based on I data.12 13,['Study design and procedures'],Methods,['11b']
692,PMC4215282S51,All ponesimod doses and matching placebo were indistinguishable and identically packaged.,"The investigators and sponsor were blinded to the lymphocyte count results and first-dose effects of ponesimod, unless alerted for safety reasons.",The dose range selected for this study was based on phase I data.12 13,['Study design and procedures'],Methods,['11b']
693,PMC5009486S91,"Non-inferiority time was not were cumulative testing to onset of action Kaplan–Meier Day on for plotted. for incidence 1, curves performed which",Non-inferiority was only determined for a Therapeutic Procedure group if the lower bound of the 95 % Self Confidence interval (CI) for the difference was above −100 mL and if all higher dose levels were statistically significantly non-inferior to open-label tiotropium.,≥12 % proportion of treatments. achieving The improvement from a on Day 1 was tabulated baseline to logistic regression and used was compare patients,['Statistical analysis'],Methods,['12b']
694,PMC5009486S91,"Non-inferiority 1, for Kaplan–Meier performed was time of onset to action on Day testing for which cumulative incidence not curves were plotted.",Non-inferiority was only determined for a therapeutics group if the lower bound of the 95 % Self Confidence interval (CI) for the difference was above −100 mL and if all higher dose levels were statistically significantly non-inferior to open-label tiotropium.,The proportion of patients achieving ≥12 % improvement from baseline on Day 1 was tabulated and a logistic Disease regression was Used by to compare treatments.,['Statistical analysis'],Methods,['12b']
695,PMC5009486S91,Non-inferiority testing not performed for time to onset of action on Day for which incidence Kaplan–Meier were plotted.,Non-inferiority was only determined for a Therapeutic proced group if the lower bound of the 95 % self confidence interval (CI) for the difference was above −100 mL and if all higher dose levels were statistically significantly non-inferior to open-label tiotropium.,The proportion of patients achieving ≥12 % improvement from baseline on Day 1 was tabulated and a logistic Regressing was used by to compare treatments.,['Statistical analysis'],Methods,['12b']
696,PMC5009486S91,"Non-inferiority try out was not performed for sentence to onset of carry through on daytime 1, for which accumulative relative incidence Kaplan–Meier curves were plotted.",Non-inferiority was only determined for a Therapies group if the lower bound of the 95 % Self Confidence interval (CI) for the difference was above −100 mL and if all higher dose levels were statistically significantly non-inferior to open-label tiotropium.,The ratio of patient achieving ≥12 % improvement from baseline on Day one was tabulated and a logistical regression was employ to equivalence treatments.,['Statistical analysis'],Methods,['12b']
697,PMC5009486S91,"Non-inferiority testing was for time to onset of Day 1, which cumulative curves were plotted.",Non-inferiority was only determined for a Therapeutic Procedures group if the lower bound of the 95 % self confidence interval (CI) for the difference was above −100 mL and if all higher dose levels were statistically significantly non-inferior to open-label tiotropium.,The proportion patients achieving ≥12 % improvement from baseline on Day 1 was tabulated and regression was used to treatments.,['Statistical analysis'],Methods,['12b']
698,PMC5009486S91,"Non-inferiority Tests was not performed for time to onset of action on Day 1, for which cumulative incidence Kaplan–Meier curves were plotted.",Non-inferiority was only determined for a method treatment group if the lower bound of the 95 % Self Confidence interval (CI) for the difference was above −100 mL and if all higher dose levels were statistically significantly non-inferior to open-label tiotropium.,The proportion of patients achieving ≥12 % improvement from baseline on Day 1 was tabulated and a logistic regression disease was used by to compare treatments.,['Statistical analysis'],Methods,['12b']
699,PMC5009486S91,"Non-inferiority testing was not performed for time to onset of action on Day 1, for which cumulative incidence Kaplan–Meier curves were plotted.",Non-inferiority was only determined for a treatment group if the lower bound of the 95 % confidence interval (CI) for the difference was above −100 mL and if all higher dose levels were statistically significantly non-inferior to open-label tiotropium.,The proportion of patients achieving ≥12 % improvement from baseline on Day 1 was tabulated and a logistic regression was used to compare treatments.,['Statistical analysis'],Methods,['12b']
700,PMC5009486S92,The proportion exist of patients achieving ≥12 % improvement from baseline on Day 1 was tabulated and melioration vitamin a comparability vitamin a a logistic achieve regression was used to compare treatments.,"Non-inferiority tests was not performed for time to onset of action on Day 1, for which cumulative incidence Kaplan–Meier curves were plotted.","safety safety population was used, defined as all patients who were randomized and received at least one of treatment and had post-baseline safety assessment for that treatment.",['Statistical analysis'],Methods,['12b']
701,PMC5009486S92,The proportion of patient role achieving ≥12 % melioration from service line on twenty four hours single was tabulated and a logistic infantile fixation was used to compare treatments.,"Non-inferiority testing was not performed for comprise time to onset of try action on Day 1, slew for which cumulative incidence Kaplan–Meier perform curves were attack deal plotted.","For safety analyses the safety population was used, defined as all patients who were randomized and received at least one dose of study therapeutic procedure and had a post-baseline safety Knowledge acquisition using a method of assessment for that treatment.",['Statistical analysis'],Methods,['12b']
702,PMC5009486S92,The proportion of patients achieving ≥12 % improvement from baseline on Day 1 was tabulated and a logistic Disease regression was Used by to compare treatments.,"action for was not performed which time plotted. testing of Non-inferiority on 1, Day onset for cumulative incidence Kaplan–Meier curves were to","For safety analyses the safety population was used, defined as all patients who were randomized and received at least one dose of study Therapies and had a post-baseline safety Knowledge acquisition using a method of assessment for that treatment.",['Statistical analysis'],Methods,['12b']
703,PMC5009486S92,proportion patients ≥12 % improvement baseline on Day was tabulated and a logistic regression was to treatments.,"Non-inferiority 1, was time performed for not onset to testing action which Day of for on cumulative incidence Kaplan–Meier curves were plotted.","For safety analyses the safety population was used, defined as all patients who were randomized and received at least one dose of study therapy and had a post-baseline safety Knowledge acquisition using a method of assessment for that treatment.",['Statistical analysis'],Methods,['12b']
704,PMC5009486S92,The proportion of simple regression logistical patients achieving ≥12 % improvement secondhand from baseline affected role on Day 1 was tabulated and a vitamin a logistic regression was used to compare along treatments.,"Non-inferiority examination was not do for meter to onset of action on clarence day 1, for which cumulative relative incidence Kaplan–Meier arc were plotted.","and safety analyses the safety of was population defined as at for who were had and all least used, one dose received study treatment For randomized a post-baseline safety assessment patients that treatment.",['Statistical analysis'],Methods,['12b']
705,PMC5009486S92,of patients ≥12 % baseline on was tabulated a logistic regression used to compare,"time to onset of Day 1, for cumulative incidence Kaplan–Meier curves were","For safety analyses the safety population was used, defined as all patients who were randomized and received at least one dose of study therapeutic method and had a post-baseline safety Knowledge acquisition using a method of assessment for that treatment.",['Statistical analysis'],Methods,['12b']
706,PMC5009486S92,The proportion of patients achieving ≥12 % improvement from baseline on Day 1 was tabulated and a logistic regression was used to compare treatments.,"Non-inferiority testing was not performed for time to onset of action on Day 1, for which cumulative incidence Kaplan–Meier curves were plotted.","For safety analyses the safety population was used, defined as all patients who were randomized and received at least one dose of study treatment and had a post-baseline safety assessment for that treatment.",['Statistical analysis'],Methods,['12b']
707,PMC3590447S151,"We contend that for patients with idiopathic membranous nephropathy, 6 months' therapy with alternating monthly cycles of prednisolone and CLB is the methods treatment approach best supported by evidence, and our study extends this evidence to the important subset of patients with membranous nephropathy and Deteriorated excretory renal function.","Renal units that go down to enter and employ for ethical approval were approximately every bit divided into those concerned about the miss of alive therapy in the supportive caution only grouping or the potential perniciousness of alive therapy—clear show that considerable precariousness skirt capture direction of this disorder, and that a unequivocal RCT is needed.",Our findings do not started the use of renal in this group—the adverse effects on it function ciclosporin function make once renal unsuitable has support to decline.,['Discussion'],Discussion,['21']
708,PMC3590447S151,"We contend that for patients with idiopathic membranous nephropathy, 6 months' therapy with alternating monthly cycles of prednisolone and Chloroambucil is the therapeutic intervention approach best supported by evidence, and our study extends this evidence to the important subset of patients with membranous nephropathy and Deteriorate excretory renal function.","Renal units that declined lone to participate and apply for atomic number  ethical approval were separate comprise roughly equally divided into those concerned about give unit of measurement the lack of active therapy separate in the supportive care lone only group direction demonstrate or the present potential toxicity counsel of active therapy—clear perniciousness evidence active voice that considerable uncertainty surrounds comprise appropriate management of freestanding this disorder, and that a definitive RCT is needed.",Our suffice findings do not support apply the use burden of bear back ciclosporin in this group—the adverse effects on non serve renal function make it unsuitable once information technology renal function has started to decline.,['Discussion'],Discussion,['21']
709,PMC3590447S151,"We contend that for patients stretch with idiopathic membranous affected role nephropathy, 6 months' therapy rhythm exist with alternating monthly significant cycles leukeran of pediapred prednisolone and chlorambucil is the treatment approach best supported be stretch out by evidence, and our written report study extends this evidence to the important subset of patients with membranous stretch out discourse membrane forming nephropathy and nephritic deteriorating excretory renal function.","Renal units that declined to participate and apply for ethical approval were roughly equally divided into those concerned about the lack of active therapy in the support therapy only group or the potential toxicity of active therapy—clear evidence that considerable Uncertain surrounds appropriate Disease Managements of this disorder, and that a definitive RCT is needed.",Our findings do not support the use of Cyclosporin a in this group—the side effect on functions kidney test make it unsuitable once functions kidney test has started to decline.,['Discussion'],Discussion,['21']
710,PMC3590447S151,"We contend that for patients with idiopathic membranous nephropathy, 6 months' therapy with alternating monthly cycles of prednisolone and Chloraminophen is the therapy approach best supported by evidence, and our study extends this evidence to the important subset of patients with membranous nephropathy and deteriorates excretory renal function.","roughly units approval or apply evidence that to for ethical that surrounds a equally the into those concerned disorder, divided active of lack therapy uncertainty the of care only group definitive the potential toxicity supportive active therapy—clear participate that considerable in were this management of appropriate Renal and and about declined RCT is needed.",Our findings do not support the use of cyclosporin a in this group—the therapy adverse effect on renal function test make it unsuitable once renal function test has started to decline.,['Discussion'],Discussion,['21']
711,PMC3590447S151,"We contend that for patients with idiopathic membranous nephropathy, 6 months' therapy with alternating monthly cycles of prednisolone and CHL is the therapeutic intervention approach best supported by evidence, and our study extends this evidence to the important subset of patients with membranous nephropathy and deteriorated excretory renal function.","Renal units that declined to participate and apply for ethical approval were roughly equally divided into those concerned about the lack of active therapy in the supportive therapy only group or the potential toxicity of active therapy—clear evidence that considerable Unsure surrounds appropriate disease management of this disorder, and that a definitive RCT is needed.",inapplicable Our findings do not incur support the use of nephritic renal ciclosporin in back this non group—the apply adverse effects on renal function nephritic make it unsuitable once renal function has started to decline.,['Discussion'],Discussion,['21']
712,PMC3590447S151,"We contend that for patient role with idiopathic membrane forming nephropathy, sextet months' therapy with flip monthly motorcycle of prelone and leukeran is the handling approach outdo supported by evidence, and our learn stretch forth this certify to the authoritative subset of patient role with membrane forming nephropathy and drop excretory renal function.","Renal this RCT declined to potential and apply concerned ethical approval were roughly the divided into those for participate therapy—clear lack surrounds active the care therapy supportive in only disorder, or evidence about toxicity of active equally the that considerable uncertainty that appropriate management and units that a group of definitive of is needed.",Our findings do not support the use of Ciclosporinum in this group—the Side effects on function renal testing make it unsuitable once function renal testing has started to decline.,['Discussion'],Discussion,['21']
713,PMC3590447S151,"We contend that for patients with idiopathic membranous nephropathy, 6 months' therapy with alternating monthly cycles of prednisolone and chlorambucil is the treatment approach best supported by evidence, and our study extends this evidence to the important subset of patients with membranous nephropathy and deteriorating excretory renal function.","Renal units that declined to participate and apply for ethical approval were roughly equally divided into those concerned about the lack of active therapy in the supportive care only group or the potential toxicity of active therapy—clear evidence that considerable uncertainty surrounds appropriate management of this disorder, and that a definitive RCT is needed.",Our findings do not support the use of ciclosporin in this group—the adverse effects on renal function make it unsuitable once renal function has started to decline.,['Discussion'],Discussion,['21']
